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1 General introduction
Genetic diversity 
Genetic diversity forms the basis of evolution. In the Origin of Species (189), 
Charles Darwin stated that ‘any variation, however slight and from whatever 
cause proceeding, if it be in any degree profitable to an individual of any species, 
in its infinitely complex relations to other organic beings and to external 
nature, will tend to the preservation of that individual, and will generally be 
inherited by its offspring. This principle, also referred to as ‘survival of the 
fittest’, is accountable for the evolution of heterogeneity within the human 
population.
Transplantation
To remove a living tissue or an organ and implant it in another part of the 
body (auto-transplantation) or in another body (allo-transplantation). Derived 
from Latin trans- ‘across’ and  plantare ‘to plant’.  
These two definitions form the basis of transplantation immunology. While the 
genetic diversity preserves us as a species, it also provides the major obstacle in kidney 
transplantation. Fortunately, ways to circumvent the problem of allograft rejection, 
caused by genetic diversity, including the introduction of immunosuppressive drugs, 
have markedly increased the success rate of transplantation. Today, one-year graft 
survival rates are exceeding 90%. However, although these short-term survival rates 
are excellent, long-term survival rates remain a matter of concern. Paradoxically, 
the continued use of immunosuppressive drugs, administered to prevent rejection 
of the allograft, can contribute to long-term graft loss. The non-specific nature of 
the immunosuppressive drugs increases the risk of opportunistic infections and the 
development of malignancies. In addition, each drug has its own array of side effects 
of which nephrotoxicity, hypertension, hyperlipidemia, and diabetes mellitus are the 
most threatening for the patient and the graft. Therefore, it is highly desirable to lower 
the amount of immunosuppression, once stable graft function is achieved, provided 
that graft rejection is prevented. Clinical studies have indicated that reduction of 
immunosuppression is successful in the majority of transplant patients, but it is 
inevitably accompanied by an increased risk of acute rejection. The development of 
in vitro monitoring tools, to monitor the immune status of transplant patients may 
allow the identification of transplant patients in whom immunosuppression can be 
safely reduced. 
13
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The ultimate goal in transplant immunology remains the induction of transplantation 
tolerance; acceptance of the allograft in the absence of immunosuppression. 
Although the exact mechanisms involved in the induction of transplantation 
tolerance remain to be elucidated, regulatory T cells have been identified as part 
of the intricate intrinsic tolerance network. It is therefore of critical importance 
that immunosuppressive drugs administered to prevent allograft rejection, do not 
interfere with the presence and function of the regulatory T cells. Furthermore, it 
is imperative to develop new immunosuppressive drugs or methods that target the 
allo-immune response in a more specific way, have fewer side effects and promote 
the induction of transplantation tolerance. The main goal of the research described 
in this thesis concerned the finding of one or more immunological markers that 
can be used to identify transplant patients in whom immunosuppression can be 
safely reduced. In addition, the impact of immunosuppressive regimens on the 
presence and function of regulatory T cells and the immunosuppressive effects of an 
experimental immunosuppressive drug were addressed. 
This chapter provides an introduction to the immunological processes involved in 
transplant rejection and tolerance, a description of the mechanism of action of 
various immunosuppressive drugs, and a summary of available tools to monitor the 
immune response towards the allograft. At the end of this chapter, the aims and 
outline of this thesis are described. 
2 Kidney transplantation 
The first experimental kidney transplantation was performed in 1902 by Emerich 
Ullmann as he successfully transplanted a dog’s kidney from its normal retroperitoneal 
position to the neck of the animal.1 In the following years the number of reports on such 
events increased rapidly and in 1906 the first human kidney (xeno-) transplantation 
was performed by Mathieu Jaboulay in Lyon, France.2 Although the transplanted 
kidneys functioned for varying lengths of time, all the hosts died eventually. Alexis 
Carrel, an expert in the field of vascular surgical techniques, concluded in 1912 that 
‘autografts were always successful, allografts may be excellent but were almost always 
ultimately unsuccessful, and xenografts always failed’.3 The surgical procedure was 
now established but there was little understanding of the barrier that caused the 
transplanted organ to be rejected causing the interest in transplantation to fade.
It was not until the 1940s before the first evidence was provided for the underlying 
mechanism of allograft rejection. Gibson and Medawar clearly showed that 
rejection of skin grafts was accompanied by the infiltration of large quantities of 
lymphocytes that displayed specificity and memory for donor tissue.4; Studies by 
14
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Gorer on the antigens involved in graft rejection eventually led to the discovery 
of the major histocompatibility complex (MHC) in mice.6 Several years later, the 
human counterpart, referred to as the human leukocyte antigen (HLA) complex, was 
identified by Dausset and van Rood.7;8 These events laid the basis of transplantation 
immunology and resulted in a rapid increase in knowledge on the alloimmune 
response and ways of inhibiting it. The introduction of immunosuppressive drugs in 
the 190s marked the start of the modern era of transplantation. 
Today, transplantation is the preferred curative therapy for patients with end-stage 
renal disease.9 Organ replacement from either a living or deceased donor is preferred 
over dialysis because transplantation provides a better quality of life and improved 
survival.9;10 In 2006, 64 patients received a kidney from a living (274) or deceased 
donor (380) in the Netherlands. Due to a shortage of organ donors, approximately 
1100 patients are waiting for a donor kidney, with an average waiting time of 4. 
years.   
3 Transplant Immunobiology
3.1 Immune system
The immune system is a complex network of specialized proteins, cells and organs 
that has evolved to defend the body against attacks by “foreign” invaders. When 
functioning properly, it fights off infections by agents such as bacteria, viruses, fungi, 
and parasites. Any substance capable of triggering an immune response is called an 
antigen and the basis of the immune system is provided by its functional ability to 
discriminate between self and non-self antigens. 
In transplantation, the transplanted organ, or allograft, is recognized by the immune 
system as non-self. The non-self antigens comprise virtually any polymorphic (from 
Greek polymorphus, poly ‘many’ + morphus ‘form’) protein expressed on cells of the 
allograft. The most heterogeneity in the humane genome is observed in the major 
histocompatibility complex (HLA) located on chromosome 6. These genes encode cell 
surface markers involved in the processing and presentation of antigens (also see 
below).11;12 The heterogeneity in the HLA complex results in an enormous number of 
slightly different HLA molecules, each capable of binding a different set of peptides. 
In addition to the HLA complex other polymorphic genes, minor histocompatibility 
antigens, can contribute to the alloimmune response, of which one of the best-known 
examples is the male H-Y-antigen.13 
The cells of the immune system originate from the bone marrow and once matured, 
they migrate through the blood and lymphatic system, continuously scanning the 
environment for pathogens.14 In general, the immune system can be divided into 
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two major arms, the innate and the adaptive arm of the immune system. The innate 
immune system acts in an antigen non-specific manner and offers the first line 
defense against invading pathogens and innate immune cells include phagocytes 
(macrophages, monocytes and dendritic cells [DC]), basophils, neutrophils, mast cells 
and natural killer (NK) cells. The adaptive immune system acts in an antigen-specific 
way. Antigens are presented in the context of HLA molecules to T and B lymphocytes, 
which each carry specificity for a single antigen. Upon activation they undergo clonal 
expansion and acquire effector function, including antibody production (B cells), 
cytokine production, and cytotoxicity (T cells). The major feature of the adaptive 
immune system is the generation of immunological memory that protects the body 
against recurrent infection by the same antigen. 
In the alloimmune response, T cells play a central role.1 Upon activation of 
alloreactive T cells, interplay exists between T cells and other immune cells, together 
resulting in a vigorous immune response against the allograft, ultimately leading 
to graft rejection.1 The T cell response against the allograft can be divided in three 
phases: 1) antigen recognition, 2) T cell activation, 3) effector function. 
3.2 PHASE I - Antigen recognition
3.2.1 The HLA complex
As mentioned above, the genes of the HLA complex encode cell surface receptors that 
play a role in antigen recognition and presentation.11;12 The HLA complex contains 
two important regions, the class I and class II region (Figure 1). The genes of the HLA 
class I region, comprising HLA-A, -B and –C genes, encode the heavy chain (44 kDa) 
that is covalently bound to β2-microglobulin (β2m) to form the HLA class I molecule. 
HLA class I molecules are expressed on the cell surface of all nucleated cells and in 
the peptide binding groove, formed by the α1 and α2 domains of the heavy chain, 
endogenously processed peptides, derived from viral or self proteins, are presented 
to the CD8+ T lymphocytes (Figure 1).11 The HLA class II region contains HLA-DR, -DQ 
and –DP genes encoding antigen-presenting molecules that are composed of an α-
chain (32 kDa) covalently bound to a β-chain (32 kDa) (Figure 1). The peptide binding 
groove is formed by the α1 and β1 domains of the α- and β-chain respectively.12 HLA 
class II molecules are only expressed by professional antigen-presenting cells (APC), 
including dendritic cells, monocytes and B cells, and present antigens to the CD4+ T 
lymphocytes (Figure 1).
3.2.2 Direct and indirect pathways of antigen presentation
Donor antigen (allo-antigen) recognition can occur via two distinct pathways, the 
direct and indirect pathway of antigen presentation. In the direct pathway of allo-
16
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recognition, patient T cells directly interact with HLA-peptide complexes from the 
donor, recognizing either a foreign peptide presented in a shared HLA molecule, or 
the non-self HLA-peptide complex as such (Figure 2A). Due to T cell cross reactivity, 
where the combination of non-self HLA–peptide complexes expressed on donor cells 
in some cases resemble self HLA–microbial complexes, a relatively high precursor 
frequency of alloreactive T cells with direct specificity is observed16 and is estimated 
at 0.1-7%17;18. The indirect pathway of allo-recognition equals the normal situation of 
an immune response against invading pathogens. Donor-derived proteins, including 
shed HLA molecules of donor origin, are taken up by professional APC of the patient, 
processed and presented in HLA class II molecules to CD4+ T lymphocytes (Figure 
2B).16      
3.3 PHASE II - T cell activation
T cells originate from haematopoietic stem cells in the bone marrow and subsequently 
migrate to the thymus, where maturation and negative selection, the removal of 
T cells with specificity for self-antigens, take place.14;19-22 The remainder of T cells 
that survive this process enter the circulation and each T cell is equipped with a 
T cell
Į3
Į1Į2
ȕ2m
CD8+CD4+
TCR
peptide
Į1 ȕ1
ȕ2Į2
HLA class IHLA class II
Figure 1: HLA class I and class II molecules. The HLA complex, located on chromosome 6 encodes cell 
surface receptors involved in the processing and presentation of antigens. HLA class I molecules, expressed on 
all nucleated cells, are composed of a heavy chain (44 kDa), containing α1, α2 and α3 domains, covalently bound 
to β2m (12 kDa). Peptides derived from intracellular proteins are presented in the peptide-binding groove, 
formed by the α1 and α2 domains, to CD8+ T lymphocytes. HLA class II molecules, only expressed on profes-
sional APC, consist of an α chain and a β chain (each 32 kDa), covalently bound together to form heterodimers. 
In the peptide-binding groove, formed by the α1 and β1 domains, peptides derived from endocytosed proteins 
are presented to CD4+ T lymphocytes. Adapted by permission from Macmillan Publishers Ltd: Nature Immunol-
ogy Reviews (Rodgers et al. Nat. Rev. Imm 5(6), 459-471), copyright (2005).164
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T cell receptor (TCR) specific for a single antigen, recognized in the context of HLA 
molecules.23;24 To deal with the wide variety of antigens, the adaptive immune system 
uses a clonal selection system in which antigen-specific T cells, initially present at 
low numbers, are selected to undergo clonal expansion to give rise to an efficient 
number of effector T cells.2    
3.3.1 Interaction between APC and T cell in the lymphoid tissues 
Antigen presentation by professional antigen-presenting cells (APC), mostly dendritic 
cells (DC), to naive T cells occurs in the secondary lymphoid tissues. Upon uptake of 
A B
Figure 2: Direct and indirect pathways of Allorecognition. (A) Direct pathway of antigen recognition. T 
cells of the patient directly interact with donor HLA molecules, responding to either non-self peptides present-
ed in HLA identical molecules or to the non-self HLA-peptide complexes directly. (B) The indirect pathway of 
Allorecognition. Donor-derived proteins, either from donor HLA molecules or from minor histocompatibility 
antigens, are taken up by recipient APC via a mechanism called endocytosis. Empty HLA class II molecules leave 
the endoplasmatic reticulum (ER) and are loaded with peptides derived from the endocytosed proteins. The 
now stable HLA-peptide complex is transported to the cell surface where the peptide is presented to CD4+ 
T lymphocytes of the recipient. Adapted by permission from Macmillan Publishers Ltd: Nature Immunology 
Reviews (Lechler et al. Nat. Rev. Imm 3, 147-158), copyright (2003).26
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donor antigen in the periphery, DC migrate to and enter the draining lymph nodes 
(Figure 3).26 Naive T cells leave the blood stream to enter the lymphoid tissues across 
high endothelial venules (HEV) in the endothelium.27 This is achieved by the expression 
of chemokines and adhesion molecules, including integrins and selectins. Naive T cells 
express the lymphocyte specific selectin CD62L that interacts with peripheral-node 
addressins (PNAD) expressed by endothelial cells of the HEV resulting in the slowing 
down and rolling of the T cell along the HEV endothelium, which brings the T cell into 
close contact with the endothelium.28;29 The expression of the chemokines CCL19 and 
CCL21 in the lymph nodes activates the expression of integrins on the T cells through the 
chemokine receptor CCR7.30;31 Subsequently, interaction between the activated integrin, 
lymphocyte function-associated antigen 1 (LFA-1), and the intracellular adhesion 
molecule 1 (ICAM-1) expressed on the endothelial cells results in the firm attachment 
of the T cell to the endothelium.32 Attracted by the CCL19 and CCL21 expression in 
the lymph node, the T cells transmigrate between adjacent endothelial cells, enter the 
lymph node and subsequently migrate to the T cell areas of the lymph node.33 
3.3.2  The immunological synapse and intracellular T cell signaling
T cell activation occurs in the T cell areas of the lymphoid tissues as a result of the 
stable interaction between the T cell and the APC, an interaction referred to as the 
immunological synapse.34-36 The first phase of immunological synapse formation 
occurs when the T cell recognizes cognate-peptide–MHC complexes presented by 
the APC (signal 1). Upon TCR ligation, various receptors are rapidly redistributed 
to the cell-cell junction, including costimulatory molecules such as CD28, CD2, 
CD4, CD8, and the integrin LFA-1.37-39 After relocation of these receptors into close 
proximity of the TCR, a second, costimulatory signal is delivered by CD80 or CD86 
on the APC to CD28 expressed on the T cell (signal 2).40;41 Next to the CD80/CD86 – 
CD28 pathway, a number of other costimulatory ligand-receptor pairs have been 
described during recent years. Together, these signals provide the basis for T cell 
activation and defects in either signal will induce apoptosis or anergy, a state of 
unresponsiveness, in the T cell.42;43 
The second phase of immunological synapse formation is the most important 
phase and determines the outcome of the T cell–APC interaction. Within seconds 
after TCR triggering, phosphorylation of the protein tyrosine kinases Lck, Fyn and 
ZAP70 takes place.44;4 This results in the subsequent activation of downstream 
signaling pathways, including increases in intracellular calcium flux, protein 
kinase C (PKC), nuclear factor kappa B (NFκB), and Ras–mitogen-activated protein 
kinase (MAPK) activation (Figure 4).4;46 These pathways activate transcription 
factors that ultimately lead to the expression of genes that control specific 
cellular responses. A rise in intracellular calcium activates calcineurin, which 
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dephosphorylates a cytoplasmic component of the nuclear factor of activated T 
cells (NFAT), allowing its transport to the nucleus where it promotes expression 
of the growth factor interleukin-2 (IL-2) gene.47;48 In combination with the 
activation of RAS-MAPK and NF-κB pathways, these signals promote cell survival 
and progression through the cell cycle progression, ultimately resulting in the 
clonal expansion of the T cell.
3.4  PHASE III - Effector function
3.4.1  CD4+ T cells
CD4+ T cells, or ‘helper’ T cells, are essential regulators of adaptive immune 
responses. CD4+ T cells recognize peptides presented on APC in the context of 
HLA class II molecules and upon activation, differentiate into effector CD4+ T 
cells that are specialized in terms of the cytokines they produce. One of the main 
hallmarks of CD4+ T cells is the production of the growth factor IL-2, important 
for efficient activation of CD4+ as well as CD8+ T cells. Effector CD4+ T cells have 
been traditionally classified into TH1- and TH2-cells based on their cytokine-
expression profiles. TH1 cells produce IFN-γ and regulate cellular immunity, 
whereas TH2 cells produce IL-4, IL- and IL-13, and mediate humoral immunity 
and allergic responses.49;0 In addition, the production of cytokines also boosts 
the differentiation towards TH1 or TH2; IL-4 produced by activated T cells drives 
TH2 differentiation (and blocks TH1 differentiation) while TH1 differentiation is 
promoted through the production of IL-12 by activated DC.1;2
Recently, an additional TH lineage, IL-17 producing CD4
+ T cells, or TH17 cells, has 
been identified.3;4 The differentiation of CD4+ TH17 cells is driven by TGF-β and 
IL-6 and IL-23 is necessary for the maintenance in vivo.-7 The pro-inflammatory 
IL-17 producing T cells are believed to be involved in the protection against 
extracellular pathogens.8 TH17 cells have been associated with a number of 
autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid 
arthritis.8
3.4.2  CD8+ T cells
CD8+ T cells recognize peptides presented in HLA class I molecules expressed on 
APC. Upon differentiation, CD8+ T cells undergo clonal expansion and acquire 
effector function. Effector CD8+ T cell function includes cytotoxicity, through 
degranulation of perforin and granzyme containing lysosomes or through the 
FasL pathway and the production of cytokines.9 Recognizing the ubiquitous 
expression of HLA class I molecules on the allograft, effector CD8+ T cells play a 
major role in allograft destruction. 
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3.5  Interplay between T cells and other immune compartments
The effector CD4+ and CD8+ T cells act in concert with other compartments of 
the immune system that have become activated, through antigen-dependent or 
antigen-independent pathways, upon transplantation. The subsequent immune 
system results in graft destruction, ultimately leading to graft rejection.
3.5.1  Surgery &Ischemia/reperfusion injury
Ischemia/reperfusion injury is the injury of the kidney as a result of the cold 
preservation and subsequent reperfusion. It involves a multi-factorial antigen-
independent inflammatory condition and has immediate and long-term 
effects on the allograft.60 Ischemia/reperfusion injury results in the activation 
of endothelial cells leading to the expression of TNF-α, IL-1, and IFN-γ as well 
as the recruitment of several cell types including DC, neutrophils and T cells, 
complement activation, and up regulated expression of adhesion molecules.61-63
Next to the ischemia/reperfusion injury, the injury from surgical procedure also 
evokes an inflammatory response, enhancing immune awareness. The initial 
inflammatory response as a result of ischemia/reperfusion injury and surgery 
has profound impact on early graft function but has also been shown to increase 
the chance of late graft loss.64  
Figure 3: Donor antigen is carried and presented by donor and patient APC to T cells in the drai-
ning lymph nodes. Donor APC, present in the allograft at time of transplantation, migrate to the draining 
lymph nodes and present antigen via the direct pathway to T cells of the patient. Patient APC, migrating through 
the allograft, can take up antigen derived from donor cells and present the antigen to the T cells via the indirect 
pathway. Adapted by permission from Macmillan Publishers Ltd: Nature Immunology Reviews (Lechler et al. 
Nat. Rev. Imm 3, 147-158), copyright (2003).26
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Figure 4: Intracellular signaling in T cells. A T cell recognizes antigen presented in HLA molecules on 
the antigen-presenting cell (APC) through its T cell receptor (TCR), referred to as signal 1. The subsequent 
immunological synapse formation results in the rapid relocation of various (costimulatory) receptors into 
the proximity of the TCR. Signal 2 is delivered through CD80/CD86 on the APC and CD28 on the T cell. The 
intracellular signaling events that follow the delivery of signals 1 and 2 determine the fate of the productive 
response. Within seconds after TCR triggering, phosphorylation of the protein tyrosine kinases Lck, Fyn and 
ZAP70 takes place, resulting in the subsequent activation of downstream signaling pathways, including increases 
in intracellular calcium flux, protein kinase C (PKC), nuclear factor kappa B(NFκB), and Ras–mitogen-activated 
protein kinase (MAPK) activation. A rise in intracellular calcium activates calcineurin, which dephosphorylates 
the cytoplasmic component of nuclear factor of activated T cells (NFAT), allowing its transport to the nucleus 
where it promotes expression of the growth factor interleukin-2 (IL-2) gene. In combination with the activation 
of RAS-MAPK and NF-κB pathways, these signals promote cell survival and progression through the cell cycle, 
ultimately resulting in the clonal expansion of the T cell.  Adapted by permission from Macmillan Publishers Ltd: 
Nature Immunology Reviews (Macian F, Nat. Rev. Imm 5(6), 472-484), copyright (2005).165
22
Chapter1
3.5.2  NK cell alloreactivity
Next to the immune response resulting from injury, innate NK cells can elicit a 
more ‘specific’ response after transplantation. NK cell activation is dependent on 
a balance between signals from inhibitory and stimulatory receptors.6-67 Self-HLA 
molecules, ubiquitously expressed on all nucleated cells, deliver inhibitory signals. 
This means that the absence of self HLA molecules on allogeneic cells can mediate 
NK cell alloreactivity, resulting in the production of large quantities of IFN-γ and 
TNF-α and the killing of allogeneic cells through the secretion of perforin and 
granzymes.68;69 Furthermore, the cytokine production by activated NK cells can boost 
T cell alloreactivity 70 and modulate DC maturation, which in turn can augment 
adaptive immune responses, especially favoring TH1 responses.
69
3.5.3  B cell alloreactivity
Comparable to T cells, B cells carry an antigen-receptor by which they recognize allo-
antigen. In response to antigen, B cells differentiate into plasma cells and produce 
antigen-specific antibodies.71 Antibody binding can, together with complement 
activation, result in opsonization for uptake by e.g. macrophages or in antibody-
dependent cell-mediated cytotoxicity (ADCC) through NK cell activation.72
Pre-existing HLA antibodies before transplantation form a major obstacle to 
transplantation since their presence can result in hyperacute rejection within 
minutes after transplantation (discussed below).73 Also, patients that carry HLA 
antibodies, but have a negative pre-transplant cross-match, experience more acute 
rejection episodes and have a lower overall graft survival compared to patients 
without HLA antibodies.74
3.6  Effector mechanisms of allograft destruction
Together, the immune compartments can mount a vigorous immune response 
against the allograft, ultimately leading to graft rejection. Three different types of 
allograft rejection can be discriminated, based on the cell type responsible for the 
destructive response: hyperacute rejection, acute rejection, and chronic allograft 
nephropathy.  
3.6.1  Hyperacute rejection
Antibody-mediated hyperacute rejection occurs within the first hours after reperfusion 
and is caused by pre-existing antibodies directed against donor HLA molecules.73;7 
Preformed allo-antibodies in a sensitized patient react with HLA antigens present 
on the vascular endothelial cells of the allograft, which results in activation of the 
classical complement pathway, intravascular coagulation, and consequently rapid 
necrosis of the transplanted tissue.73;7 These pre-existing antibodies can arise from 
23
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prior transplantation, blood transfusions or pregnancies. Hyperacute rejection has 
become an uncommon event since the introduction of routine cross-match testing 
and advances in pre-transplant detection of anti-HLA antibodies.
3.6.2  Acute rejection
In contrast to hyperacute rejection, acute rejection episodes can occur days to years 
after transplantation, but is predominant in the first 6 months after transplantation. 
Acute rejection is a T-cell mediated process.1 Activation of CD4+ T cells either by direct 
or indirect antigen recognition results in the formation of effector CD4+ T cells that 
produce large amounts of IL-2. CD4+ T cells with direct specificity are believed to be 
the most important players in acute rejection due to their high numbers as a result 
of cross-reactivity.76 However, also CD4+ T cells with indirect specificity can cause 
acute rejection.77 During a rejection episode, activated CD4+ T cells attract a wide 
variety of cell types to the allograft, including cytotoxic CD8+ T lymphocytes, B cells, 
macrophages and NK cells (Figure ).1 Of these effector mechanisms, selective cell-
mediated cytotoxicity by the perforin/granzyme B pathway is the most important.78
3.6.3  Chronic allograft nephropathy
Chronic allograft nephropathy (CAN) is responsible for the major part of long-term 
allograft loss.  The term CAN refers to interstitial fibrosis, tubular atrophy, and 
narrowing of blood vessels, ultimately leading to progressive allograft dysfunction.79 
CAN can result from immunological and non-immunological processes, including 
nephrotoxicity caused by calcineurin inhibitor administration.79-81 With regard to 
the immunological factors, it has been shown that the direct T cell response fades 
over time,82;83 while the indirect pathway is sustained and gives rise to increased T 
cell responses in patients undergoing chronic rejection.82;84
4 Immunosuppressive drugs
The introduction of immunosuppressive drugs has decreased the risk of allograft 
rejection. Today, a wide variety of immunosuppressive drugs are available which 
interfere with different steps in the immune response against the allograft.8;86 
However, the immunosuppressive drugs target the immune system in a non-specific 
way thereby increasing the risk for opportunistic infections and the development of 
malignancies.87 In addition, some of the targets of immunosuppressive drugs are also 
expressed by non-immune cells, resulting in unwanted destruction of these cells. 
Above all, the long-term administration of immunosuppressive drugs is associated 
with serious adverse events, including nephrotoxicity (Table 1).86 Therefore, there is 
24
Chapter1
a continuous search for new immunosuppressive drugs or methods that 1) target 
the alloimmune response in a more specific way, 2) have less toxic side-effects and 3) 
allow the induction of transplantation tolerance. In this section, the mechanism of 
action of the immunosuppressive drugs currently used to prevent allograft rejection 
is described. A number of adverse events associated with immunosuppressive drug 
administration are listed in Table 1.
4.1  Calcineurin inhibitors
The calcineurin inhibitors (CNI) cyclosporine and tacrolimus are very efficacious in 
preventing acute rejection following kidney transplantation (Table 1). Cyclosporine 
is a cyclic undecapeptide isolated from the fungus Tolypocladium inflatum found 
Figure 5: Allorecognition mediates acute graft rejection. After reperfusion of the allograft, donor DC 
and recipient DC can migrate from the graft to the draining lymphoid tissues. There, antigen is presented by do-
nor DC (direct pathway) and recipient DC (indirect pathway) to CD4+ T cells. Upon activation, CD4+ T cells 
differentiate into effector CD4+ T cells producing large amounts of IL-2 to help the differentiation of CD8+ T 
cells. Cytotoxic CD8+ T cells can kill allogeneic target cells through the production of perforin and granzymes. 
Effector CD4+ TH1 cells can stimulate a delayed-type hypersensitivity response mediated by macrophages by 
the secretion of IFN-γ. In addition, CD4+ TH1 cells are able to kill Fas-expressing allogeneic target cells through 
their expression of Fas ligand. IL-4 and IL-5 producing effector CD4+ TH2cells can stimulate the differentiation 
of B cells into antibody producing plasma cells, which, in turn, can bind allogeneic cells and induce complement 
activation or antibody-dependent cellular cytotoxicity (ADCC). Adapted by permission from Macmillan Publis-
hers Ltd: Nature Immunology Reviews (Lechler et al. Nat. Rev. Imm 3, 147-158), copyright (2003) 26.  
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in soil samples.88 Tacrolimus is a lipophilic macrolide product of Streptomyces 
tsukubaensis and was shown to be 0 times more potent that cyclosporine on weight 
basis.89
The mechanism of action of CNI depends on the inactivation of the phosphatase 
calcineurin, which is activated by increased intracellular calcium levels resulting from 
TCR triggering (Figure 4).90 Cyclosporine binds to cyclophilin (and tacrolimus binds to 
the FK06 binding protein FKBP-12), thereby preventing the activation of calcineurin 
and the downstream signal transduction including the dephosphorylation of NFAT 
and its translocation to the nucleus (Figure 6). The subsequent blockade of cytokine 
gene transcription prevents the activation and proliferation of T cells. 
4.2  mTOR inhibitor
Sirolimus (rapamycin) also binds to FK-BP12 but unlike tacrolimus, does not interfere 
with calcineurin activity. Instead, the sirolimus-FK-BP12 complex specifically inhibits 
the mammalian target of rapamycin (mTOR). Inhibition of mTOR has a profound 
effect on the cell signaling pathway required for cell-cycle progression and cellular 
proliferation, resulting in the blockade of T cell activation by preventing progression 
of the cell cycle from the G1 to the S phase (Figure 6).91 Since sirolimus was also 
shown to inhibit the proliferation of a number of non-immune cell types, including 
hepatocytes, vascular endothelial cells, smooth muscle cells, and fibroblasts, it may 
potentially interfere with the recovery of tubular cells after ischemic–reperfusion 
injury. Everolimus is another compound with a similar mode of action as sirolimus.
4.3  Proliferation inhibitors 
Anti-proliferative immunosuppressive drugs include azathioprine and mycophenolate 
mofetil (MMF). Azathioprine is metabolized to 6-mercaptopurine (6-MP) through 
reduction by glutathione, and then converted to 6-thioguanine (6TG). These 
compounds are incorporated in the DNA and halt replication. MMF is converted 
Table 1. Immunosuppressive drugs; immunosuppressive potency and side effects
Immuno 
suppressive 
Potency
Nephro
toxicity
Neuro 
toxicity
Hyper 
trichosis
Skin rash Diabetes Diarrhoea
Marrow 
suppression
Cyclosporine +++ ++ + ++ - + - -
Tacrolimus ++++ ++ ++ - - ++ - -
Sirolimus +++ - - - + - + +
Azathioprine + - - - - - - +
MMF ++ - - - - - ++ +
Corticosteroids + - - ++ - ++ - -
−: no effect; +: mild (or low incidence) toxicity/potency; ++++: extreme toxicity or potency. Reprinted from 
Taylor et al, Crit. Rev. Oncol. Hematol., 2005, 56(1), 23-46.86 
26
Chapter1
into the active form mycophenolic acid (MPA), that inhibits inosine monophosphate 
dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo synthesis of purines, 
essential for DNA synthesis. The use of inhibitors of de novo purine synthesis for 
immunosuppression was based on the observation that errors in this pathway result 
in immunodeficiency without damaging other organs, in contrast to errors in the 
purine salvage pathway.92
4.4  Corticosteroids
Corticosteroids are still an important component of most immunosuppressive 
regimens. High dose intravenous steroids are commonly used for the treatment 
for acute allograft rejection.93 Corticosteroids cross the cell membrane and bind 
to glucocorticoid receptors anchored in the cytoplasm by a complex of heat shock 
proteins. The complex is translocated into the cell nucleus where it inhibits the 
transcription of several pro-inflammatory cytokines, resulting in a decreased 
inflammatory response through reduced production of IL-1, IL-2, IL-6, IFN-γ and TNF-
α (Figure 6).94 
4.5  Polyclonal antibodies
Anti-thymocyte globulin (ATG) is prepared by inoculating rabbits with human 
lymphocytes. The purified immunoglobulin fraction contains antibodies directed 
against many different cell-surface molecules expressed on T cells, B cells, NK cells 
and macrophages and is used to treat acute allograft rejection.9 The administration 
of ATG results in rapid and profound lymphopenia in the majority of patients, 
probably due to complement mediated cell lysis and the uptake of opsonised T cells.96 
In addition to depletion, polyclonal antibodies have been described to cross-link the 
TCR, causing partial T cell activation and the induction of T cell anergy.97 
4.6  Monoclonal antibodies
The development of monoclonal antibodies (mAb), directed against cell types or 
activation markers, has allowed more specific targeting of alloreactive cells and their 
signaling pathways. In transplantation, mAbs used for immunosuppression include 
daclizumab and basiliximab, a humanized and chimeric antibody directed against 
CD2, the α-chain of the IL-2 receptor, respectively.98;99 The IL-2 receptor is rapidly up 
regulated upon T cell activation and blockade of the IL-2 receptor by daclizumab or 
basiliximab does not result in depletion of CD2-bearing cells but rather prevents full 
T cell activation (Figure 6). Interestingly, no clinical side effects have been reported 
following the administration of anti-CD2 antibodies.98  
OKT3 is directed against the CD3 molecule expressed on all T cells. The CD3 complex is 
essential for transducing intracellular signals that result from the engagement of the 
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TCR with antigen and OKT3 administration results in a profound lymphodepletion 
within minutes after administration by massive T cell lysis.100 OKT3 is used to treat 
acute rejection.101 
Alemtuzumab (Campath-1H) is a monoclonal antibody directed against CD2, 
expressed on lymphocytes, monocytes and macrophages.102 Its administration results, 
comparable to ATG, in profound lymphopenia.
4.7  New immunosuppressive drugs 
The drug FK778 is a malononitrilamide103 and its primary mechanism of action 
involves restriction of the de novo pyrimidine synthesis through the inhibition of 
dihydro-orotate dehydrogenase (DHODH), the rate-limiting enzyme in the de novo 
pyrimidine synthesis pathway.104-106 In addition, FK778 is, similar to the related 
compound leflunomide, believed to interfere with the phosphorylation of several 
tyrosine kinases, proteins involved in initial T-cell activation.10;107
FTY720 affects the migration pattern of lymphocytes. After in vivo phosphorylation 
into the active metabolite FTY720-P, it targets the cell receptor for the natural lipid 
sphingosine 1-phosphate (S1P). This results in homing and trapping of lymphocytes 
in the lymphoid organs, with a subsequent reduction in the population of circulating 
lymphocytes.108 
FK778 and FTY720 have been used in clinical trials, but due to lack of benefit over 
other treatment options and the occurrence of side effects, the clinical development 
of these drugs has been interrupted.
Belatacept (LEA29Y) is a second generation cytotoxic-T-lymphocyte-associated antigen 
immunoglobulin (CTLA4-Ig) that blocks the interaction between CD80/86 and CD28 
costimulatory pathways. It is the first biological compound shown to be as effective 
as cyclosporine when administered in combination other drugs. Clinical trials with 
this promising drug are ongoing. 
5 Transplantation tolerance
Transplantation tolerance is defined as a state of donor specific immunological 
unresponsiveness in the absence of immunosuppression while maintaining immune 
responsiveness towards pathogens and 3rd party antigens.109 Anecdotal stories of 
tolerant  transplantation patients after discontinuation of immunosuppression have 
indicated that transplantation tolerance can be achieved in selected cases.110 The 
underlying mechanism responsible for the induction of transplantation tolerance 
has been a continuous subject of interest over the past decades. 
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Figure 6: Intervention places for immunosuppressive drugs. The calcineurin inhibitors cyclosporine 
and tacrolimus inhibit the phosphatase calcineurin. Sirolimus acts on cytokine-signal transduction (signal 3). 
CD25-specific monoclonal antibodies disrupt the binding of interleukin-2 (IL-2) to its receptor. Mycophenolic 
acid (MPA) inhibits guanosine-base synthesis. The monoclonal antibody OKT3 binds the T cell receptor, resul-
ting in T cell depletion. APC, antigen-presenting cell; CTLA4, cytotoxic T lymphocyte antigen 4; GMP, guanosine 
monophosphate; IB, inhibitory B; IMP, inosine monophosphate; JAK3, Janus kinase 3; L, ligand; MTOR, mammalian 
target of rapamycin; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor kappa-B; PKκB, protein 
kinase B; R, receptor; STAT5, signal transducer and activator of transcription 5; TCR, T-cell receptor; TLR4, Toll-
like receptor 4; ZAP70, zeta-chain-associated protein 70. Adapted by permission from Macmillan Publishers Ltd: 
Nature Immunology Reviews (Kahan BD. Nat. Rev. Imm 3, 831-838), copyright (2003) 166.
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The immune system has developed two ways of maintaining tolerance towards self-
antigens, central and peripheral tolerance. Central tolerance is induced in the thymus 
through negative selection of self-reactive T cells. Peripheral tolerance mechanisms 
serve to silence T cells that have escaped the thymic selection process, and include 
deletion, ignorance, induction of T cell anergy, or active regulation by suppressor 
cells. In transplantation, central tolerance mechanisms can be exploited to induce 
transplantation tolerance by intrathymic injection of donor antigens, resulting in 
the deletion of alloreactive T cells.111 Peripheral tolerance inducing mechanisms, in 
particular the use of suppressor cells, are a major focus of  research112;113 Already in the 
1970s, the existence of suppressor cells was proposed.114 In 199, the identification of the 
CD4+CD2high regulatory T cells,11 boosted the field of transplantation tolerance.     
5.1  CD4+CD25high regulatory T cells (Treg)
In 199, Sakaguchi et al. revealed that depletion of the subpopulation of CD4+ T cells that 
expressed CD2, the α-chain of the IL-2 receptor, resulted in the development of several 
autoimmune diseases in mice.11 Soon afterwards, a comparable counterpart of these 
cells, comprising approximately -10% of peripheral blood CD4+ T cells, was identified in 
man.116-119 Naturally occurring Treg emerge from the thymus as a separate cell lineage and 
play a crucial role in maintaining peripheral tolerance towards self-antigens.120 Next to 
CD2, Treg express CTLA-4, GITR, CD103 and the forkhead transcription factor FoxP3,120-122 
and IL-2 signaling is critically important for survival of Treg in the periphery.123;124 Freshly 
isolated Treg are anergic, as they fail to proliferate upon TCR stimuli in vitro, a state 
which can be rescued by the addition of exogenous IL-2.116-119 Following antigen-specific 
activation, Treg are capable of suppressing the effector function of CD4+CD2- T cells,116-119 
CD8+ T cells,12 NK cells,126;127 and  B cells128. The mechanism of action of suppression by 
naturally occurring Treg has yet to be fully elucidated but was shown to depend on cell-
cell contact rather than on cytokine dependent mechanisms.116-118 Accumulating evidence 
is presented that, next to regulating autoimmunity, Treg are capable of inhibiting the 
alloimmune response as well.109;120;129-132    
5.2  Other regulatory T cell subsets
Next to the naturally occurring Treg, a number of other human T cell subsets with 
regulatory activity have been reported, including TR1 cells,
133 TH3 cells,
134 NKT cells,13 
CD8+CD28- T cells,136 CD8+CD103+ T cells,137 CD3+CD4-CD8- T cells,138 and γδ T cells 139. 
TR1 regulatory T cells were first described to arise in vitro after stimulation of CD4
+ T cells 
in the presence of IL-10 and are capable of producing large amounts of IL-10 and TGF-
β.133 A recent study showed that treatment of mice with IL-10 and rapamycin induced 
tolerance in diabetic mice, and that tolerance could be transferred by adoptive transfer 
of TR1 regulatory T cells.
140
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TGF-β producing TH3 regulatory T cells have been identified as regulators of oral 
tolerance in vivo and in vitro.134 Oral administration of antigen has been shown 
to induce tolerance in a number of autoimmune diseases. In transplantation, oral 
delivery of donor antigen was shown to prolong graft survival in a murine cardiac 
model, indicating that oral delivery of allo-antigen may suppress anti-donor 
responses.141 
NKT cells, also referred to as invariant NKT cells, are restricted by a non-polymorphic 
MHC-class I like molecule CD1d that presents self-antigen glycolipids. Although 
their exact role remains unclear, NKT cells have been associated with the control 
of a number of autoimmune diseases.13;142;143 In transplantation, NKT cells were 
able of preventing graft-versus host disease (GVHD) after allogeneic bone marrow 
transplantation.144
CD8+CD28- regulatory T cells, described to arise after repetitive allo-stimulation in 
vitro,14 were capable of rendering DC tolerogenic resulting in failure to stimulate 
CD4+ T cells.136 In mice, the transfer of CD8+CD28-, but not CD8+CD28+ T cells could 
suppress the development of autoimmunity.146 CD8+CD28- T cells have been detected 
in the peripheral blood of operational tolerant transplant patients, but a correlation 
between the presence of CD8+CD28- T cells and the onset of tolerance has not been 
reported.147;148 
CD8+CD103+ T cells form a small subset of CD8+ T cells in normal in-vivo conditions, 
but increased numbers of CD8+CD103+ T cells can be induced after allo-stimulation 
in vitro.137 These in-vitro induced CD8+CD103+ T cells produce large amounts of IL-10 
and are potent inhibitors of T cell proliferation. So far, no reports are available on the 
presence of regulatory CD8+CD103+ T cells in vivo. 
CD3+CD4-CD8- (DN) regulatory T cells were first isolated from tolerant mice that had 
received donor lymphocyte transfusions prior to transplantation.138 DN regulatory T 
cells are able to kill alloreactive CD8+ T cells via the Fas-FasL pathway and to inhibit 
the proliferation and effector function of alloreactive CD4+ T cells.    
Finally, innate T cells that express a γδ TCR rather than an αβ TCR are abundantly 
present in epithelium-rich organs such as the skin, intestine and reproductive tract, 
and have been shown to act as regulatory cells in autoimmunity.139 However, their 
role in the induction of transplantation tolerance remains to be established.
5.3  Immunosuppressive drugs and regulatory T cells 
While there is increasing evidence for the importance of regulatory T cells in the 
induction of transplantation tolerance, the exact mechanism responsible for 
tolerance induction after transplantation remains to be elucidated. Regarding the 
maintenance of immune homeostasis, it appears important that there is a correct 
balance between effector/memory and regulatory mechanisms.26;149;10 Tipping the 
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balance towards alloreactivity, as a result of e.g. insufficient suppression of effector 
mechanisms, increases the risk of allograft rejection while tipping the balance 
towards alloregulation will favor the induction of transplantation tolerance. In 
this light, it is critically important to know the impact of immunosuppressive drug 
administration on the presence and function of regulatory T cell subsets.
6 Immunological monitoring
The better understanding of the immunological processes involved in rejection 
and tolerance has turned focus towards the development of strategies to promote 
the induction of transplantation tolerance. Accurate assessment of the immune 
status of the transplant recipient, using in vitro monitoring assays, is important 
in this strategy for a number of reasons.11;12 First of all, monitoring the evolution 
of anti-donor responses in individual transplant patients can be used to unravel 
the mechanisms of tolerance induction. Secondly, given the detrimental effects 
associated with immunosuppressive drug administration, immunological 
monitoring can be used to identify transplant patients in who (near) tolerance has 
developed and immunosuppression can be tapered. Thirdly, the effectiveness of 
potentially tolerogenic therapeutic strategies can be determined. Fourthly, as new 
drugs and biological agents are introduced, monitoring assays are vitally important 
in determining whether they are ‘tolerance-promoting’ or whether they impede the 
development of immune tolerance. 
A number of techniques have been used over the years to characterize alloreactive 
anti-donor responses. Early attempts to characterize alloreactivity have focused on 
the functional capacity of alloreactive T cells in mixed lymphocyte reactions (MLC), 
but these assays showed little predictive value in transplantation.13 More detailed 
information was provided by MLC-based limiting dilution assays, estimating the 
precursor frequencies of CTL (CTLp) and IL-2 producing helper T cells (HTLp).14 In 
bone marrow transplantation, high CTLp frequencies were associated with prolonged 
leukemia free survival time.1 However, the benefit of CTLp assessment in solid 
organ transplantation remains controversial.16;17 Using Elispot assays, low numbers 
of donor-specific IFN-γ producing T cells were associated with stable long-term renal 
function.18;19
In contrast to alloreactivity, studies on the characterization of alloregulatory 
mechanisms following transplantation are limited, which is mainly due to the low 
number of Treg in the blood circulation. The indirect assessment of Treg function 
in depletion assays, showed that Treg are able to regulate anti-donor responses after 
transplantation,160;161 but firm evidence for their role in protection against rejection 
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remains to be provided. Reports on Treg function in a number of autoimmune studies 
have indicated that a defective function rather than decreased numbers of Treg were 
associated with the onset of disease.162;163 
Aims and outline of this thesis
The central aim of the research described in this thesis was the identificaton of 
one or more immunological markers that could be used to identify transplant 
patient in whom immunosuppression can be safely reduced. At our renal transplant 
center, an immunosuppression treatment regimen was employed that included the 
withdrawal of a calcineurin inhibitor in immunological low-risk patients with stable 
graft function. We evaluated a number of immunological markers in patients who 
experienced an acute rejection following the reduction of immunosuppression and 
compared these with findings in patients in whom immunosuppression was safely 
reduced. 
After an introduction on the immunological processes involved in transplantation in 
chapter 1, the results of the immunological monitoring of renal transplant patients 
are described in chapters 2 to . In chapter 2, an in vitro Treg expansion protocol 
is described that allows functional analysis of small number of Treg without loss 
of function. Evaluation of T cell markers, including the analysis of Treg function, 
is described in chapter 3. The predictive value of NK cell alloreactivity, based on 
KIR gene analysis, on the development of acute rejection is described in chapter 4. 
In chapter 5, the impact of circulating HLA antibodies on the occurrence of acute 
rejection is addressed.
Next, the impact of daclizumab, a monoclonal antibody directed against the α-
chain of the IL-2 receptor (CD2), on the size and function of the naturally occurring 
CD4+CD2high regulatory T cell population was investigated in chapter 6.  
Finally, in chapter 7 and chapter 8, the effects of FK778, an immunosuppressive drug 
under consideration for use in clinical therapy, on alloreactive CD4+ and CD8+ T cells 
respectively are described.  
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Abstract
Regulatory T cell (Treg) function is associated with immune tolerance and could 
serve as a biomarker for optimization of immunosuppressive regimens. This is 
hampered by the limited number of Treg in the blood circulation; functional Treg 
analysis requires large volumes of blood or is dependent on indirect analysis. A more 
attractive strategy is the ex vivo expansion of Treg, provided the original T cell pool 
remains unaltered. Here, we show that it is possible to ex vivo expand Treg from 
limited amounts of blood, preserving the original TCR Vβ repertoire and suppressive 
capacity. The protocol proved successful in selected renal transplant recipients and 
leukopenic patients. Sampling of 10–20 ml blood sufficed; Treg numbers increased 
over 100-fold during the 2–3 week expansion period, easily reaching cell numbers 
required for functional analysis (>106 cells). This protocol will facilitate the monitoring 
of Treg function in patients in order to address the role of Treg in transplantation 
tolerance.
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Introduction
Transplantation tolerance is defined as a state of donor-specific unresponsiveness in 
the absence of chronic immunosuppression, while preserving responsiveness towards 
pathogens and third party antigens.1 Although a number of tolerant transplant 
recipients have been described,2 the mechanisms responsible for the induction of 
tolerance in these cases are not clear. From experimental studies it is known that 
clonal deletion, T cell anergy and active regulation by regulatory T cells can all be 
involved in tolerance induction.3 Many types of regulatory T cells have been described 
so far, but the best defined population is the subset of CD4+ T cells that expresses the 
highest levels of CD2, the α-chain of the IL-2 receptor, and this subset comprises 
approximately 1–2% of the total CD4+ T cell population.4 These CD4+CD2high regulatory 
T cells (Treg) are involved in the maintenance of tolerance towards self-antigens, but 
have also been shown to regulate responsiveness towards allo-antigens.1; Therefore, 
donor-specific CD4+CD2high regulatory T cells might be one of the key players in 
the induction and maintenance of transplantation tolerance. If so, the presence of 
CD4+CD2high regulatory T cells with donor-specificity in the peripheral circulation 
could potentially serve as a marker to identify a tolerant state in transplant recipients 
and could therefore guide the tapering of individual immunosuppressive regimens. 
Several studies have investigated the number and function of the CD4+CD2high 
regulatory T cells in human immune disorders, including autoimmune diseases and 
graft versus host disease (GVHD).6-11 These studies showed that there was indeed a 
defect in the function rather than the number of the CD4+CD2high regulatory T cells 
associated with disease. Therefore, post-transplantation immunological monitoring 
should also include the functional analysis of CD4+CD2high T cells. A major practical 
obstacle, however, is the limited number of CD4+CD2high regulatory T cells in the 
peripheral blood circulation. To circumvent this problem in previous studies, the 
functional capacities of Treg were assessed indirectly by comparing the response of 
whole CD4+ T cells with that of a CD2+ T cell depleted population.12 In cases where 
direct evidence was presented, it appeared necessary to draw large volumes of blood 
from the patients which is highly undesirable for longitudinal monitoring studies. 
A possible solution to this problem is the ex vivo expansion of the CD4+CD2high 
regulatory T cells, thereby permitting repetitive sampling of relatively small blood 
volumes. The expansion of human CD4+CD2+ regulatory T cells in vitro has been 
described before.13-16 However, the protocols described were used for the expansion of 
regulatory T cells isolated from healthy individuals at relatively high cell densities. It 
is not known whether these protocols can be directly translated into use in transplant 
patients and whether they can be adjusted to lower cell numbers. Furthermore, it 
is of critical importance to verify that the CD4+CD2high regulatory T cell pool is 
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not significantly altered by ex vivo expansion. In this study, we have developed a 
protocol for the ex vivo expansion of CD4+CD2high regulatory T cells isolated from 
small amounts of peripheral blood of transplant recipients, thereby facilitating the 
monitoring of CD4+CD2high regulatory T cell function.
Materials and methods
Transplant patients
All patients received a renal allograft (first graft) at the Radboud University Nijmegen 
Medical Centre. Immunosuppressive therapy consisted of tacrolimus, mycophenolate 
mofetil and prednisolone. Blood samples from transplant patients were collected 
after informed consent. Buffy coats from healthy blood donors were obtained from 
the Sanquin Blood Bank (Region South East, Nijmegen, the Netherlands).
Cell isolation
Buffy coats from healthy blood donors (Sanquin Blood Bank, Region South East, 
the Netherlands) and blood samples from transplant recipients were obtained with 
informed consent. Peripheral blood mononuclear cells (PBMC) were isolated by density 
gradient centrifugation using Lymphoprep (Nycomed Pharma AS,Oslo, Norway) and 
LeucoSep® (Greiner Bio-One, Frickenhausen, Germany) and stored in liquid nitrogen 
until further use. CD4+ T cells were purified from PBMC by negative selection using 
monoclonal antibodies (mAb) directed against CD8 (RPA-T8), CD14 (ME2), CD16 (3G8), 
CD19 (4G7), CD33 (P67.6) and CD6 (B19) (BD-Biosciences, Erembodegem, Belgium) 
combined with sheep anti-mouse Ig-coated magnetic beads (DAKO, Glostrup, 
Denmark). This resulted in a CD4+ T cell enrichment of >9%. The resultant CD4+ T cells 
were incubated with CD2-PE conjugated antibody (clone MA21, BD Bioscience, NY, 
USA). CD4+CD2high and CD4+CD2neg control cells were separated using high purity 
flow cytometric cell sorting (Altra flow cytometer, Beckman Coulter, Miami, USA), 
typically resulting in around 9% purity. Sorted CD4+CD2high and CD4+CD2neg T cells 
were used immediately after isolation. Splenocytes were isolated from small fractions 
of spleen tissue obtained from deceased donors. The spleen tissue was minced in PBS 
supplemented with 0.3% sodium-citrate and the cell suspension was passed over a 
sterile 74 μM netwell filter (Costar, Corning International, NY, USA). The splenocytes 
were isolated from the spleen suspension by density gradient centrifugation. The 
cells were stored in liquid nitrogen until further use. HLA typing was conducted 
according to ASHI standards.
Flow cytometry
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Cells were phenotypically analyzed by four color flow cytometry. Briefly, cells were 
washed twice with PBS containing 0.2% BSA and labeled for 20 min with the antibodies 
of interest conjugated with FITC, PE, ECD or PC. After washing, 0.–1.0×104 living 
cells were collected and analyzed on a XLA Coulter flow cytometer (Beckman Coulter, 
Fullerton, CA). Isotype matched antibodies were used to define marker settings. The 
following conjugated antibodies were used: CD2-PE (BD-Biosciences, NY, USA), CD27-
FITC (Dako, Glostrup, Denmark), CD3-ECD, CD4-ECD, CD8-ECD (Beckman Coulter 
Corporation, Miami, FI, USA), CD62L-ECD, CD4-PC and CD8-PC  Immunotech, 
Marseille, France). Cell purity of the subsets after cell sorting was analyzed on the 
Altra flow cytometer, as part of the cell sorting procedure.
Analysis of T cell receptor (TCR) rearrangement by Vβ analysis
The TCR Vβ repertoire of CD4+CD2high and CD4+CD2neg T cells was analyzed using flow 
cytometry. The CD4+ T  cells were stained with CD2-PC (MA-21, BD Biosciences, NY, 
USA) in combination with PE-conjugated antibodies directed against 21 Vβ families 
(Immunotech, Marseille, France), covering approximately 70% of the total human 
TCR Vβ repertoire. Cells were gated based on CD2 expression (CD2high and CD2neg) 
and analyzed or Vβ expression.
Polyclonal in vitro expansion of CD4+CD25high regulatory T cells
All cultures were conducted in 96-well round bottom plates (Greiner, Frickenhausen, 
Germany) in 200 μl culture medium (RPMI-1640 medium supplemented with 20 mM 
L-glutamine, 20 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (all 
from Gibco) and 10% heat-inactivated human pooled serum (HPS)). CD4+CD2high and 
CD4+CD2neg cells were expanded using αCD3/αCD28-coated expander beads (Dynal; 
cell/bead ratio 1:1) in 200 μl culture medium, supplemented with T cell growth factors 
(TCGF) (1 U/ml rIL-2 (Proleukine) and 10 ng/ml rIL-1 (Biosource International)). Where 
indicated, 2×104 γ-irradiated autologous feeder PBMC were added. The content of the 
wells was split every 2–3 days, and fresh medium with TCGF was added to the wells. 
After 14–21 days, cells were harvested and rested 2–3 days prior to functional analysis. 
Expansion rates were calculated as follows: expansion rate = (# cells after expansion 
/# cells at start of culture). Expansion rates were compared using a Kruskal–Wallis 
test for three separate groups or Mann–Whitney U-test for comparison between two 
groups. P-values ≤0.0 were considered statistically significant.
Stimulation assays to study T cell anergy in expanded CD4+CD25high Treg
T cell anergy was examined in stimulation assays. 2×104 (expanded) CD2high or 
CD2neg control T cells were stimulated with 2×104 αCD3/αCD28-coated expander 
beads in the presence or absence of 1 U/ml IL-2. Proliferation was examined by 
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3H-thymidine incorporation using a Gas Scintillation Counter (Canberra Packard, 
Matrix 96 Beta-counter, Meriden, USA) at day 3. The 3H-incorporation is expressed as 
mean ± S.D. counts per  min of triplicate measurements.
Primary mixed lymphocyte cultures
Primary mixed lymphocyte cultures (MLC) were performed by culturing ×104 
isolated PBMC with ×104 HLA  mismatched γ-irradiated (30 Gy) stimulator PBMC. 
Proliferation was analyzed at days  and 6 by 3H-thymidine incorporation. 
Co-cultures to study suppressive capacity of (expanded) CD4+CD25high Treg
The regulatory capacity of the (expanded) CD2high regulatory T cells and CD2neg 
control T cells was studied in co-culture suppression assays. The cells of interest 
were added to a newly set-up primary MLC consisting of original responder PBMC 
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Figure 1. Isolation and expansion of CD4+CD25high Treg from healthy individuals. (A) CD4+CD25high 
and CD4+CD25neg T cells were isolated from purified CD4+ T cells using flow cytometric cell sorting. CD25-
PE expression (x-axis) plotted against CD4 expression (y-axis) of the total CD4+ (left panel), CD4+CD25high 
(middle panel) and CD4+CD25neg (right panel) T cells, as analyzed on the Altra flow cytometer, as part of the 
cell sorting procedure. (B) Expansion rates (y-axis) (= # cells after expansion / # cells at start of culture) 
of CD4+CD25high from healthy individuals expanded ex vivo at various cell densities in the presence or ab-
sence of autologous, γ-irradiated, feeder PBMC. Ns = not significant. (C) Purity of the CD4+CD25high (left) 
and CD4+CD25neg (right) T cells after expansion, analyzed on the XLA flow cytometer. One representative 
experiment out of three is presented
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stimulated with γ-irradiated stimulator PBMC. For transplant recipients, the 
(expanded) CD2high and CD2neg T cells were added to a primary MLC consisting of 
responder PBMC from the transplant recipient, stimulated with either γ-irradiated 
splenocytes from the graft donor or fully HLA-mismatched third party splenocytes. 
Proliferation was examined by 3H-thymidine incorporation at days  and 6. For 
each individual analysis, he time point yielding the highest 3H counts was used to 
calculate the suppressive potential. Relative suppression was calculated according 
to the following equation: %-suppression = (1−(3H-incorporation co-culture/ 3H-
incorporation control MLC)×100%). The results were compared using an unpaired 
Student’s t-test. P-values ≤0.0 were considered statistically significant.
Results
Ex vivo expansion of CD4+CD25high regulatory T cells from small amounts of blood
With the aim of designing a protocol that allows successful ex vivo expansion 
of purified CD4+CD2high Treg from as few PBMC as possible, we started out by 
optimizing the culture conditions using CD4+CD2high Treg from healthy individuals. 
CD4+CD2high Treg and CD4+CD2neg control cells were isolated from PBMC using flow 
cytometric cell sorting. Purity was typically ≥90% (Fig. 1A). Following optimization 
studies, including the determination of the minimum required cell density and 
evaluation of the effect of feeder cell addition, the expansion protocol was validated 
by phenotypic and functional analysis of the expanded cells. First, multiple cell 
densities were tested, namely 2.×104, 1×104 and 0.3×104 cells/well. In two out of 
three experiments, the CD4+CD2high Treg were easily expanded at all tested initial 
cell densities. In the remaining experiment, the culture starting with 0.3×104 cells/
well showed no proliferation, while the same cells could be expanded at higher 
initial cell densities. The expansion rates of the CD4+CD2high Treg at the various cell 
densities showed that the cell density had no significant effect on the expansion rate 
of the CD4+CD2high Treg (Fig. 1B). Based on these results, the optimum cell density 
was defined at 1×104 cells/well. The CD4+CD2neg control T cells were easily expanded 
at all tested initial cell densities. Other studies have shown that the addition of 
feeder cells during expansion can facilitate the expansion of CD4+CD2high Treg.17 
In the presence of 2×104 autologous, γ-irradiated feeder PBMC, increased expansion 
rates were observed compared with expansion in the absence of feeder cells (Fig.1). 
However, this increase was relatively small and since the addition of feeder cells poses 
the risk of contamination of the CD4+CD2high Treg with other cell types, expansion 
in the absence of feeder cells was preferred. Using these optimized conditions, 
CD4+CD2high Treg, isolated from healthy individuals, could be expanded on average 
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10-fold over a period of 2 weeks. After expansion, cell purity was maintained, since 
the CD4+CD2high Treg population consisted predominantly of CD3+CD4+ cells and 
was not overgrown by other cell populations (Fig. 1C).
The diversity of the CD4+CD25high Treg pool is maintained after expansion
Next, it remained to be established whether the expanded T cell populations 
retained their original diversity. To this end, the TCR Vβ repertoire of the 
CD4+CD2high Treg was compared before and after expansion. The freshly isolated 
CD4+CD2high Treg showed a broad spectrum of TCR Vβ usage (Fig. 2A). Re-analysis 
of the TCR Vβ repertoire after expansion showed that the TCR Vβ diversity within 
the cell population was unaffected (Fig. 2A). Similar to the CD4+CD2high Treg, the 
TCR Vβ repertoire of the CD4+CD2neg control T cell population was not altered 
following expansion (Fig. 2A).
The phenotype and functional characteristics of the CD4+CD25high Treg pool are maintained 
after expansion
The phenotype of the freshly isolated and expanded CD4+CD2high and CD4+CD2neg 
T cells was compared using flow cytometry. We and others have previously shown 
that CD27 and CD62L are useful markers to differentiate Treg subsets.18,19 The freshly 
isolated CD4+CD2high Treg showed expression of CD27 and CD62L (Fig. 2B). After 
expansion, the distribution of cell surface marker expression on the CD4+CD2high 
Treg was not altered (Fig. 2B). The phenotype of the CD4+CD2neg T cells before and 
after expansion revealed sustained CD27 expression, while the expression of CD62L 
was downregulated on the CD4+CD2neg T cells (Fig. 2B). Finally, the functional 
characteristics of the CD4+CD2high and CD4+CD2neg T cells were analyzed before and 
after expansion. CD4+CD2high Treg are known to be anergic by nature and capable of 
suppressing the proliferation of conventional T cells.20 After stimulation with αCD3/
αCD28 beads, the freshly isolated and expanded CD4+CD2high Treg showed anergy, 
manifested as the absence of proliferation which was reversible by the addition of 
exogenous IL-2 (Fig. 2C). Stimulation of the freshly isolated and expanded CD4+CD2neg 
control T cells showed normal T cell proliferation, even further enhanced by the 
addition of IL-2 (Fig. 2C). Analysis of the suppressive capacity of CD4+CD2high Treg 
showed that the freshly isolated Treg inhibited the proliferation of the primary 
MLC in a dose-dependent manner up to 70% at a responder/suppressor ratio of 1:1 
(Fig. 2D). After expansion, the suppressive capacity of the CD4+CD2high Treg was not 
significantly altered (Fig. 2D). The addition of freshly isolated or in vitro expanded 
CD4+CD2neg control T cells did not inhibit the proliferation of responder cells (Fig. 
2D).
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Figure 2. TCR diversity, phenotype and functional characteristics of CD4+CD25high T cells from 
healthy individuals are not affected by polyclonal ex vivo expansion. (A) TCR Vβ diversity was deter-
mined using flow cytometry with PE-conjugated antibodies directed against 21 Vβ families. The percentage of 
positive cells (y-axis) is depicted for each Vβ family (x-axis) before (black bars) and after (white bars) ex vivo 
expansion of CD4+CD25high T cells (upper graph) and the control CD4+CD25neg T cells (lower graph). (B) Cell 
surface expression of CD27 (x-axis) and CD62L (y-axis) on the CD4+CD25high T cells (left panels) and the 
control CD4+CD25neg (right panels) T cells before (upper panels) and after (lower panels) expansion analyzed 
using flow cytometry. The percentage of positive cells is depicted in each plot. (C) The proliferation (y-axis) of 
2×104 CD4+CD25high or control CD4+CD25neg T cells after stimulation with 2×104 αCD3/αCD28 beads for 
3 days in the absence (black bars) or presence (white bars) of 15 U/ml IL-2, before (upper) and after (lower) 
expansion. (D) Suppressive potential of CD4+CD25high and control CD4+CD25neg T cells before and after ex-
pansion was investigated in a co-culture suppression assay. Percentage inhibition of proliferation of a primary 
MLC at day 6 (y-axis), consisting of 5×104 responder PBMC stimulated with 5×104 fully HLA-mismatched γ-ir-
radiated stimulator PBMC, is shown with increasing numbers (x-axis) of CD4+CD25high T cells (left panel) or 
control CD4+CD25neg T cells (right panel) before (black circles) or after (white circles) ex vivo expansion. One 
representative experiment out of three is presented.
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Expansion of CD4+CD25high regulatory T cells from renal transplant recipients 
Four renal transplant recipients, receiving maintenance immunosuppression with 
stable graft function and without a history of rejection episodes, were selected to 
validate the expansion protocol. All four patients had a normal leukocyte count. 
The percentage of CD4+CD2high Treg of the total CD4+ T cell pool was comparable to 
healthy individuals (data not shown). Isolation of the CD4+CD2high Treg, from these 
four patients, yielded 0.7×103, 1.4×103, 2.8×103 and 4.×103 cells/ml, respectively. In 
these patients, the CD4+CD2neg T cell yield was 20×103, 40×103, 22×103 and 20×103 cells/
ml, respectively. The isolated CD4+CD2high and CD4+CD2neg T cells were expanded 
using the optimized ex vivo expansion protocol as described above. CD4+CD2high 
Treg from three transplant recipients were expanded for 2 weeks, resulting in a 
120-, 140- and 390-fold expansion. In the remaining case, the cells were expanded 
for 3 weeks, resulting in a 1000-fold expansion. For comparison, expansion of the 
CD4+CD2neg T cells resulted in a 280-, 40- and 690-fold expansion after 2 weeks and 
an 180-fold expansion after 3 weeks. Overall, the expansion rates of CD4+CD2high 
Treg from renal transplant recipients were not different from the figures obtained in 
healthy individuals using the same protocol (Fig. 3B). Following expansion, purity of 
the CD4+CD2high Treg pool was preserved together with CD2 expression (Fig. 3C).
Functional analysis of expanded CD4+CD25high regulatory T cells from renal transplant 
recipients
In accord with the results observed in healthy individuals, the original diversity of 
the CD4+CD2high and the CD4+CD2neg T cell populations, assessed by their TCR Vβ 
repertoire, was conserved after expansion (Fig. 4A). Moreover, the freshly isolated 
and the expanded CD4+CD2high Treg were functionally anergic (Fig. 4B). Addition of 
freshly isolated or expanded CD4+CD2high Treg from transplant recipients resulted 
in a similar dose-dependent inhibition of proliferation of the primary MLC (Fig. 4C), 
indicating that the suppressive capacity of the CD4+CD2high Treg was also conserved 
following expansion. The CD4+CD2neg control T cells from these patients, either 
freshly isolated or expanded, did not show T cell anergy or suppression of the primary 
MLC (Fig. 4B and C, respectively). In transplant recipients, several factors, such as the 
use of anti-proliferative drugs, can result in decreased numbers of lymphocytes in the 
peripheral blood. To assess whether our protocol can also be applied in leukopenic 
patients, blood was collected from two patients with a severe leukopenia (<0.9×109/
l), both suffering from acute myeloid leukaemia. Isolation of the CD4+CD2high Treg 
yielded 49 and 610 cells/ml, respectively. This indicated that in these cases 20 ml 
of blood was sufficient to obtain 104 CD4+CD2high Treg, the minimum cell number 
required for ex vivo expansion. The expansion rates of the CD4+CD2high Treg from 
leukopenic patients were comparable to those observed in transplant recipients 
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(Fig. 3B) and following expansion the CD4+CD2high Treg were capable of inhibiting 
the proliferation of αCD3/αCD28 stimulated CD4+CD2neg T cells (data not shown). 
Taken together, these data show that CD4+CD2high Treg can be successfully isolated 
and expanded from limited amounts of blood of transplant recipients, even from 
leukopenic patients. 
The ability of CD4+CD25high Treg from renal transplant recipients to suppress donor-specific 
MLC
We utilized the ex vivo expansion protocol to study the ability of the CD4+CD2high 
Treg to suppress an anti-donor MLC. The expanded CD4+CD2high Treg from three 
renal transplant recipients were added to a new primary MLC consisting of 
responder PBMC of the transplant recipient stimulated with splenocytes from either 
the kidney donor or a HLA-mismatched third party donor. In all three patients, 
addition of increasing numbers of expanded CD4+CD2high T cells resulted in a dose-
dependent inhibition of the proliferation of the primary MLC. Notably, in two of 
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Figure 3. Isolation and expansion of CD4+CD25high Treg from renal transplant recipients. (A) 
CD4+CD25high and CD4+CD25neg T cells were isolated from purified CD4+ T cells using flow cytometric cell 
sorting. CD25-PE expression (x-axis) plotted against CD4 expression (y-axis) of the total CD4+ (left panel), 
CD4+CD25high (middle panel) and the CD4+CD25neg (right panel) T cells, analyzed on the Altra flowcytometer, 
as part of the cell sorting procedure. (B) Expansion rates (y-axis) (= # cells after expansion / # cells at start of 
culture) of CD4+CD25high from healthy individuals (left), transplant recipients (middle) and leukopenic patients 
(right). Ns = not significant. (C) Purity of the CD4+CD25high (left) and CD4+CD25neg (right) T cells after expan-
sion, analyzed on the XLA flow cytometer. One representative experiment out of four is presented.
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Figure 4. TCR diversity and suppressive capacity of CD4+CD25high T cells from renal transplant 
recipients are unaffected by polyclonal ex vivo expansion. (A) TCR Vβ diversity was determined using 
flow cytometry with PE-conjugated antibodies directed against 21 Vβ families. The percentage of positive cells 
(y-axis) is depicted for each Vβ family (x-axis) before (black bars) and after (white bars) ex vivo expansion of 
CD4+CD25high Treg (upper graph) and control CD4+CD25neg T cells (lower graph). (B) The proliferation (y-axis) 
of 2×104 CD4+CD25high or CD4+CD25neg T cells after stimulation with 2×104 αCD3/αCD28 beads for 3 days 
in the absence (black bars) or presence (white bars) of 15 U/ml IL-2, before (upper) and after (lower) expan-
sion. (C) The suppressive potential of CD4+CD25high Treg from renal transplant recipients was investigated in 
a co-culture suppression assay before and after expansion. The percentage inhibition of proliferation at day 6 
(y-axis) of naive PBMC (5×104) from the transplant recipient stimulated with fully HLA-mismatched stimulator 
PBMC (5×104) in the presence of increasing numbers of CD4+CD25high (upper) and CD4+CD25neg (lower) T 
cells before (black circles) and after (white circles) ex vivo expansion. One representative experiment out of 
four is presented.
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the three cases, the CD4+CD2high Treg were also capable of inhibiting third party 
alloreactivity to a comparable extent. Comparison of the three individual transplant 
recipients revealed that there were clear differences in the degree of suppression 
at the various responder/suppressor ratios. Taken together, the ex vivo expansion 
protocol presented here, can facilitate longitudinal studies in larger cohorts, both 
for functional analysis of the CD4+CD2high Treg and to address the role for the 
CD4+CD2high Treg in the development of transplantation tolerance.
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Figure 5. Functional analysis of expanded CD4+CD25high from renal transplant recipients. Prolife-
ration of 5×104 PBMC (y-axis) of the three transplant recipients (SR, KD and TH) stimulated with 5×104 γ-ir-
radiated splenocytes from the graft donor (left) or from an HLA-mismatched third party (right) in the presence 
or absence of increasing numbers (x-axis) of expanded CD4+CD25high (white circles) and CD4+CD25neg (black 
circles) T cells. *p<0.05.
6
Chapter2
Discussion
Due to their low number in the peripheral blood circulation, donor-specific 
CD4+CD2high Treg have never before been studied directly in transplant recipients. 
Data provided so far came from,12 who studied the function of the CD4+CD2high Treg 
by comparing CD4+ T cell reactivity before and after depletion of the CD4+CD2high Treg 
subset. The drawback of this kind of depletion assay is that only indirect evidence of 
regulation by CD4+CD2high Treg is provided. The ex vivo expansion protocol presented 
here provides a tool for direct functional analysis of the CD4+CD2high Treg. Using this 
protocol, the functional capacity of the CD4+CD2high Treg pool can be monitored 
to investigate the role of CD4+CD2high Treg in transplantation tolerance (Fig. ). 
Although ex vivo expansion of CD4+CD2high Treg obtained from healthy volunteers 
has been described before,13-16 we optimized and validated the culture conditions 
such that they can be used for the expansion and functional analysis of CD4+CD2high 
Treg from transplant recipients. We also showed that the protocol is applicable to 
leukopenic patients. In this protocol, we isolated Treg on the basis of CD2 expression. 
However, CD2 is not uniquely expressed by Treg, but is also expressed on activated 
conventional T cells, posing the risk of contamination of the Treg pool with activated 
T cells. A more specific marker would be the transcription factor FoxP3, expressed by 
both murine and human regulatory T cells CD4+ regulatory T cells.21;22 However, the 
detection of FoxP3 protein requires intracellular antibody staining for which fixation 
of the cells is mandatory, thereby abrogating the potential of the Treg to proliferate. 
However, although FoxP3 cannot be used as a marker to select the regulatory T 
cells from PBMC, the proportion of FoxP3 expressing cells within the CD4+CD2high 
population is informative. However, due to limited cell numbers, we were not 
able to measure FoxP3 protein expression directly after cell sorting. In addition, 
accumulating data now show that, in the human setting, FoxP3 is also upregulated 
upon activation of conventional CD4+ T cells.19;23 Baecher-Allan et al.24 have shown 
that selection of the CD2high subset of the CD4+CD2+ T cells minimizes the risk 
of co-isolation of activated T cells and optimally yields the human counterpart of 
the murine CD4+CD2+ regulatory T cells. The main components of our protocol are 
stimulation with αCD3/αCD28-coated expander beads in the presence of rIL-2 and 
rIL-1. The addition of γ-irradiated autologous feeder PBMC resulted in a marginal 
increase of cell numbers after expansion, most likely due to the effect of cytokine 
production by the feeder cells. Godfrey et al.16 showed that the use of cell-culture 
supernatants, instead of autologous feeder cells, resulted in comparable increases in 
cell expansion. Because we preferred to avoid the risk of cell contamination, the use 
of feeder cells was discarded. In the absence of feeder cells, an optimal cell density 
is essential for sufficient activation and expansion. For reliable interpretation of the 
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results of functional analysis of CD4+CD2high Treg in patients, it is crucial that the 
diversity of the original population is maintained upon expansion. We showed that 
the TCR Vβ repertoire of the CD4+CD2high Treg was unaltered by ex vivo expansion, 
which is in accord with previously published data.13 Moreover, we demonstrated that 
the expansion protocol did not change the phenotype and suppressive capacity of the 
CD4+CD2high Treg. In conclusion, we present here a protocol for the ex vivo expansion 
of CD4+CD2high Treg from renal transplant recipients. A limited volume of blood, in 
the range of 10–20 ml, suffices for a full functional and phenotypic analysis, even in 
the case of leukopenic patients. This protocol can now be used in a clinical setting, to 
monitor the suppressive capacity and antigen-specificity of CD4+CD2high regulatory 
T cells, not only after transplantation but also in autoimmune disorders.
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Abstract
 Transplant patients would benefit from reduction of immunosuppression providing 
that graft rejection is prevented. We have evaluated a number of immunological 
markers in blood of patients in whom tacrolimus was withdrawn after renal 
transplantation. The alloreactive precursor frequency of CD4+ and CD8+ T cells, the 
frequency of T cell subsets and the functional capacity of CD4+CD2+FoxP3+ regulatory 
T cells (Treg) were analyzed before transplantation and before tacrolimus reduction. 
The results were compared between patients with and without acute rejection after 
tacrolimus withdrawal. 
Prior to tacrolimus reduction, the ratio between memory CD8+ T cells and Treg was 
higher in rejectors compared to non-rejectors. Rejectors tended to have a higher 
ratio between memory CD4+ T cells and Treg, and low ratios (<20) were only observed 
in non-rejectors. Between the time of transplantation and the start of tacrolimus 
withdrawal, an increase in naive T cell frequencies and a reciprocal decrease 
of effector T cell percentages was observed in rejectors. The proportion of Treg 
within the CD4+ T cells decreased after transplantation, but anti-donor regulatory 
capacity of Treg remained unaltered in rejectors and non-rejectors. In conclusion, 
immunological monitoring revealed an association between acute rejection following 
the withdrawal of tacrolimus and 1) the ratio of memory T cells and Treg prior to the 
start of tacrolimus reduction, and 2) changes in the distribution of naive, effector 
and memory T cells over time. Combination of these two biomarkers allowed highly 
specific identification of patients in whom immunosuppression could be safely 
reduced. 
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Introduction
Currently, 1-year graft survival rates after renal transplantation are exceeding 90%. 
However, the life-long administration of immunosuppressive drugs is accompanied 
by many side effects. Next to increased risk of infections and malignancies,1 the use 
of the calcineurin inhibitors (CNI) cyclosporine and tacrolimus is associated with 
nephrotoxicity, which can contribute to long-term graft failure.2;3 Withdrawal of 
CNI, once stable graft function is achieved, has therefore been attempted in several 
studies but was associated with an increased risk for acute rejection.4; On the other 
hand, successful discontinuation of CNI results in improved renal function and 
blood pressure, and long-term follow up of patients after CNI withdrawal has shown 
a favorable outcome.6;7 Thus, it is highly desirable to identify transplant patients in 
whom CNI withdrawal can be successful. To this end, there is a need for in vitro 
monitoring tools.
CD4+ and CD8+ effector T cells play a central role in the pathogenesis of allograft 
rejection.8 CD4+CD2+FoxP3+ regulatory T cells (Treg) are involved in maintaining 
tolerance towards self antigens, and they can regulate alloreactivity as well.9;10 The 
quantification of alloreactivity, in terms of balance between effector cells and Treg, 
might allow the identification of patients at risk for acute rejection. Early attempts 
to characterize alloreactivity have focused on the functional capacity of alloreactive 
T cells in mixed lymphocyte reactions (MLR), but these assays showed little predictive 
value in transplantation.11 Better information was provided by MLR-based limiting 
dilution assays, estimating the precursor frequencies of cytotoxic T lymphocytes (CTLp) 
and helper T cells (HTLp).12 In bone marrow transplantation, high CTLp frequencies 
were associated with prolonged leukemia free survival time.13 However, the benefit 
of CTLp assessment in solid organ transplantation remains controversial.14;1 Using 
Elispot assays, low numbers of donor-specific IFN-γ producing T cells were associated 
with stable long-term renal function.16;17 Moreover, a high pre-transplant reactivity 
to a panel of allogeneic stimulator cells was correlated with an increased risk for 
acute rejection after renal transplantation.18 Protein profiling of serum to predict 
rejection has shown promising results in experimental models, but these data have 
to be confirmed in clinical studies.19
To date, studies on alloreactivity of Treg are limited due to the low number of Treg in 
the circulation. The indirect assessment of Treg function in depletion assays, showed 
that Treg are able to regulate anti-donor responses after transplantation,20;21 but firm 
evidence for their role in protection against rejection remains to be provided. 
In this study, the level of immunosuppression after renal transplantation was reduced 
to a CNI free regimen, and blood samples were collected before transplantation and 
before the start of tacrolimus withdrawal. A number of phenotypical and functional 
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T cell markers were evaluated and compared between patients that experienced an 
acute rejection period following the reduction of immunosuppression and patients 
in whom immunosuppression was reduced successfully. 
Material & Methods
Transplant patients and immunosuppression 
Patients received a renal allograft in our hospital between January 2003 and 
December 2004. Immunosuppression consisted of tacrolimus in combination 
with mycophenolate mofetil (MMF) and prednisolone. Patients received 100 mg 
of prednisolone intravenously during the first 3 days after transplantation and 
subsequently an oral dose of 1-2 mg/day, tapered to a maintenance dose of 0.1 
mg/kg/day. Tacrolimus was started at day 1 or 2 after transplantation at 0.1 mg/
kg/day and the dose was subsequently adjusted to achieve whole-blood trough 
concentrations of 1-20 ng/mL during days 0-14, 10-1 ng/mL during weeks 3-6, and 
-10 ng/mL from week 7. Whole blood tacrolimus concentrations were measured by 
the IMx analyzer (Abbott Laboratories, Abbott Park, IL, USA). MMF was administered 
at 1000 mg twice daily with a dose reduction to 70 mg twice daily at 2 weeks after 
transplantation. Induction therapy with polyclonal or monoclonal antibodies was 
not used.
At 4 months after transplantation, patients were selected for reduction of their 
immunosuppression (including withdrawal of tacrolimus) when they met the 
following inclusion criteria: stable graft function, and at least 1 HLA-B and 1 HLA-DR 
match between donor and recipient. Patients who received a kidney from a HLA-
identical living donor, patients with two or more previously failed grafts, patients 
with PRA > 8%, non-Caucasian patients, and patients that had experienced a steroid-
resistant acute rejection episode after their current transplantation were excluded. 
In addition, patients with severe osteoporosis and patients with bone marrow 
depression were not included. At first instance, MMF was substituted for azathioprine 
(Aza, 3 mg/kg daily). The dose of Aza was adjusted in case of leukocytopenia or 
elevated liver enzymes. When patients did not tolerate a minimum Aza dose of 2 mg/
kg/day, MMF was reintroduced. Two months later, six months after transplantation, 
the tacrolimus dose was gradually reduced to zero over a period of 4 weeks. 
Meanwhile, the prednisolone dose was increased to 0.1 mg/kg/day. The resulting 
immunosuppressive therapy after conversion consisted of azathioprine (at least 2 
mg/kg/day; otherwise MMF 70 mg twice daily) and prednisolone (0.1 mg/kg/day). 
All patients were evaluated for acute rejection episodes during the first 6 months 
after withdrawal of tacrolimus. IRB approval was obtained for this study.
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Cell isolation and culture conditions
Blood samples (20 ml) were collected before transplantation (T0) and prior to 
tacrolimus withdrawal (T1). Donor cells were obtained from peripheral blood 
(living donors) or spleen tissue (deceased donors). For 3rd party controls, buffy coats 
were obtained from healthy blood donors (Sanquin Blood Bank region South East, 
Nijmegen, the Netherlands). Cell isolation and culture were conducted as described 
elsewhere.27 HLA typing was conducted according to ASHI standards. 
Expression of cell surface markers and of FoxP3
PBMC (1*10) were labeled with fluorochrome-conjugated monoclonal antibodies in 
PBS-BSA buffer for 20’ at room temperature (RT) in the dark. Samples were measured 
on a Coulter Epics XL flowcytometer (Beckman Coulter, Fullerton, CA) and analyzed 
using Coulter Epics Expo 32 software. The following antibodies were used: anti-
CD8-FITC (DK2), anti-CD27-FITC (M-T271), anti-CD4RO-FITC (UCHL1), anti-CD2-PE 
(M-A21), anti-CD28-PE (CD28.1), anti-CD4RA-PE (HI100), anti-CD3-ECD (UCHT1), 
anti-CD62L-ECD (DREG6), anti-CD8-PC (B9.11), and anti-CD4-PC (13B8.2). FoxP3-
FITC (PCH101) staining was performed according to the manufacturer’s procedures 
(eBioscience, San Diego, CA, USA). Appropriate isotype control mAbs were used for 
marker settings.
CFSE-based MLR
The number of donor- and 3rd party-reactive CD4+ and CD8+ T cells was determined 
using a CFSE-based mixed lymphocyte reaction (CFSE-MLR).29;30 Patient PBMC (10 x 
106) were labeled with 1 μM CFSE (Molecular Probe, Eugene, OR, USA) in CFSE labeling 
buffer (PBS containing 0.02% HPS) for 10 minutes at RT in the dark and the labeled 
cells  (1 x 10) were stimulated with irradiated (30 Gy) PKH (Sigma-Aldrich, St Louis, 
USA) labeled donor cells (1 x 10) in 96-wells round bottom plates. As controls, 
patient PBMC were cultured with either PKH labeled irradiated pooled 3rd party 
PBMC, cultured alone (negative control), or cultured in the presence of αCD3/αCD28 
expander beads (positive control). At day 6, the cells were stained for CD4 and CD8.    
Expansion and functional analysis of CD4+CD25high regulatory T cells
Patient PBMC (-10 x 106) were incubated with CD4-FITC (clone MT310, Dako, Glostrup, 
Denmark) and CD2-PE (clone M-A21, BD Bioscience, USA) for 20 minutes at RT in the 
dark. CD4+CD2high and CD4+CD2neg control cells were separated using high purity 
fluorescence activated cell sorting (FACS, Altra flowcytometer, Beckman Coulter, USA). 
Sorted CD4+CD2high and CD4+CD2neg T cells were expanded as described previously.27 
To analyze their suppressive potential, a primary MLC was set up, consisting of 4th 
party responder PBMC and donor or 3rd party stimulator cells. Fourth party responder 
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PBMC were used instead of patient PBMC because of the low proliferative response 
of the patient PBMC in response to the donor stimulator cells resulting from close 
HLA matching, which hampered the read-out of the putative suppression by Treg. 
The expanded CD4+CD2high and CD4+CD2neg (control) cells were added at increasing 
ratios to this MLC.
Statistical analysis
Patients who experienced an acute rejection after tacrolimus withdrawal and a 
control group of non-rejecting patients, were matched for the following items: age 
of donor and recipient (<0 versus ≥0), number of HLA-mismatches, percentage PRA 
(<%, ≥%), and first or re-transplantation. Data obtained from flow cytometry and 
CFSE-MLR analyses were compared between groups using a Kruskal-Wallis analysis. 
Differences between two groups at a given time point were analyzed using a Mann-
Whitney U-test. For analysis of changes in time within patients a Wilcoxon signed 
rank test was used. Recognizing the fact that multiple statistical analyses were 
performed, p-values ≤ 0.01 were considered statistically significant.
Results
Patient characteristics
Sixty-six patients fulfilled the inclusion criteria and were treated according to the 
protocol. Twenty-four patients (36%) experienced an acute rejection following the 
withdrawal of tacrolimus. All but 2 of these rejections were histologically proven 
according to the Banff ’97 classification. We analyzed blood samples from 1 rejectors 
Table 1. Patient characteristics
Rejectors (n=15) Non-rejectors (n=28) p-value
Gender (male/female) 9/6 18/10 0.782
Patient age (years) 43 ± 15 40 ± 13 0.647
Donor age (years) 49 ± 14 49 ± 10 0.889
Donor living/deceased 6/9 8/20 0.446
HLA mismatches (0/ ≥1)  HLA-A     5/10 15/13 0.205
                                          HLA-B 4/11 9/19 0.709
                                          HLA-DR 0/15 8/20 0.022
Cold ischemia time (hours)* 20 ± 8 17 ± 5 0.300
PRA pretransplant (≥ 5%) 1 6 0.188
Retransplantations 0 6 0.053
Acute rejection prior to inclusion 1 0 0.167
* deceased donors only
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Figure 1. The frequency of effector, memory and regulatory T cell subsets in the peripheral blood 
of renal transplant patients immediately before the start of tacrolimus dose reduction (T1). R = 
rejectors (n=14), NR = non-rejectors (n=23). (A) The percentage of naïve (TN, CD45RA
+CD62L+), effector (TE, 
CD45RA+CD62L-), central memory (TCM, CD45RO
+CD62L+) and effector memory (TEM, CD45RO
+CD62L-) 
T cells within the total CD4+ T cell subset. R vs. NR = not significant. (B) As described under A, for CD8+ T 
cells. R vs. NR = not significant. (C) The percentage of CD4+CD25+FoxP3+ regulatory T cells (Treg). R vs. NR = 
not significant. (D) The ratio between the percentage of memory T cells and the percentage of Treg. Data are 
missing for four patients (2 R, 2 NR).
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(cases) and 28 non-rejectors (matched controls). Clinical characteristics did not differ 
significantly between rejectors and non-rejectors (Table 1). 
Frequencies of effector, memory and regulatory T cell subsets
T cell subset distribution was analyzed in blood samples collected before the start of 
tacrolimus dose reduction (T1). Using antibodies directed against CD62L and isoforms 
of CD4, naive (TN, CD4RA
+CD62L+), effector (TE, CD4RA
+CD62L-), effector memory 
(TEM, CD4RO
+CD62L-) and central memory (TCM, CD4RO
+CD62L+) T cell subsets were 
identified.22;23 Neither in the CD4+ T cell pool, nor in the CD8+ T cell compartment 
did the distribution of the four subsets differ between rejectors and non-rejectors 
(Figure 1). 
Immediately prior to the start of tacrolimus dose reduction, the median frequency of 
Treg was 1.6% and 2.0% of the total CD4+ T cell subset for rejectors and non-rejectors, 
respectively (NS; Figure 1C). 
Next to the size of the T cell subsets, the balance between reactive and regulatory T 
cells might be an important determinant of the risk of rejection.24-26 Interestingly, 
the ratio between the percentage of CD8+ memory T cells (TEM and TCM combined) 
and the percentage of Treg was significantly higher in rejectors compared with non-
rejectors (p=0.007). In the CD4+ T cell compartment, a comparable trend was observed 
(p=0.031), and low ratios (< 20) were only observed for non-rejectors (Figure 1D).   
CD4+ and CD8+ alloreactive T cell precursor frequency and mitotic activity 
The precursor frequencies of donor reactive CD4+ and CD8+ T cells ranged from 0.1-
6.8%, increasing with the number of HLA mismatches, and did not differ between 
rejectors and non-rejectors (Figure 2A). Differences were neither observed in the 
precursor frequencies of 3rd party-reactive CD4+ or CD8+ T cells (Figures 2B).
The number of mitotic events was higher in third party alloreactive T cells as compared 
to donor reactive CD4+ and CD8+ T cells, but did not differ between rejectors and non-
rejectors (Figures 2C and 2D). 
Suppressive potential of Treg
The suppressive capacity of peripheral blood Treg was studied in 9 patients ( rejectors 
and 4 non-rejectors). CD4+CD2high were isolated from PBMC. To obtain sufficient 
cell numbers for functional analysis, the cells were expanded using a previously 
validated expansion protocol.27 Treg of each transplant patient showed potent ability 
to suppress both anti-donor and anti-3rd-party responses. Considerable variation 
was observed in the suppressive potential of Treg between individual patients, but 
overall no differences were observed between rejectors and non-rejectors (Figure 3). 
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The expanded CD4+CD2- control T cells did not reveal suppressive capacity in any of 
the patients (data not shown).  
Changes in the distribution of effector and memory T cell subsets over time
Having established a difference in the ratio between memory and Treg before the 
reduction of tacrolimus (T1), we wondered whether changes over time would provide 
additional information. Analysis of the immunological markers before transplantation 
(T0), showed no differences between rejectors and non-rejectors. Interestingly, with 
regard to CD4+ T cells, all rejectors showed a relative increase between T0 and T1 in 
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Figure 2. The functional capacity of allo- and 3rd party-reactive CD4+ and CD8+ T cells and 
CD4+CD25high regulatory T cells isolated from the peripheral blood of transplant patients imme-
diately before the start of tacrolimus dose reduction (T1). R = rejectors (n=15), NR = non-rejectors 
(n=26). A CFSE-MLR was used to determine the precursor frequency and mitotic events of alloreactive CD4+ 
(left) and CD8+ (right) T cells. CFSE labeled patient PBMC (1 x 105) were stimulated with PKH labeled donor 
or 3rd party cells (1 x 105) for 6 days. Using flow cytometry, patient T cells were gated based on forward/side 
(FS/SS) scatter and PKH exclusion and subsequent CD4 and CD8 staining. The precursor frequency and mi-
totic events of alloreactive CD4+ and CD8+ T cells were calculated on the basis of the CFSE dilution pattern 
using Modfit LT™ software.29 (A) The precursor frequency of donor reactive CD4+ and CD8+ T cells. (B) 
The precursor frequency of 3rd party reactive CD4+ and CD8+ T cells. (C) The number of mitotic events of 
alloreactive CD4+ and CD8+ T cells. (D) The number of mitotic events of 3rd party reactive T cells. R vs. NR = 
not significant.
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the percentage of naive T cells and all but one showed a decrease in the percentage 
of effector T cells, while in non-rejectors the pattern of changes was diverse (Figure 
4A). In the CD8+ T cell compartment, there were comparable shifts in T cell subset 
percentages, but less outspoken than in the CD4+ T cell population (Figure 4B). 
For both rejectors and non-rejectors, the median percentage of Treg within the CD4+ 
T cells was lower prior to tacrolimus reduction (1.6% and 2.0%, respectively) compared 
to pretransplant values (2.6% and 2.9%, respectively, p<0.01) (Figure 4C).  
Taken together, a decrease in the percentage of naïve T cell levels identified transplant 
patients at low risk for acute rejection following reduction of immunosuppression. 
Changes in the functional capacity of CD4+ and CD8+ T cells over time 
The precursor frequency and mitotic events of donor and 3rd party reactive CD4+ and 
CD8+ T cells showed little variation over time and the changes did not differ between 
rejectors and non-rejectors (Figures A and B). In addition, the ability of isolated 
Treg to suppress alloreactivity was not altered after transplantation (Figure C).
Predictive value of immunological markers for the occurrence or freedom of rejection 
As stated above, two markers were associated with successful reduction of 
immunosuppression: 1) a low ratio (<20) of memory CD4+ T cells: Treg prior to the start 
of immunosuppression reduction, and 2) a decrease in the percentage of naive T cells 
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Figure 3. The suppressive potential of Treg isolated from transplant patients immediately before 
the start of tacrolimus dose reduction. R = rejectors (n=5), NR = non-rejectors (n=4). CD4+CD25high and 
CD4+CD25- control cells were isolated from patient PBMC using fluorescence activated cell sorting resulting 
in >95% purity. The cells were expanded using αCD3/αCD28 coated expander beads in combination with IL-2 
and IL-15 for 14-21 days. After expansion, Treg were rested for 2-3 days after which their capacity to suppress 
anti-donor and anti-3rd party responses was evaluated in a suppression assay, in which Treg were added at 
increasing ratios to a newly setup MLR (with donor or 3rd party stimulator cells). Proliferation was measured 
at day 6 using 3H incorporation The percentage inhibition of proliferation (y-axis) of anti-donor (left) or anti-
3rd-party (right) responses by Treg, added at increasing ratios (x-axis) to the MLR, isolated from rejectors and 
non-rejectors. R vs. NR = not significant.
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Figure 4. Changes in the frequency of naïve, effector, memory and regulatory T cell subsets in the 
peripheral blood of transplant patients between the time of transplantation (T0) and the start 
of tacrolimus withdrawal (T1).  R = rejectors (n=14), NR = non-rejectors (n=23). A positive value indicates 
an increase and a negative value indicates a decrease of the value in time. The change in the percentage of naïve 
(TN, CD45RA
+CD62L+), effector (TE, CD45RA
+CD62L-), central memory (TCM, CD45RO
+CD62L+) and effector 
memory (TEM, CD45RO
+CD62L-) T cell subsets within (A) the total CD4+ T cell population (data are missing 
for 4 patients, 4 R and 0 NR), and (B) the CD8+ T cell population (data are missing for 3 patients, 1 R and 2 NR). 
(C) The change in the percentage of peripheral blood CD4+CD25+FoxP3+ T cells within the total CD4+ T cell 
population. Data are missing for 6 patients (2 R and 4 NR). R vs. NR = not significant.
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before start of tacrolimus reduction compared to pre-transplant values. Combination 
of these two markers resulted in a test with a high predictive value. We defined a 
positive test result (associated with rejection) as the absence of both markers, and a 
negative test result (associated with absence of rejection) as the presence of one or 
both markers. Both markers were available in 33 patients (12 rejectors and 21 non-
rejectors). The sensitivity of the test for detecting a subsequent rejection was 100% 
(12/12) while the specificity was 76% (16/21). The positive predictive value (markers 
absent = positive test) with respect to subsequent rejection was 76% (12/17), while 
the negative predictive value (one or both markers present = negative test) was 100% 
(16/16). In conclusion, the combination of the two biomarkers was very useful to 
identify patients in whom the immunosuppressive therapy could be safely reduced. 
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Figure 5. Changes in the functional capacity of T cells isolated from the peripheral blood of trans-
plant patients between the time of transplantation (T0) and the start of tacrolimus withdrawal 
(T1). R = rejectors (n=15), NR = non-rejectors (n=25). A positive value indicates an increase and a negative va-
lue indicates a decrease of the value in time. A CFSE MLR in combination with Modfit LT™ software was used 
to calculate the precursor frequency and the number of mitotic events of allo- and 3rd-party-reactive CD4+ and 
CD8+ T cells. (A) The change (y-axis) in the precursor frequency of alloreactive CD4+ and CD8+ T cells. (B) The 
change in the number of mitotic events (ME) of CD4+ and CD8+ alloreactive T cells. (C) The functional capacity 
to suppress anti-donor responses of Treg isolated before transplantation (T0, white circles) and before the start 
of tacrolimus reduction (T1, black circles) in 5 rejectors (upper graphs) and 4 non-rejectors (lower graphs).
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Discussion 
In this case-control study, we have evaluated a number of T cell markers to predict 
the occurrence of acute renal allograft rejection following the discontinuation of 
tacrolimus. In samples taken immediately before the withdrawal of tacrolimus, the 
ratio between memory CD8+ T cells and Treg was significantly higher in patients 
who experienced a rejection episode compared to non-rejectors. Apparently, an 
enhanced memory T cell: Treg ratio did not result in rejection as long as sufficient 
immunosuppression was provided. Reduction of immunosuppression tipped the 
balance towards rejection in a number of these patients. Our findings underscore 
the importance of a balance between effector/memory and regulatory mechanisms 
in the maintenance of immune homeostasis as has been demonstrated in several 
studies.24-26 
In addition, we observed that the change in T cell subset distribution between 
transplantation and the initiation of tacrolimus withdrawal was different between 
rejectors and non-rejectors. In the group of rejectors, an increase was observed in 
the percentage of naive T cells in the peripheral blood, with a reciprocal decrease 
in the percentage of effector T cells. Although more pronounced for CD4+ T cells, 
this phenomenon was also observed for CD8+ T cells. Without the analysis of other 
immune compartments and graft tissue, it is difficult to interpret these intriguing 
findings. One explanation might be that recruitment of effector T cells to the 
allograft, resulting in a lower portion in the peripheral blood, predisposes the patient 
for acute rejection after reduction of the level of immunosuppression.
The combination of the memory T cell: Treg ratio and the changes in T cell subsets 
over time, resulted in a test, that is highly sensitive in the detection of patients that 
will develop a rejection after the withdrawal of tacrolimus at six months after renal 
transplantation. Accordingly, when confirmed in another study, this test could be 
very useful to identify renal transplant patients in whom immunosuppression can 
be safely reduced. 
Until now, in vitro monitoring tools in solid organ transplantation have mostly been 
used to predict the course early after transplantation, and the most relevant information 
has been provided by functional assays of anti-donor reactivity.28 One study concerned 
the prediction of acute rejection following reduction of immunosuppression by 
measuring CTLp frequencies.14 The authors found that low CTLp frequencies (<10/10 x 
106 PBMC) identified patients in whom immunosuppression could be safely reduced. 
The low CTLp frequencies observed by van Besouw et al. might be viewed as a state of 
immune quiescence, which in some way appeared to be reflected by a low memory 
T cell: Treg ratio in our study. Combining the assessment of CTLp frequencies and 
memory T cell: Treg ratios might provide a strong monitoring tool.
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The design of our study and the interpretation of the data have some limitations. 
First, the results are based on a relatively small sample size, but similar studies 
with comparable or larger number of patients have not been published. Second, the 
results should ideally be confirmed in a second validation cohort of patients. Third, 
we recognize that in a number of the assays we used, overall reactivity rather than 
donor reactivity was measured. In clinical practice however, monitoring tools will 
especially be welcomed if they are easy and fast to perform, give reproducible results, 
require small blood volumes of the patient, and require no donor material. 
In conclusion, in this study we have monitored a variety of phenotypic and functional 
T cell markers in the peripheral blood of renal transplant patients in order to find 
a marker that would help to predict the occurrence of acute rejection following the 
discontinuation of tacrolimus. Flow cytometric T cell analysis was found to be the 
most informative in our study and revealed an association between the occurrence 
of rejection and 1) the ratio of memory T cells and Treg immediately prior to the 
start of tacrolimus reduction and 2) changes in the distribution of naive, effector and 
memory T cells over time. These findings may contribute to the development of in 
vitro monitoring tools to identify transplant patients in whom immunosuppression 
can be safely reduced in order to avoid long-term side effects.
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Abstract
The identification of transplant patients at high-risk for rejection following reduction 
of immunosuppression would allow minimization of immunosuppression and 
avoidance of side effects in low-risk patients. Next to T cells, innate natural killer (NK) 
cells may contribute to graft rejection. NK cell activation depends on the balance 
between activating and inhibitory signals, delivered by self HLA through binding 
of killer-cell immunoglobulin receptors (KIR). In transplantation, KIR and/or HLA 
mismatching may lead to NK cell activation. 
In this study, we have evaluated whether acute rejection following reduction of 
immunosuppression after renal transplantation was associated with peripheral 
blood NK cell frequencies or with predicted NK cell alloreactivity based on KIR-gene 
and –ligand analysis. HLA- and KIR- genotyping was used to analyze the presence 
of single KIR genes and haplotypes and to predict NK cell alloreactivity based on 
the ‘missing self’ and ‘missing ligand’ hypothesis. NK cell frequencies were analyzed 
using flow cytometry. 
No association was found between NK cell alloreactivity based on KIR gene analysis 
or peripheral blood NK cell subset frequencies and the occurrence of acute rejection 
after reduction of immunosuppression. 
Concluding, our data suggest that in a setting where immunosuppression is reduced, 
prior analysis of NK cell reactivity can not identify patients at risk for subsequent 
graft rejection. 
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Introduction
The administration of immunosuppressive drugs following solid organ 
transplantation is essential to prevent rejection of the allograft, but is accompanied 
by increased morbidity and mortality of patients. Calcineurin inhibitors (CNI), 
including cyclosporine A and tacrolimus, are the most potent immunosuppressive 
drugs in preventing acute allograft rejection. However, long-term CNI administration 
is associated with severe nephrotoxicity, which can contribute to graft failure.1;2 
Therefore, CNI withdrawal once stable graft function is achieved, has been attempted 
in several studies, but was universally associated with an increased risk of acute 
rejection.3-6 On the other hand, successful discontinuation of CNI generally results 
in improved renal function and blood pressure control, and long-term follow-up 
of patients after CNI withdrawal shows a favorable outcome.7;8 The identification 
of patients at risk for acute rejection following CNI withdrawal would allow the 
development of individualized immunosuppression regimens, thereby preventing 
under-immunosuppression in a high-risk subset with simultaneous avoidance of 
long-term CNI toxicity in the majority of patients. 
T cells and professional antigen presenting cells (APC) are major players in 
alloreactivity. Activation of CD4+ and CD8+ T cells by donor-derived antigens leads to 
the clonal expansion of alloreactive effector T cells that can infiltrate and destruct 
the allograft. Natural killer (NK) cells are cells of the innate immune system that can 
kill target cells through the degranulation of granules containing lytic proteins such 
as perforin and granzymes.9 In transplantation, activated NK cells can function as a 
bridge between innate and adaptive alloimmune responses.9;10 Interferon-γ (IFN-γ), 
that is abundantly produced by activated NK cells, can boost T cell alloreactivity 9 
and stimulate dendritic cell (DC) maturation, which in turn can augment adaptive 
immune responses, especially favoring TH1 responses.
10
The activation of NK cells depends on a balance between signals from inhibitory 
and activating receptors.11;12 Among these are the killer-cell immunoglobulin-like 
receptors (KIRs), which are encoded on chromosome 19 and can be divided in two 
subclasses dependent on the number of external immunoglobulin domains (2D or 
3D). The intracellular tail of the KIRs determines the outcome of interaction with 
their natural ligands. Where a long intracellular tail (e.g. 2DL1) provides an inhibitory 
signal, an activating signal is delivered by KIRs with a short (e.g. 2DS1) intracellular 
tail.12 The ligands for inhibitory KIRs have been defined as HLA class I molecules but 
the ligands for most activating KIRs remain to be elucidated.13-1 As postulated in 
the ‘missing self’ hypothesis, NK cell activation therefore depends on the absence 
of an inhibitory signal delivered by self HLA class I molecules. In transplantation, 
the missing expression of self HLA molecules on donor cells can mediate NK cell 
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alloreactivity.11;16;17 The importance of NK cell alloreactivity has been shown in haplo-
identical haematopoietic stem cell transplantations (HSCT), where the absence 
of donor KIR ligands (i.e. HLA-C molecules) in the host resulted in donor NK cell 
alloreactivity, which was associated with a reduced risk of relapse and increased 
leukemia-free survival.18;19  
Two distinct NK cell subsets can be identified based on the expression level of CD6.20-
22 The CD6dim NK cell subset is mainly cytotoxic of nature and expresses KIRs and 
high levels of the Fc-gamma receptor III (CD16).20;23 In contrast, CD6bright NK cells 
express no or only low levels of CD16 and perforin, and their function depends more 
on the production of immunoregulatory cytokines.20;23 
We hypothesized that if alloreactive NK cells play a role in the immune response 
against solid organ grafts, the degree of NK cell alloreactivity might in part 
determine the amount of immunosuppression that is required to prevent rejection. 
In this case-control study, we therefore determined the genotype of NK cell receptors, 
NK cell alloreactivity based on KIR-gene and –ligand analysis and the frequency of 
peripheral blood NK cell subsets in patients who experienced an acute rejection 
episode following the discontinuation of tacrolimus and compared the results with 
patients in whom immunosuppression was successfully reduced. 
Methods
Transplant patients and immunosuppressive treatment
The study was designed with the aim of evaluating a regimen of reduced 
immunosuppression. Patients received a renal allograft at the Radboud University 
Nijmegen Medical Centre between January 1999 and December 2004 and were 
selected for reduction of their immunosuppression when they met the following 
inclusion criteria: at least for 4 months after transplantation, stable graft function, 
and at least 1 HLA-B and 1 HLA-DR match between donor and recipient. Patients 
who received a kidney from a HLA-identical living donor, patients with two or more 
previously failed grafts, patients with PRA > 8%, non-Caucasian patients, and 
patients that had experienced a steroid-resistant acute rejection episode after their 
current transplantation were excluded. In addition, patients with severe osteoporosis 
and patients with bone marrow depression were also excluded. 
Standard triple-therapy immunosuppression consisted of tacrolimus in combination 
with mycophenolate mofetil and prednisolone. Tacrolimus was started at day 1 or 2 
after transplantation at 0.1 mg/kg/day (administered twice daily orally) and the dose 
was subsequently adjusted to achieve target whole-blood trough concentrations of 1-
20 ng/mL during days 0-14, 10-1 ng/mL during weeks 3-6, and -10 ng/mL from week 7. 
81
KIRgeneandKIRligandanalysis
Whole blood tacrolimus concentrations were measured by the IMx analyzer (Abbott 
Laboratories, Abbott Park, IL, USA). Mycophenolate mofetil (MMF) was administered 
at 1000 mg twice daily with a dose reduction to 70 mg twice daily at 2 weeks after 
transplantation, unless the patient weighed more than 90 kg. Patients received 100 
mg of prednisolone intravenously during the first 3 days after transplantation and 
subsequently an oral dose of 1-2 mg/day (depending on body weight), which was 
tapered to a maintenance dose of 0.1 mg/kg/day. After 3 months, the steroid dose was 
further tapered to zero in a subset of patients.
Some patients had participated in a clinical trial in which they received daclizumab 
(1 mg/kg on days 0 and 14 after transplantation), with discontinuation of steroids at 
three days after transplantation.24 Other induction therapy with anti-T cell antibodies 
was not used. 
The tapering schedule was as follows: at first instance, MMF was substituted for 
azathioprine (Aza, 3 mg/kg daily), and prednisolone (0.1 mg/kg/day) was added in 
patients that did not use steroids anymore. The dose of Aza was adjusted in case 
of leukocytopenia or elevated liver enzymes. In case patients did not tolerate a 
minimum Aza dose of 2 mg/kg/day, MMF was reintroduced (70 mg twice daily). Two 
months later, the tacrolimus dose was gradually reduced to zero over a period of 
4 weeks. Meanwhile, the prednisolone dose was increased to 0.1 mg/kg/day. The 
resulting maintenance immunosuppressive therapy after conversion thus consisted 
of azathioprine (at least 2 mg/kg/day; otherwise MMF 70 mg twice daily) and 
prednisolone (0.1 mg/kg/day). All patients were evaluated for acute rejection episodes 
during the first 6 months after withdrawal of tacrolimus. A schematic overview of 
the minimization protocol is given in Figure 1. IRB approval was obtained for this 
study.
Transplantation:
tacrolimus
MMF
steroids
MMF Aza
(+ restart steroids)
T0 T1
100%o 50%
tacrolimus withdrawal
2 monthst 4 months
50%o 25%
2 wks 2 wks
25%o 0%
Figure 1. Outline of the immunosuppressive treatment protocol and timepoints of blood sampling.
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Sample collection and cell isolation
Blood samples (20 ml) of transplant patients were collected before transplantation 
(T0) and immediately prior to the first dose reduction of tacrolimus (T1). Donor cells 
were obtained from peripheral blood (100 ml) of living donors or from small fractions 
of spleen tissue of deceased donors. Buffy coats were obtained from healthy controls 
(voluntary blood donors, Sanquin Blood Bank, region South East). Peripheral Blood 
Mononuclear Cells (PBMC) were isolated by density gradient centrifugation with 
Lymphoprep (Nycomed Pharma AS, Oslo, Norway) using LeucoSep® tubes (Greiner Bio-
One, Frickenhausen, Germany) and were stored in liquid nitrogen until further use. 
Flow cytometry
The frequency of NK cell subsets within the peripheral blood lymphocyte pool was 
analyzed by flow cytometry. PBMC (1*10) were washed with PBS-BSA (0.2%) and 
labeled with fluorochrome-conjugated monoclonal antibodies (mAb) for 20’ at 
room temperature (RT) in the dark. Samples were washed twice to remove unbound 
antibodies, measured on a Coulter Epics XL flow cytometer (Beckman Coulter, 
Fullerton, CA) and analyzed using Coulter Epics Expo 32 software. Lymphocytes were 
gated based on FS/SS (forward/side scatter) patterns. Appropriate isotype control 
mAbs were used for marker settings. The following antibodies were used: CD16-
FITC (Dako, Glostrup, Denmark) CD3-PE, CD8-ECD and CD6-PC (Beckman Coulter 
Corporation, Miami, FI, USA).
KIR genotyping and HLA-Cw and HLA-Bw4 typing
KIR genotyping was performed on genomic DNA isolated from patient and donor 
cells using the QIAamp DNA blood mini kit (Qiagen). A single PCR-SSP typing 
protocol as described by Gagne et al 2 (with minor modifications) was used for KIR 
typing allowing the identification of 4 inhibitory KIRs (KIR2DL1, 2DL2, 2DL3, 3DL1) 
and 6 stimulatory KIRs (KIR2DS1, 2DS2, 2DS3, 2DS4, 2DS, 3DS1). A limited HLA-C 
locus typing was performed using a PCR-SSP protocol solely aimed at discriminating 
between the polymorphisms located at exon 2 encoded amino acid positions 77 and 
80, relevant for KIR recognition. The HLA-C alleles were thus divided into two groups: 
HLA-C1 (HLA-Cw [Ser77Asn80] alleles with serine at position 77 and asparagine at 
position 80) and HLA-C2 (HLA-Cw [Asn77Lys80] alleles with asparagine at position 77 
and lysine at position 80). HLA-Bw4 assignment was based on the serological typing 
result as obtained by standard HLA-B locus serology, using a microcytotoxicity assay.
KIR haplotypes were assigned according to the following algorithm: Group A 
haplotypes contain only a single stimulatory KIR gene, 2DS4, whereas group B 
haplotypes contain various combinations of 2DS1, 2DS2, 2DS3, 2DS, 3DS1, and 
2DS4. 
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Statistical analysis
The study had a case-control design. Patients who experienced an acute rejection 
after withdrawal of tacrolimus (cases) were compared with controls comprising 
non-rejecting patients from the same study cohort, with optimal matching for 
the following items: age of donor and recipient (<0 versus ≥0), number of HLA-
mismatches, percentage PRA (<%, ≥%), and first or retransplantation.
HLA-KIR gene distribution results were evaluated in contingency tables and the 
observed values were compared with expected values using a Χ2-test. NK cell 
frequencies obtained from flowcytometric analyses were compared between patient 
groups and healthy controls using a Kruskal-Wallis analysis. Differences between 
two groups at a given timepoint were compared using Mann-Whitney U analysis. For 
analysis of changes in time within patients, a Wilcoxon matched pairs test was used. 
Recognizing the fact that multiple statistical analyses were performed, p-values ≤ 
0.01 were considered statistically significant. To calculate the alternative hypothesis 
that could be detected with 80% power given the sample size of cases and controls, 
we used Power and sample size calculations version 2.1.31.26
Results
Patient characteristics
During the study period, a total of 102 patients were included and were treated 
according to the immunosuppressive minimization protocol (Figure 1). The median 
interval between renal transplantation and start of tacrolimus withdrawal was 7.1 
months (range .3 – 39.3 months). Thirty-four patients (33%) experienced an acute 
Table 1. Patient characteristics
Rejectors (n=24) Non-rejectors (n=45) p-value
Gender (male/female) 16/8 28/17 0.715
Patient age (years) 42 ± 16 47 ± 14 0.163
Donor age (years) 47 ± 12 52 ± 12 0.120
Donor (living/deceased) 14/10 25/20 0.825
HLA mismatches (0 / ≥1)      HLA-A 10/14 18/27 0.839
                                           HLA-B 7/17 18/27 0.373
                                           HLA-DR 3/21 11/34 0.240
Cold ischemia time (hours)* 15 ± 6 19 ± 5 0.103
PRA >5% 2 7 0.372
Retransplantations 1 6 0.230
Daclizumab induction therapy 0 4 0.132
Acute rejection prior to inclusion 1 0 0.168
* in case of deceased donor only
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rejection following the withdrawal of tacrolimus. All but 4 of these rejections were 
proven by histology according to the Banff ’97 classification. In four patients, the 
clinical picture and response to therapy was quite compatible with acute rejection, 
but no graft biopsy was performed. All acute rejection episodes were treatable and 
none of the patients lost their graft within the follow-up period of six months after 
tacrolimus withdrawal. KIR gene analysis was performed in 24 rejectors (cases) and 
4 non-rejectors (matched controls). Sufficient PBMC to analyze NK cell frequencies 
were available from 21 rejectors and 28 non-rejectors. Clinical characteristics did not 
differ significantly between rejectors and non-rejectors (Table 1). 
The absence of self HLA epitopes on the donor graft is not associated with the occurrence of 
acute rejection following the reduction of  immunosuppression
According to the ‘missing self’ hypothesis, the activation of NK cells results from 
a lack of an inhibitory signal pre-dominantly delivered by self HLA-Cw and HLA-
Bw4 associated epitopes. To evaluate whether the absence of these epitopes on the 
allograft  was indeed associated with the occurrence of acute rejection following 
the reduction of immunosuppression, we analyzed HLA-Cw and –Bw4 in patients 
and donors. In the rejector group, 6 of 24 donors (2%) missed one or more HLA-
Cw and –Bw4 epitopes that were present in the patient and this ‘missing self’ 
phenomenon was observed in 8 of 4 non-rejectors (18%) (Table 2). These proportions 
did not significantly differ indicating that the absence of one or more inhibitory 
HLA epitopes on the donor graft was not associated with the occurrence of acute 
rejection following the reduction of immunosuppression. 
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Figure 2. KIR gene distribution in transplant patients and donors. KIR genotyping in renal transplant 
patients (n=69) and donors was performed using PCR-SSP. The frequencies (y-axis) of KIR genes (x-axis) are 
shown for patients (black bars) and donors (white bars). 
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No association between the presence of particular KIR genes or KIR haplotypes and the 
occurrence of acute rejection following the reduction of immunosuppression 
Figure 2 shows the distribution of KIR genes in both patients and donors. The 
observed frequencies were not significantly different from frequencies observed in 
healthy populations.12;27;28 The presence of particular KIR genes was not different 
between patients with and without rejection after reduction of immunosuppression 
(Table 2).
On the basis of KIR gene content, two groups of KIR haplotypes can be distinguished.12;29 
Group A haplotypes carry only a single stimulatory KIR gene, while group B haplotypes 
carry several combinations of mostly activating KIR genes. We evaluated whether the 
presence of a certain combination of haplotypes in the recipient was associated with 
the occurrence of acute rejection after withdrawal of tacrolimus. The genotype AB 
was most prevalent (6%) and genotypes AA and BB were present in 32% and 3% of 
the patient group respectively. The presence of a certain genotype was not associated 
with the occurrence of acute allograft rejection (Table 2). 
Because of the large variation in composition of the KIR genotype, KIR mismatching 
can easily occur between donor and recipient. This may have functional implications, 
exemplified by the finding that the degree of KIR (mis)matching was associated with 
the outcome of  bone marrow transplantation.2 We therefore determined the degree 
of KIR matching between patient and donor, discriminating four distinct patterns: 1) 
the KIR genes present in the donor were identical to those in the patient, 2) the donor 
carried additional KIR genes to those of the patient, 3) the patient carried additional 
KIR genes to those of the donor, and 4) both patient and donor carried additional KIR 
genes to the shared ones. None of the four patterns appeared to be associated with 
the occurrence of acute rejection following the reduction of immunosuppression 
(Table 2).
The presence of KIR ligands on the donor is not associated with the occurrence of acute 
rejection following reduction of immunosuppression
Next to the ‘missing self’ hypothesis, which states that the absence of self HLA 
epitopes on donor cells can result in NK cell alloreactivity, the ‘missing ligand’ 
hypothesis states that for each KIR expressed in the patient, the inhibitory ligand 
needs to be present on the donor cells to avoid NK cell alloreactivity.18;30 We therefore 
determined which inhibitory or stimulatory KIRs were present in each patient and 
whether the corresponding KIR ligands (HLA associated epitopes) were present on 
the donor cells. The HLA epitopes that function as KIR ligands are the HLA-C1 epitope 
for KIR2DL2/DS2 and KIR2DL3/DS3, the HLA-C2 epitope for KIR2DL1/DS1, and the 
HLA-Bw4 epitope for KIR3DL1/DS1. As shown in Table 2, the number of patient-donor 
combinations in which the donor did not express the KIR ligands corresponding to 
86
Chapter4
the KIRs expressed in the patient was not significantly different between rejectors 
and non-rejectors.
NK cell frequencies and the distribution of NK cell subsets are not associated with the 
occurrence of acute rejection following the reduction of immunosuppression
In order to determine whether the frequency of NK cells within the total lymphocyte 
population was associated with the occurrence of acute rejection following the 
reduction of immunosuppression, we determined the frequencies of CD6+CD3- 
NK cells in blood samples of transplant patients collected immediately prior to the 
withdrawal of tacrolimus. Comparison of rejectors and non-rejectors showed no 
significant differences in NK cell frequency (Figure 3A). 
Within the human NK cell pool, two functional subsets can be identified based on 
the level of cell surface expression of the CD6 molecule,20-22 the so-called CD6dim NK 
cells and CD6bright NK cells. In our patients, the distribution of CD6dim and C6bright 
Table 2. HLA-Cw and -Bw4 matching and KIR - KIR ligand incompatibility in patients with and without acute 
rejection after reduction of immunosuppression
Rejectors (n=24) Non-rejectors (n=45) p-value
Missing self (yes/no) 6/18 8/37 0.276
KIR gene present (yes/no) 2DL1 24/0 43/1¥ 0.457
                                   2DL2 14/10 21/24 0.356
                                   2DL3 22/2 40/5 0.716
                                  2DS1 8/16 19/26 0.471
                                  2DS2 14/10 20/25 0.272
                                  2DS3 5/19 10/35 0.894
                                  2DS4 24/0 42/3 0.196
                                  2DS5 4/20 12/33 0.349
                                   3DS1 8/16 16/29 0.854
                                  3DL1 24/0 42/3 0.188
KIR genotype (AA/AB/BB) 7/17/0 15/28/2 0.514
KIR matching (1/2/3/4)# 10/4/7/3 10/13/9/13 0.147
Missing ligand (yes/no)§ KIR2DL1 - HLA-C2 10/14 19/24 0.842
                    KIR2DL2 - HLA-C1 0/14 1/20 0.414
                     KIR2DL3 - HLA-C1 0/22 2/38 0.286
                   KIR3DL1 - HLA-Bw4 12/12 14/28 0.183
Missing ligand (yes/no)§     KIR2DS1 - HLA-C2 2/6 8/11 0.401
                    KIR2DS2 - HLA-C1 0/14 1/19 0.396
                     KIR2DS3 - HLA-C1 0/5 0/10 -
                  KIR3DS1 - HLA-Bw4 1/7 4/12 0.446
# 1) KIR genes present in the donor are identical to those in the patiënt, 2) donor carries additional KIR 
genes to those of the patiënt, 3) patient carries additional KIR genes to those of  the donor, 4) both patient 
and donor carry additional KIR genes to the shared ones
§ for combination patient KIR – donor HLA
¥ Data are missing for one patient
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Figure 3. NK cell frequencies and the distribution of CD56dim and CD56bright NK cells are not as-
sociated with the occurrence of acute rejection following the withdrawal of immunosuppression. 
(A) Frequencies of CD56+CD3- NK cells within the total lymphocyte population were determined in the pe-
ripheral blood of renal transplant patients prior to withdrawal of tacrolimus and compared between rejectors 
(R) and non-rejectors (NR). (B) Within the total CD56+CD3- NK cell pool, the percentage of CD56dim NK cells 
and CD56bright NK cells was determined.  
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NK cells within the total NK cell pool was not associated with the occurrence of acute 
rejection following reduction of immunosuppression (Figure 3B).
Discussion
In this study, we have evaluated whether the incidence of acute rejection following 
the reduction of immunosuppression after renal transplantation was associated 
with peripheral blood NK cell frequencies, the presence of single KIR genes or KIR 
haplotypes, and NK cell alloreactivity based on ‘missing self’ or ‘missing ligand’ 
analysis. We found no association between the evaluated NK cell markers and the 
occurrence of acute rejection upon minimization of immunosuppression. This 
implicates that the assays described in this paper are not suitable for the selection of 
patients in whom the immunosuppression can be tapered safely. 
So far, few studies have addressed the effects of NK cell alloreactivity based on KIR-
genotyping on the outcome of solid organ transplantation.31-33 Two studies evaluated 
the effect of NK cell alloreactivity based on the ‘missing self’ hypothesis.31;33 In a cohort 
of liver transplant patients, patients receiving a graft that lacked the expression of self 
HLA-Cw and HLA-Bw4 epitopes experienced a significantly higher number of acute 
rejection episodes in the first year after transplantation as compared to patients that 
received a graft that expressed the same HLA epitopes as the patient.31 The group 
of Opelz et al. could not identify a relation between renal graft survival and KIR 
ligand matching in a cohort of 277 renal transplant patients, but the precise setting 
of rejection after immunosuppressive regimen reduction was never addressed.32 
Extensive KIR gene analysis was only performed in one study. Vampa et al. compared 
anti-donor NK cell cytotoxicity before and 3 days after transplantation and showed 
that patients in whom anti-donor NK cytotoxicity increased during the first days 
after transplantation carried more activating KIR genes.33 In our case-control study, 
we have analyzed NK cell alloreactivity from different angles, based on the ‘missing 
self’ as well as the ‘missing ligand’ hypothesis, presence of particular KIR genes and 
haplotypes, and the degree of KIR mismatching between patient and donor, but we 
did not find an association with the occurrence of acute rejection following the 
reduction of immunosuppression. 
It can be questioned whether the relatively small number of patients in our study 
could have led to a type 2 statistical error. Prior to the collection of samples, it was 
very difficult to conduct a power analysis, since it was not clear what the frequency of 
potential endpoints would be in the control population (non-rejectors). Nevertheless, 
the design of our study was in favor of smaller group sizes, since we had a homogeneous 
group of patients (high-risk patients were excluded) that were treated with the same 
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combination of immunosuppressive drugs and a uniform tapering regimen. With 
the data available, we have recalculated the difference between groups that could 
be detected with a power of 80% given the probability of the endpoint in the control 
group. Therefore, we analyzed the number of donor-recipient pairs with KIR-ligand 
incompatibility (‘missing self’ according to the algorithm used by Ruggeri et al.34 
In the control group, the probability of this combination with potential NK cell 
alloreactivity was 18 % (8/4; see first line of Table 2). Our hypothesis was that the 
probability of this condition would be much higher in the cases (rejectors). With the 
number of patients (24) and controls (4) in our study, we had 80% power to detect an 
increase to 0% or more. Based on this post-hoc power calculation, and comparing 
our group size with that in other studies on the same topic,33;3 we think that the 
results are valuable.
There are several ways in which NK cell alloreactivity could affect the outcome after 
transplantation. In the stem cell transplantation setting, KIR ligand mismatching in 
the graft-versus-host direction, resulted in donor NK cell activation due to a lack of 
expression of self HLA epitopes on the patient cells. These findings were associated 
with beneficial effects on the relapse rate and leukemia-free survival time.18;30;36 
Murine data showed that following haematopoietic stem cell infusion, donor NK cells 
migrate to the haematopoietic sites and kill all recipient lympho-haematopoietic 
cells.34 Remarkably, these mice did not develop graft-versus-host-disease (GVHD). 
The observation that NK cells appeared to kill preferably lympho-haematopoietic 
cells but not organ tissue was explained by the fact that healthy organ cells do 
not express LFA-1, a ligand that is essential for NK cell mediated killing.36;37 These 
data may imply that in solid organ transplantation, activated alloreactive NK cells 
may not be able to kill the allograft due to the lack of LFA-1 expression on the 
allograft in normal circumstances. However, transplantation associated processes 
like ischemia-reperfusion injury have been shown to result in the upregulation of 
adhesion molecules on renal endothelial cells 38, making the graft susceptible to NK 
cell mediated damage. Next to the direct killing of graft cells, alloreactive NK cells 
can produce large amounts of immunomodulatory cytokines like IFN-γ, which may 
stimulate dendritic cell maturation and boost the adaptive immune response.9;10 
Alternatively, NK cell alloreactivity might also have some protective effect on graft 
rejection. Immediately after transplantation, donor derived dendritic cells, present 
in the allograft, are responsible for the direct presentation of allo-antigens. Since 
dendritic cells abundantly express LFA-1, they should be susceptible to alloreactive 
NK cell killing.39 The resulting depletion of donor-derived dendritic cells should 
disable them to provoke potent alloimmune responses.40
It cannot be excluded that T cell reactivation as a result of minimization of 
immunosuppression may be masking the putative impact of NK cell alloreactivity 
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in our setting. Therefore, the implications of NK cell alloreactivity, if any, on the 
outcome of solid organ transplantation remain to be further elucidated. In our 
study we did not find an association between NK cell alloreactivity based on KIR 
gene analysis or the level of NK cell frequencies in the peripheral blood of renal 
transplant patients and the incidence of acute rejection following the reduction of 
immunosuppression.           
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Abstract
Due to the adverse events associated with the administration of immunosuppressive 
drugs, reduction of immunosuppression following solid organ transplantation is 
highly desirable provided that graft rejection is prevented.  In our transplant centre, 
we employed an immunosuppression reduction regimen in stable renal transplant 
patients. Since the presence of HLA antibodies has been negatively associated with 
transplant outcome, we evaluated the impact of HLA antibodies on the occurrence 
of acute rejection after immunosuppression reduction. The presence and antigen-
specificity of HLA IgG antibodies in serum samples were detected using ELISA and 
single-antigen bead assays. Donor-specific cytotoxic potential was tested by standard 
CDC cross-match analysis.   
The presence of donor-specific or total HLA antibodies was not predictive for the 
occurrence of acute rejection following the reduction of immunosuppression. In 
addition, the presence of HLA antibodies did not preclude successful reduction of 
immunosuppression. After reduction of immunosuppression, newly formed HLA 
antibodies were seldom detected. Interestingly, evaluation of the cytotoxic potential 
of the detected HLA antibodies revealed that the one patient who developed donor 
specific HLA antibodies and experienced a subsequent rejection episode, was the 
single patient who carried cytotoxic HLA antibodies. This fuelled the notion that the 
functional capacity, rather than the mere presence of donor-specific HLA antibodies 
is indicative for transplant outcome. In conclusion, the presence of HLA antibodies 
does not preclude the successful reduction of immunosuppression in renal transplant 
patients with stable graft function.
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Introduction
The administration of immunosuppressive drugs is associated with serious adverse 
events, which can affect long-term transplant outcome.1;2 Therefore, the reduction 
of immunosuppression following solid organ transplantation is highly desirable, 
provided that graft rejection is prevented. In our renal transplant centre, we have 
employed an immunosuppressive treatment regimen that included the withdrawal 
of a calcineurin inhibitor (CNI) in immunological low-risk patients with stable graft 
function. The rationale for this treatment protocol was that despite an increased 
risk of acute rejection, long-term follow-up of patients after CNI withdrawal shows a 
favorable outcome with improved renal function and blood pressure.3;4
It has been demonstrated that the presence of HLA antibodies in organ transplant 
patients has negative implications on graft outcome.-8 Pre-existing HLA antibodies 
before transplantation, as a result of prior transplantations, blood transfusions or 
pregnancies, can lead to a vigorous immune response against the allograft resulting 
in hyperacute rejection within minutes after transplantation.6 The introduction 
of routine pre-transplant cross match analysis has allowed the rapid detection of 
pre-existing cytotoxic HLA antibodies and has made hyperacute rejection a rare 
phenomenon nowadays. However, patients that carry HLA antibodies, but have a 
negative pre-transplant cross-match, experience more acute rejection episodes and 
have a lower overall graft survival compared to patients without HLA antibodies.7 
Next to pre-existing HLA antibodies, also HLA antibodies that arise de novo after 
transplantation are associated with a higher risk of acute and chronic rejection 
and poor graft outcome.7-10 The relationship with rejection was especially found for 
the presence of donor specific HLA antibodies. However, some studies also showed 
an association between the presence of HLA antibodies in general, independent of 
antigen-specificity, and transplant outcome.11
In this study, we have evaluated whether the presence of HLA antibodies before 
and after transplantation was predictive for the occurrence of acute rejection after 
tapering of immunosuppression. Furthermore, we investigated the presence of 
HLA antibodies after tapering of immunosuppression and the association with the 
subsequent clinical course. 
Material & Methods
Transplant patients and immunosuppressive treatment
Patients received a renal allograft at the Radboud University Nijmegen Medical 
Centre between January 2003 and December 2004. Standard triple-therapy 
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immunosuppression consisted of tacrolimus in combination with mycophenolate 
mofetil and prednisolone. Patients received 100 mg of prednisolone intravenously 
during the first 3 days after transplantation and subsequently an oral dose of 1-2 
mg/day (depending on body weight), which was tapered to a maintenance dose of 0.1 
mg/kg/day. Tacrolimus was started at day 1 or 2 after transplantation at 0.1 mg/kg/day 
(administered twice daily orally) and the dose was subsequently adjusted to achieve 
target whole-blood trough concentrations of 1-20 ng/mL during days 0-14, 10-1 ng/
mL during weeks 3-6, and -10 ng/mL from week 7 onwards. Whole blood tacrolimus 
concentrations were measured by the IMx analyzer (Abbott Laboratories, Abbott Park, 
IL, USA). Mycophenolate mofetil (MMF) was administered at 1000 mg twice daily with 
a dose reduction to 70 mg twice daily at 2 weeks after transplantation, unless the 
patient weighed more than 90 kg. Induction therapy with polyclonal or monoclonal 
antibodies was not used.
At 4 months after transplantation, patients were selected for reduction of their 
immunosuppression (including withdrawal of tacrolimus) when they met the 
following inclusion criteria: stable graft function, and at least 1 HLA-B and 1 HLA-DR 
match between donor and recipient. Patients who received a kidney from a HLA-
identical living donor, patients with two or more previously failed grafts, patients 
with PRA > 8% before transplantation, non-Caucasian patients, and patients that 
had experienced a steroid-resistant acute rejection episode after their current 
transplantation were excluded for immunological reasons. In addition, patients 
with severe osteoporosis and patients with bone marrow depression were excluded. 
At first instance, MMF was substituted for azathioprine (Aza, 3 mg/kg daily). The 
dose of Aza was adjusted in case of leukocytopenia or elevated liver enzymes. In case 
patients did not tolerate a minimum Aza dose of 2 mg/kg/day, MMF was reintroduced 
(70 mg twice daily). Two months later, six months after transplantation, the 
Table 1. Patient characteristics
Rejectors (n=19) Non-rejectors (n=39) p-value
Sex (male/female) 12/7 25/14 0.944
Patient age (years) 43 ± 14 40 ± 13 0.620
Donor age (years) 47 ± 14 48 ± 10 0.868
Donor living/deceased 10/9 16/23 0.404
HLA mismatches (0/ ≥1)  HLA-A     6/13 18/21 0.290
                                      HLA-B 3/16 12/27 0.221
                                      HLA-DR 1/18 12/27 0.029
Cold ischemia time (hours)* 20 ± 8 18 ± 4 0.356
PRA (≥ 5%) 2 8 0.386
Retransplantations 0 7 0.052
Acute rejection prior to inclusion 1 0 0.148
* deceased donors only
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tacrolimus dose was gradually reduced to zero over a period of 4 weeks. Meanwhile, 
the prednisolone dose was increased to 0.1 mg/kg/day. The resulting maintenance 
immunosuppressive therapy after conversion consisted of azathioprine (at least 2 
mg/kg/day; otherwise MMF 70 mg twice daily) and prednisolone (0.1 mg/kg/day). A 
schematic overview of the immunosuppressive treatment protocol is given in Figure 
1. Patients were evaluated for acute rejection episodes during the first 6 months after 
withdrawal of tacrolimus and all patients had a follow-up of at least two years after 
transplantation. IRB approval was obtained for this study.
Sample collection
Serum samples were collected from transplant patients before transplantation (T0), 
prior to the start of tacrolimus reduction (T1, 6 months after transplantation) and 
after tacrolimus withdrawal (T2, 10 months after transplantation; Figure 1). Donor 
cells were obtained from peripheral blood (living donors) or spleen tissue (deceased 
donors). Peripheral blood mononuclear cells (PBMC) from living donors were isolated 
by density gradient centrifugation using Lymphoprep (Nycomed Pharma AS, Oslo, 
Norway). Cell isolation from spleen tissue was performed as described before.12
HLA class I and class II typing
All patients and donors were HLA typed using both serological and DNA based 
methods. Serological HLA typing of patients and donors (HLA-A, -B, (-C), -DR and -DQ) 
was performed by standard microcytotoxicity assays. Low-intermediate resolution 
DNA typing for HLA-A, -B, -DRB1, -DQB1 was performed by a PCR-SSO multiplex 
technique (Tepnel Lifecodes, Stamford, CT, USA). All assays were performed according 
to ASHI standards.  
Transplantation:
tacrolimus
MMF
steroids
MMF Aza
T0 T1
100%o 50%
tacrolimus withdrawal
2 months4 months
50%o 25%
2 wks 2 wks
25%o 0%
T2
146
Figure 1. Schematic overview of immunosuppressive treatment protocol and timing of blood sampling.
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Detection of IgG HLA antibodies
Patient serum samples were screened for the presence of IgG antibodies directed 
against HLA class I or class II antigens using ELISA (LAT™, One Lambda, Montpellier, 
France) according to the manufacturer’s instructions. The antigen-specificity of 
positive serum samples was subsequently analyzed in a Luminex single-antigen 
bead assay (Tepnel Lifecodes, Stamford, CT, USA). In short, serum samples were 
incubated with a panel of different beads, each coupled with a defined single 
class I or class II HLA glycoprotein for 30 minutes at room temperature. Unbound 
antibodies were washed away and antibody-bead complexes were incubated with a 
goat-anti-human-IgG antibody conjugated to phycoerythrin (PE) for an additional 
30 minutes at room temperature. Fluorescence intensity was detected using the 
LifeMatch® Fluoroanalyzer (Luminex® Corporation, Oosterhout, the Netherlands). 
The mean fluorescence intensity (MFI), corrected for background values, was used 
to define a positive bead reaction. Cut-off values were set arbitrarily at an MFI 
of 2000 for HLA-A, -B, -C , -DR and –DQ antibodies,  and at an MFI of 000 for DP 
antibodies. 
Crossmatch analysis (Complement dependent cytotoxicity (CDC)) 
If the Luminex single-antigen bead assay revealed the presence of donor specific 
HLA antibodies, donor reactivity of the HLA antibodies was further analyzed 
by complement dependent cytotoxicity (CDC). In this analysis, whole PBMC 
suspensions and immunobead-separated T- and B-cell fractions were used 
with or without DTT treatment, as described previously.13 Pre-transplant CDC 
cross-match analyses were negative for all patients according to the transplant 
protocol.
Statistical analysis
Patients that experienced an acute rejection after withdrawal of tacrolimus 
(cases) were compared with a control group that was composed of non-rejecting 
Table 2. The presence of HLA antibodies in patients who experience an acute rejection following tacrolimus 
withdrawal (rejectors, n=19) and patients in whom tacrolimus is successfully withdrawn (non-rejectors, 
n=39).
Pre-transplant  
(T0)
Before tacrolimus  
reduction (T1)
After tacrolimus  
reduction (T2)
positive * negative positive * negative positive * negative
Rejectors 1 (0) 18 2 (0) 17 3 (1) 16
Non-rejectors 7 (1) 32 7 (3) 31§ 9 (6) 30
* Number of patients with HLA antibodies. Numbers between brackets denote the number of patients with 
donor-specific HLA antibodies
§ Data are missing for one non-rejector
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patients from the same study cohort, with optimal matching for the following 
items: age of donor and recipient (<0 versus ≥0), number of HLA-mismatches, 
percentage PRA (<%, ≥%), and first or re-transplantation. HLA antibody results 
were evaluated and correlated with the occurrence of acute rejection using 
contingency tables. The observed values were compared with expected values 
using a Χ2-test. For analysis of changes of serum creatinine in time within patients, 
a Wilcoxon matched pairs test was used. Differences between two groups at a 
given time point were analyzed with a Mann-Whitney U-test. P-values <0.0 were 
considered statistically significant.
Results
Patient characteristics
During the study period, 66 patients fulfilled the inclusion criteria and were 
treated according to the immunosuppressive minimization protocol (Figure 
1). Twenty-four patients (36%) experienced an acute rejection following the 
withdrawal of tacrolimus. All but 2 of these rejections were proven by histology 
according to the Banff ’97 classification. In the remaining two patients the 
clinical course and response to therapy fitted the diagnosis of acute rejection 
but no graft biopsy was performed. Serum samples from 19 rejectors (cases) 
and 39 non-rejectors (matched controls) were available for analysis. Except for a 
imbalance in the degree of HLA-DR matching, the clinical characteristics did not 
differ significantly between rejectors and non-rejectors (Table 1). 
The presence of HLA antibodies does not predict the occurrence of acute rejection 
following the reduction of immunosuppression
To determine whether the presence of circulating HLA antibodies was 
associated with an increased risk for acute rejection following the reduction of 
immunosuppression, we analyzed patient sera collected before transplantation 
and before the start of tacrolimus dose reduction for the presence of HLA class I 
and class II IgG antibodies using ELISA. As shown in Table 2, the presence of HLA 
antibodies, both donor-specific and total HLA antibodies before transplantation 
was not associated with the occurrence of acute rejection after the withdrawal 
of tacrolimus (p = 0.189). The same was true for HLA antibodies detected 
immediately before the withdrawal of tacrolimus (p = 0.34). Interestingly, in four 
of the 39 control patients who did not experience a rejection after withdrawal 
of tacrolimus, donor specific HLA class I antibodies were detected at T0 or T1 
(Table 3). These data indicate that the presence of donor specific HLA antibodies, 
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detected by solid phase technology, does not preclude the successful reduction of 
immunosuppression. 
The formation of HLA antibodies after reduction of immunosuppression is infrequent
Next to analysis of the predictive value of HLA antibodies, we evaluated the impact 
of reduction of immunosuppression on the formation of HLA antibodies. We 
hypothesized that HLA antibody formation after reduction of immunosuppression 
might especially occur in patients that experienced an acute rejection. However, 
there were only three patients (1 rejector, two non-rejectors) in whom HLA antibodies 
were detected after tacrolimus withdrawal. In these patients, no HLA antibodies had 
been detected previously (Table 3). Notably, complement dependent cytotoxicity 
(CDC) analysis revealed that of the patients with newly detected donor specific 
HLA antibodies, only the patient who experienced an acute rejection carried donor 
specific HLA antibodies with cytotoxic potential.
The presence of donor-specific HLA antibodies does not affect graft function after tapering of 
immunosuppression
In our 39 control patients that underwent successful withdrawal of tacrolimus, six 
carried donor specific HLA antibodies at 3 months after discontinuation of tacrolimus. 
We have compared the course of renal function in patients with and without HLA 
antibodies during a follow-up of two years after transplantation. As is shown in Table 
Table 3. Transplant patients with circulating HLA antibodies as detected by solid phase assays.
Patient no Rejection Pre-transplant Before tacrolimus 
reduction
After tacrolimus reduction
class I class II class I class II class I class II
1 + + - + - + -
2 + - - + + + -
3 + - - - - - + (D) CTX
4 - - - - - - + (D)
5 - + (D) + (D) - + - + (D)
6 - - - - - + + (D)
7 - - - - + - +
8 - + + nd nd - +
9 - - + + - - -
10 - + - + (D) + + + (D)
11 - + + - + + +
12 - + - + (D) - + (D) -
13 - + + + (D) - + (D) + (D)
+: positive for HLA IgG antibodies, - : negative for HLA IgG antibodies, D: donor specific HLA antibodies, CTX:  
donorspecific cytotoxic HLA antibodies as determined with CDC,  nd : not done. 
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4, the presence of donor specific HLA antibodies had no influence on the course of 
graft function (p=0.106 for creatinine levels two years after transplantation).
Discussion
In this study, we have evaluated whether the presence of HLA antibodies was 
associated with an increased risk for the occurrence of acute rejection after the 
withdrawal of tacrolimus. Since all patients in the study group received identical 
immunosuppression which was reduced using a standard conversion scheme, we 
were able to study the impact of HLA antibodies in a well defined, although relatively 
small, group of patients. 
A number of techniques can be used to detect circulating HLA antibodies. CDC 
detects the presence of complement activating HLA antibodies and is routinely 
used in pre-transplant screening.13 The introduction of ELISA and flow cytometry 
based methods has allowed a 10-20 fold more sensitive detection of HLA antibodies. 
Recently, single-antigen assays, based on beads coated with single antigens of 
HLA class I and II, have become available that can reliably determine the antigen-
specificity of HLA antibodies.14 Despite arguments that ELISA methods do not 
provide information on the functional meaning of the detected antibodies, a strong 
correlation has been found between the presence of HLA antibodies, detected by 
ELISA, and the occurrence of acute rejection 11 and graft survival . In our study, we 
did not find an association between the presence of donor specific (confirmed in 
Luminex bead based Crossmatch assay, data not shown) or total HLA antibodies and 
the occurrence of acute rejection after reduction of immunosuppression. Notably, 
we observed successful withdrawal of tacrolimus in four patients with donor specific 
HLA class I antibodies. The reduction of immunosuppression only seldom resulted 
in the detection of newly formed HLA antibodies, even in patients who experienced 
an acute rejection after tapering of their immunosuppression. Interestingly, the 
single patient who developed donor-specific HLA antibodies and experienced an 
acute rejection after the withdrawal of tacrolimus, was the only patient in whom the 
standard microcytotoxicity analysis revealed cytotoxic HLA antibodies. These data 
suggest that not only the presence, but also the cytotoxic potential of the donor-
specific HLA antibodies is crucially important, but more data to support and analyze 
this phenomenon are needed. 
The induction of HLA antibodies after transplantation has been associated with an 
increased risk for the development of chronic allograft nephropathy (CAN).1 The 
exact mechanisms by which HLA antibodies may cause damage to the allograft 
are not completely understood. It is well established that certain subclasses of HLA 
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antibodies are able to activate the complement system, subsequently resulting in 
immune activation. In addition, a recent study showed that HLA antibodies are 
able to cross-link HLA molecules on endothelial cells resulting in the release of pro-
inflammatory molecules.16 In our study population, in six out of the seven patients 
that carried donor specific HLA antibodies, these antibodies were unable to activate 
complement. In fact, retrospective IgG Luminex Single Antigen analysis revealed the 
presence of donor specific HLA class I and class II antibodies before transplantation in 
one patient. Since pre-transplant CDC cross match analysis was negative, indicating 
that the HLA antibodies were either non complement-binding or very weak, there 
were no objections against transplantation of the proposed donor kidney according 
to the transplant protocol.  Whether these HLA antibodies will have a detrimental or 
potential beneficial effect on transplantation outcome over time is unclear. However, 
two-year follow up showed that graft function did not differ between patients with 
and without HLA antibodies. It has been previously shown that HLA antibodies can be 
present without causing endothelial injury, a phenomenon called accommodation.17 
Another mechanism explaining a putative beneficial potential is that the harmless 
HLA antibodies may bind to cells of the allograft, thereby protecting the allograft 
from attack by other immune cells or harmful antibodies. 
In search for other factors that might differ between rejectors and non-rejectors, 
we only found a significantly higher number of HLA-DR mismatches in the rejector 
group compared with the non-rejector group. This finding does not appear to be 
correlated directly with HLA-antibody production. It merely indicates that withdrawal 
of a calcineurin inhibitor should be considered more carefully in donor-recipients 
combinations with one or more HLA-DR mismatches.
Taken together, our results suggest that the presence of HLA antibodies is not 
predictive for the occurrence of acute rejection following the subsequent reduction 
of immunosuppression. Furthermore, the presence of HLA antibodies does not 
preclude successful reduction of immunosuppression. 
Table 4. Serum creatinine (μmol/l) in patients with successful withdrawal of tacrolimus, according to the 
presence or absence of donor-specific HLA antibodies at 3 months after discontinuation of tacrolimus.
Donor-specific
HLA antibodies
Before tacrolimus 
witdrawal
1 Yr after transplantation 2 Yrs after transplantation
Present (n=6)  99 ± 22  96 ± 30  93 ± 12
Absent (n=33) 111 ± 32 108 ± 35 122 ± 34
10
HLAantibodiesandimmunosuppressionreduction
References
1.  Andres A. Cancer incidence after immunosuppressive treatment following kidney trans-
plantation. Crit Rev.Oncol.Hematol. 200;6:71-8.
2.  van Hooff JP, Christiaans MH. Use of tacrolimus in renal transplantation. Transplant.
Proc. 1999;31:3298-3299.
3.  Bakker RC, Hollander AA, Mallat MJ et al. Conversion from cyclosporine to azathioprine 
at three months reduces the incidence of chronic allograft nephropathy. Kidney Int. 
2003;64:1027-1034.
4.  Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced 
calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 
2001;9:167-173.
.  Susal C, Opelz G. Good kidney transplant outcome in recipients with presensitization 
against HLA class II but not HLA class I. Hum.Immunol. 2004;6:810-816.
6.  Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplanta-
tion. N.Engl.J.Med. 1969;280:73-739.
7.  McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplan-
tation. Transplantation 2000;69:319-326.
8.  Mao Q, Terasaki PI, Cai J et al. Extremely High Association Between Appearance of HLA 
Antibodies and Failure of Kidney Grafts in a Five-Year Longitudinal Study. Am J Trans-
plant. 2007;7:864-871.
9.  Susal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic 
testing in kidney transplantation. Transplant.Proc. 2004;36:29-34.
10.  Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective 
trial. Am J Transplant. 2004;4:438-443.
11.  Monteiro F, Buelow R, Mineiro C, Rodrigues H, Kalil J. Identification of patients at high 
risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies 
by enzyme-linked immunosorbent assay. Transplantation 1997;63:42-46.
12.  Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD2 treatment, 
a functional CD4+CD2+ regulatory T-cell pool is present in renal transplant recipients. 
Am J Transplant. 2007;7:249-2.
13.  ten Hoor GM, Coopmans M, Allebes WA. Specificity and Ig class of preformed alloantibo-
dies causing a positive crossmatch in renal transplantation. The implications for graft 
survival. Transplantation 1993;6:298-304.
14.  Vaidya S, Partlow D, Susskind B et al. Prediction of crossmatch outcome of highly sen-
sitized patients by single and/or multiple antigen bead luminex assay. Transplantation 
2006;82:124-128.
1.  Campos EF, Tedesco-Silva H, Machado PG et al. Post-transplant anti-HLA class II antibodies 
as risk factor for late kidney allograft failure. Am J Transplant. 2006;6:2316-2320.
16.  Yamakuchi M, Kirkiles-Smith NC, Ferlito M et al. Antibody to human leukocyte antigen 
triggers endothelial exocytosis. Proc.Natl.Acad.Sci.U.S.A 2007;104:1301-1306.
17.  Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized 
patients: a potential role for Bcl-xL and alloantibody. Am J Transplant. 2001;1:260-269.
106
Chapter 6
Following anti-CD25 treatment, a functional CD4+CD25+ Treg 
pool is present in renal transplant recipients
Ellen Kreijveld, Hans J.P.M. Koenen, Ina S. Klasen, Luuk B. 
Hilbrands and Irma Joosten
American Journal of Transplantion, 2007 Jan 7(1): 249-55.
When spring comes, the grass grows by itself
- Tao Te Ching - 
Chapter5
107
Anti-CD25treatmentandCD4+CD25+Treg
Chapter 6
Following anti-CD25 treatment, a functional CD4+CD25+ Treg 
pool is present in renal transplant recipients
Ellen Kreijveld, Hans J.P.M. Koenen, Ina S. Klasen, Luuk B. 
Hilbrands and Irma Joosten
American Journal of Transplantion, 2007 Jan 7(1): 249-55.
When spring comes, the grass grows by itself
- Tao Te Ching - 
108
Chapter6
Abstract
Daclizumab, a humanized antibody directed against the α-chain of the interleukin-2 
receptor (CD2), has shown efficacy in the prevention of acute rejection following 
organ transplantation. However, anti-CD2 therapy can be expected to affect not only 
alloreactive effector T cells, but also CD4+CD2+ regulatory T (Treg) cells that are shown 
to play an important role in the induction of transplantation tolerance. Therefore, 
the size and function of the Treg pool in human renal allograft recipients after 
single-dose daclizumab administration was investigated in this study. Approximately 
8 weeks after administration, daclizumab was cleared from the circulation and the 
Treg population then present appeared not different from that observed before 
transplantation. Functional analysis revealed that the Treg possessed a normal 
capacity to suppress mixed lymphocyte reactions in vitro. These data indicate that 
after daclizumab therapy a Treg population, normal in number and function, is 
present in the peripheral blood of renal transplant recipients.
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Introduction
The administration of immunosuppressive drugs following solid organ 
transplantation is essential to control the activation of alloreactive T cells and 
prevent rejection of the allograft. However, life-long administration of these 
drugs is accompanied by increased risk for infections and malignancies as well 
as other serious adverse effects.1 The development of monoclonal antibodies 
(mAb), directed against cell types or activation markers, has allowed more 
specific targeting of the effector cell and its signaling pathways. Daclizumab, 
a humanized antibody directed against the α-chain of the interleukin-2 (IL-2) 
receptor (CD2), is one of the drugs designed for this purpose.2 In renal transplant 
recipients, daclizumab administration significantly decreased the incidence of 
acute rejection and allowed the minimization of the use of steroids or the delay 
of calcineurin inhibitor administration.2;3 Furthermore, no side-effects were 
observed following administration of daclizumab.2 IL-2 was initially identified 
as a growth factor for effector T cells.4 However, mice rendered deficient in IL-
2 or in the α- or β-chain of the IL-2 receptor (IL-2R) succumbed to aggressive 
lymphoproliferation. These animals seem to lack the functional population of 
CD4+CD2+ regulatory T cells (Treg). This subset of CD4+ T cells is hyporesponsive 
following TCR stimulation and capable of suppressing the activity of self-reactive 
CD4+ and CD8+ T cells.6-8 These observations, together with the fact that Treg 
express high levels of the IL-2R, have implied a role for IL-2 signaling in Treg 
development or function. Initial studies suggested that IL-2 delivers an essential 
signal during the thymic development of Treg,9 but accumulating data now 
provide evidence that IL-2 signaling is particularly essential for the survival and 
competitive fitness of mature Treg in the periphery.10;11 These observations have 
raised the question whether interference with IL-2 signaling through daclizumab, 
might compromise the number or function of human Treg. It is unknown whether 
daclizumab therapy leads to the depletion of the Treg population and whether this 
population is restored and functionally active after daclizumab clearance. This 
is of clinical relevance in transplantation since, next to regulating autoreactive 
T cells, Treg have been shown able of regulating alloresponses and to be involved 
in the induction of graft tolerance.12;13 Therefore, we have analyzed the size and 
function of the CD4+CD2+ T-cell population of renal transplant patients that 
received induction therapy with daclizumab. Our data show that after clearance 
of the antibody from the blood circulation, a CD4+CD2+ Treg population, normal 
in size and function, is present in the peripheral blood of daclizumab treated 
renal transplant patients.
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Material and Methods
Transplant patients
Patient characteristics, transplantation information and sample dates are given in 
Table 1. All patients received a renal allograft (first graft) at the Radboud University 
Nijmegen Medical Centre. Immunosuppressive therapy consisted of rapamycin, 
mycophenolate mofetil and prednisolone. A single dose of daclizumab (1 mg/
kg i.v.) was administered at the day of transplantation. Transplant controls also 
received a renal allograft but did not receive daclizumab and immunosuppressive 
therapy consisted of tacrolimus, mycophenolate mofetil and prednisolone. Blood 
and urine samples from transplant patients were collected after informed consent. 
At the time of blood sampling, all daclizumab treated and control patients had 
stable renal function and had not experienced any acute rejection episodes. Buffy 
coats from healthy blood donors were obtained from the Sanquin Blood Bank 
(Region South East, Nijmegen, the Netherlands). IRB approval was obtained for 
this study.
Soluble IL-2R alpha (sIL-2Rα ) measurement
Soluble IL-2Rα levels were determined in weekly collected urine samples using a 
commercially available immunometric assay (Immulite®, DPC, Los Angeles, CA, 
USA) as described before.14
Cell isolation
Peripheral blood mononucleated cells (PBMC) were isolated from recipient 
blood samples (taken at timepoints indicated in Table 1) by density gradient 
centrifugation using Lymphoprep (Nycomed Pharma AS, Oslo, Norway). CD4+ T 
cells were purified from PBMC by negative selection using monoclonal antibodies 
(mAb) in combination with sheep anti-mouse Ig coated magnetic beads (DAKO, 
Glostrup, Denmark) as described elsewhere.1 This resulted in a CD4+ T-cell 
enrichment of >9 %. From the resultant CD4+ T cells, the CD2+ and CD2− cells 
were separated using MACS isolation according to the manufacturer’s instructions 
(Miltenyi GmbH, Germany). Donor splenocytes were isolated from small fractions 
of spleen tissue obtained from deceased organ donors. The spleen tissue was 
minced in PBS supplemented with 0.3% citrate and passed over a sterile 74 μM 
netwell filter (Costar, Corning International, NY, USA) and the splenocytes were 
isolated from the spleen suspension by density gradient centrifugation. The cells 
were stored in liquid nitrogen until further use. In the case of living organ donors, 
100 mL blood was collected from the donor and PBMC were isolated and stored as 
described above. HLA typing was conducted according to ASHI standards.
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Figure 1: (A) The size of the CD4+CD25+ T cell population of transplant patients after daclizu-
mab therapy is not altered. The percentage of CD25+ cells (y-axis) of the total CD4+ T-cell population of 
renal transplant patients before (1st column) and after (2nd column) daclizumab therapy (upon clearance of the 
antibody), healthy individuals (3rd column) and renal transplant patients after transplantation that were not 
treated with daclizumab (samples are taken at timepoints comparable to the samples taken in the daclizumab 
group after transplantation) (4th column). The values before and after daclizumab treatment were compared 
with a non-parametric test for paired samples. The values in columns 2–4 were compared using Kruskal–Wallis 
analysis. p ≤ 0.05 was considered statistically significant. ns: not significant. (B) FoxP3 analysis of two transplant 
patients (Table 1, patients 6 and 7), before and after daclizumab treatment. FoxP3 (x-axis) plotted against CD4 
(y-axis), gated on CD4+CD25+ cells.
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Figure 2: CD4+CD25+ T cells from renal transplant patients are anergic after daclizumab therapy. 
Timepoints posttransplantation and post daclizumab clearance are given in Table 1. (A) The proliferative capa-
city of 2 × 104 CD4+CD25+ T cells (white bars) and CD4+CD25− control T cells (black bars) stimulated with 
1 × 105 stimulator cells (30 Gy γ-irradiated) obtained from the transplant donor (left) or a HLA mismatched 
third party donor (middle) or unstimulated (right) is shown. (B) The hyporesponsive state appears reversible 
by the addition of exogenous IL-2. Proliferation was examined by 3H-thymidine incorporation at day 6 and is 
expressed as mean ± SD counts per 5 min of triplicate measurements. One representative example out of five 
is shown (patient 4, 18 weeks post Tx, 7 weeks after daclizumab clearance).
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Flow cytometry
The percentage of CD4+CD2+ cells was determined using four-color flow cytometry. 
Briefly, the cells were washed with PBS–BSA (0.2%) and labeled with fluorochrome-
conjugated monoclonal antibodies (mAb). Samples were incubated in the dark for 20 
min, washed twice and analyzed. The following antibodies were used: CD3-FITC (Dako, 
Glostrup, Denmark), CD2-PE (clone MA21, BD-Biosciences, NY, USA), CD4-ECD (Beckman 
Coulter Corporation, Miami, FL, USA).
Stimulation assays to study T cell anergy
T cell anergy was studied in stimulation assays, as described elsewhere.6;8 2 × 104 CD2+ 
or CD2− T cells were cultured in the presence of 1 × 10  γ-irradiated (30 Gy) stimulator 
cells from either the organ donor (splenocytes in the case of deceased donors and PBMC 
in the case of  living donors) or HLA mismatched third party donor PBMC in the presence 
or absence of 1 U/mL IL-2. Proliferation was examined by 3H thymidine incorporation 
using a Gas Scintillation Counter (Canberra Packard, Matrix 96 Beta-counter, Meriden, 
USA) at day 6. To this end, 1 μCi tritium (3H)-labeled thymidine (ICN Pharmaceuticals, 
Irvine, CA) was added to the wells and was present during the last 8 h of culture. The 3H 
incorporation is expressed as mean ± SD counts per  min of triplicate measurements.
Co-cultures to study suppressive capacity
A primary mixed lymphocyte culture (MLC) was set-up by culturing  × 104 PBMC from 
the patient with  × 104 HLA mismatched γ-irradiated (30 Gy) stimulator cells from the 
organ donor or a HLA mismatched third party donor. Proliferation was analyzed at day 6 
by 3H-thymidine incorporation. The suppressive capacity of the CD2+ and CD2− control 
T cells was studied by addition of the cells at different ratios to the primary MLC, as 
described before.6;8
Table 1: Patient characteristics and transplantation information
Positive Sample HLA
sCD25 urine date mismatches
(weeks (weeks donor-recipient Max %
Patient Sex Age Donor post Tx) post Tx) (HLA-A,-B,-DR) PRA Immunosuppression
1 M 28 CAD 13 22 0,1,0 2 Dac, Rapa, MMF, Pred
2 F 37 CAD 8 14 1,0,1 0 Dac, Rapa, MMF, Pred
3 M 53 LRD 12 17 2,2,1 0 Dac, Rapa, MMF, Pred
4 M 69 CAD 7 18 0,1,0 2 Dac, Rapa, MMF, Pred
5 F 43 CAD 13 17 0,0,0 0 Dac, Rapa, MMF, Pred
6 M 37 LRD 7 11 1,1,1 5 Dac, Rapa, MMF, Pred
7 M 60 LRD 5 21 1,1,1 2 Dac, Rapa, MMF, Pred
8 M 45 LRD nd 4 2,2,1 nd Dac, Tacro, MMF, Pred
9 M 49 CAD 17 1,1,1 0 Tacro, MMF, Pred
10 F 46 LRD 23 1,1,1 0 Tacro, MMF, Pred
11 F 45 LRD 36 1,1,1 0 Tacro, Aza, Pred
12 M 39 CAD 28 0,1,2 83 Tacro, Aza, Pred
13 M 54 LRD 25 0,0,0 4 Tacro, Aza, Pred
14 F 50 CAD 29 1,0,2 nd Tacro, Aza, Pred
CAD, cadaveric donor; LRD, living donor; PRA, panel reactive antibody; Dac, Daclizumab; Rapa, rapamycin; Tacro, Tacrolimus; Aza,
azathioprine; MMF, mycophenolate mofetil; Pred, prednisone; nd, not done.
114
Chapter6
Statistical analysis
The percentages of CD4+CD2+ regulatory T cells before and after daclizumab treatment 
were compared using a nonparametric Wilcoxon test for paired values. A nonparametric 
Kruskal–Wallis analysis was used to compare the data after daclizumab treatment with 
those from transplant and healthy controls. The 3H incorporation in suppression assays 
was compared using a nonparametric Mann–Whitney U analysis. p-values ≤ 0.0 were 
considered statistically significant.
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Figure 3: CD4+CD25+ T cells from renal transplant recipients after daclizumab therapy contain 
regulatory activity. (A) The suppressive potential of CD4+CD25+ T cells from the daclizumab patients was 
examined in co-culture suppression assays. A primary MLC, consisting of 5 × 104 responder PBMC from the 
patient stimulated with 5 × 104 stimulator cells (30 Gy, γ-irradiated) from the organ donor (left) or from a HLA-
mismatched third party donor (right), was setup. Freshly isolated CD4+CD25+ (o) or CD4+CD25− control (I) 
T cells were added to this primary MLC at different ratios. Proliferation of the MLC was examined by 3H-
thymidine incorporation at day 6 and is expressed as mean ± SD counts per 5 min of triplicate measurements. 
Counts were compared using Mann–Whitney U analysis and p ≤ 0.05 was considered statistically significant 
(*). One representative example out of five is shown (patient 5; 17 weeks post Tx, 13 weeks after daclizumab 
clearance). (B) The suppressive capacity of CD4+CD25+ and CD4+CD25− cells against donor and third-party 
alloreactivity for all five transplant patients. SD were typically <25%. nd = not done.
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Results
Seven renal transplant recipients were selected to study the CD4+CD2+ T cell 
population after single-dose daclizumab induction therapy. Patient characteristics 
are given in Table 1. We have previously reported that measurement of sIL-2Rα 
concentrations in the urine is an excellent predictor of CD2 blockade on peripheral 
blood lymphocytes by daclizumab in the peripheral blood.14 Therefore, sIL-2Rα 
concentrations were monitored in urine samples on a weekly basis to determine the 
moment of daclizumab clearance from the circulation. Analysis of urine samples 
showed that the sIL-2Rα concentration dropped to undetectable levels immediately 
after daclizumab administration and was restored to detectable levels after 8 ± 3 
weeks. Within 9 weeks after the recurrence of sIL-2Rα in the urine, blood samples 
were collected and CD4+CD2+ cells were isolated (Table 1). At that time graft function 
was stable in all patients and none of them had experienced an acute rejection 
episode. In the study group, the mean percentage of CD2+ cells within the total CD4+ 
T-cell population after daclizumab treatment was 4.7 ± 2.2%. This percentage was not 
significantly different from that observed in samples taken before transplantation in 
the same patients (.1 ± 2.%), healthy controls (.0 ± 1.6%) or patients that underwent a 
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Figure 4: Suppressive potential of CD4+CD25+ regulatory T cells isolated from healthy (left fi-
gure) and non-daclizumab treated transplant controls (right figure). Freshly isolated CD4+CD25+ 
(o) or CD4+CD25− control (I) T cells were added at different ratios to a primary MLC, consisting of 5 × 104 
responder PBMC stimulated with 5 × 104 HLA mismatched stimulator cells (30 Gy, γ-irradiated). Proliferation 
of the MLC was examined by 3H-thymidine incorporation at day 6 and is expressed as mean ± SD counts per 
5 min of triplicate measurements. Counts were compared using Mann–Whitney U analysis and p ≤ 0.05 was 
considered statistically significant (*). One typical example (nhealthy = 5, nnon-daclizumab = 3) per group is given.
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renal transplantation but did not receive daclizumab therapy (.4 ± 1.6%) (Figure 1A). 
FoxP3 expression was analyzed in two patients and showed that the majority of the 
CD4+CD2+ cells expressed FoxP3 (Figure 1B). The percentage of FoxP3+ cells appeared 
slightly lowered after daclizumab clearance (79.0 ± 1.0% versus 71. ± 0.%). However 
the group was too small to detect a significant difference. Functional analysis of the 
CD4+CD2+ T cells from five patients included analysis of the proliferative capacity 
after TCR stimulation using donor cells or HLA mismatched third party cells and 
their capacity to inhibit the proliferation of conventional T cells to these stimuli. 
First, the proliferative capacity of the CD4+CD2+ cells was investigated to ensure 
that the CD2+ T-cell population displayed anergy, a feature of regulatory T cells, and 
did not merely represent activated T cells. The CD4+CD2+ cells from patients treated 
with daclizumab were anergic towards both donor and third party cells, since they 
did not proliferate in a primary MLC, while the addition of exogenous IL-2 was able 
to reverse this hyporesponsive state (Figure 2). In co-culture suppression assays, the 
CD4+CD2+ cells showed dose dependent inhibition of the proliferation of conventional 
responder T cells to allogeneic stimuli (Figure 3). However, inter-patient variety was 
observed in the potency of CD4+CD2+ cells to suppress allogeneic responses. At high 
responder: suppressor ratios all five patients were capable of suppressing both donor 
and third-party responses. However, at lower concentrations, the individual patients 
revealed different responses. Whereas in two patients the anti-donor suppression was 
stronger as compared to third-party responses, opposite results were observed in the 
other three patients. In addition, their overall suppressive capacity was not different 
from that observed in healthy individuals or transplant controls (Figure 4). 
Unfortunately, we were not able to analyze the fate of the CD4+CD2+ regulatory 
T-cell pool during daclizumab blockade in the study population. However, we have 
indications to believe that Treg are transiently affected by daclizumab treatment. 
First, in vitro incubation of PBMC with daclizumab showed a decrease of the percentage 
CD4+CD2+ cells in time (Figure A). Concomitant analysis of FoxP3 expression 
showed that especially the CD4+CD2+FoxP3+ T-cell subset was affected by daclizumab 
treatment (Figure A). Interestingly, this same phenomenon was observed in a 
transplant patient that received induction therapy with daclizumab. Flow cytometric 
analysis of PBMC isolated before and 1, 2 and 4 weeks after transplantation (and 
daclizumab administration) showed a decrease in the percentage of CD4+CD2+FoxP3+ 
cells, without an equivalent increase in CD4+FoxP3+ cells (illustrated for week 4 
in Figure B). These data suggest that CD2 blockade by daclizumab may lead to 
a transient reduction in the number of regulatory CD4+CD2+FoxP3+ cells. Taken 
together, our data show that following daclizumab therapy, a CD4+CD2+ regulatory 
T-cell population, normal in size and function, is present in the peripheral blood of 
renal transplant patients.
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Discussion
It has become evident that IL-2 delivers an indispensable signal to CD4+CD2+ 
regulatory T cells, crucially important for their survival in the periphery.10;11 With 
this finding, the concern was raised whether daclizumab, an antibody blocking the 
IL-2 receptor alpha chain, might have a harmful and possibly irreversible effect on 
the naturally occurring CD4+CD2+ Treg population. In this paper, we show that 
in transplant patients, treated with daclizumab at the time of transplantation, a 
functional Treg population is present upon clearance of the antibody. First of all, we 
established that in our patients, who had regular levels of CD4+CD2+ Treg before 
transplantation, daclizumab treatment was effective in impairing CD2 expression, 
using sIL-2R− measurement in urine, proven to be an excellent predictor for CD2 
blockade on peripheral blood lymphocytes.14 There is as yet insufficient insight in 
whether effective levels of daclizumab truly impair the number of circulating Treg 
or simply interfere in marker expression. Daclizumab is a so-called non-depleting 
antibody, suggesting that binding of daclizumab to CD2-expressing cells as such 
is not likely to result in the acute depletion of these cells from the circulation by, 
e.g. antibody dependent cytotoxicity (ADCC). A recent in vitro study, using pancreatic 
islet autoreactive effector T cells, showed that daclizumab efficiently inhibited T- 
cell proliferation, but could not induce ADCC, complement-dependent cytotoxicity 
(CDC), or apoptosis.16 However, there may be indirect consequences of CD2 blockade; 
data obtained in a mouse model indicated that in the absence of IL-2 or its receptor, 
mature CD4+CD2+ Treg can not survive in the periphery,10;11 fuelling the notion that 
daclizumab induced CD2 blockade might lead to cell death through IL-2 deprivation. 
In a renal transplant setting, Vincenti et al. 2 confirmed a reduction in the number of 
circulating CD2+ T cells using a staining antibody directed against a different epitope 
of CD2 than the one recognized by daclizumab. The observed reduction in CD2+ 
cells might reflect a reduction in CD4+CD2+ regulatory T cells; a hypothesis that is 
supported by our observations that, both in vitro and in vivo, daclizumab blockade 
resulted in a reduction of the percentage of CD4+CD2+FoxP3+ cells. However, whether 
CD2 blockade by daclizumab truly results in the depletion of CD4+CD2+ regulatory 
T cells, presumably through IL-2 deprivation, needs further investigation. After 
daclizumab clearance, the percentage of CD4+CD2+ Treg in our transplant patients 
was similar to the level found before transplantation. In addition, the number of 
CD4+CD2+ Treg in daclizumab treated patients did not differ from that observed 
in healthy individuals or in patients that underwent transplantation, but that 
were not treated with daclizumab. Although small differences in cell proportions 
between groups may have been missed due to the small sample size (type II error), our 
results indicate that daclizumab therapy does not irreversibly damage the number 
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of CD4+CD2+ Treg. Importantly, CD4+CD2+ Treg obtained from these patients after 
clearance of the antibody contained adequate suppressive capacity towards both 
donor and third-party stimulator cells, at a level comparable to that of CD4+CD2+ Treg 
obtained from healthy blood donors. This suggests that, next to numbers, daclizumab 
does not affect long-term suppressor function of CD4+CD2+ Treg. Interestingly, recent 
data have shown that rapamycin facilitates the function of CD4+CD2+ Treg.17;18 Our 
daclizumab treated patients received concomitant immunosuppressive therapy that 
consisted of rapamycin, MMF and prednisolone. We here show that the favorable effect 
of rapamycin on CD4+CD2+ Treg is not reversed by daclizumab and that combinational 
therapy of daclizumab and rapamycin preserves the function of the CD4+CD2+ Treg. 
Finally, it should be noted that the patients in this study only received a single dose of 
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Figure 5: CD4+CD25+FoxP3+ cells are negatively affected during daclizumab blockade. (A) FoxP3: 
CD25 analysis of PBMC, unstimulated (left plot) or incubated with daclizumab (25 μg/mL for 48 h, right plot) in 
vitro. (B) FoxP3: CD25 analysis of a transplant patient (patient 8), before transplantation (left plot) and 26 days 
after transplantation and daclizumab administration (right plot).
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daclizumab (1 mg/kg) while other regimes often consist of repetitive dosing. The effect 
of more prolonged blockade of CD2 on CD4+CD2+ Treg is unknown. 
In summary, our data show that after clearance of the antibody, a CD4+CD2+ Treg 
population, comparable in size and function to healthy individuals, is present in 
the peripheral blood of daclizumab treated renal transplant recipients. These data 
indicate that daclizumab does not irreversibly damage the Treg population generally 
assumed to be important for the induction of transplantation tolerance.
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Abstract
The induction of transplantation tolerance involves a T-cell–mediated process of 
immune regulation. In clinical transplantation, the use of immunosuppressive 
drugs that promote or facilitate this process would be highly desirable. Here, we 
investigated the tolerance-promoting potential of the immunosuppressive drug 
FK778, currently under development for clinical therapy. Using a human allogeneic 
in vitro model we showed that, upon T-cell receptor (TCR) triggering, FK778 induced 
a regulatory phenotype in CD4+CD2- T cells. Purified CD4+CD2- T cells primed in the 
presence of FK778 showed hyporesponsiveness upon restimulation with alloantigen 
in the absence of the drug. This anergic state was reversible by exogenous interleukin-
2 (IL-2) and was induced independent of naturally occurring CD4+CD2+ regulatory 
T cells. Pyrimidine restriction was a crucial requirement for the de novo induction 
of regulatory activity by FK778. The FK778-induced anergic cells showed suppressor 
activity in a cell-cell contact–dependent manner; were CD2high, CD4RO+, CD27, 
and CD62L-; and expressed cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), 
glucocorticoid-induced tumor necrosis factor receptor (GITR), and FoxP3. The cells 
revealed delayed p27kip1 degradation and enhanced phosphorylation of STAT3. In 
conclusion, the new drug FK778 shows tolerizing potential through the induction of 
a regulatory T-cell subset in CD4+CD2- T cells.
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Introduction
The use of immunosuppressive agents after solid-organ transplantation is crucial for the 
prevention of transplant rejection. In the past few decades, potent immunosuppressive 
regimens have been developed, currently leading to 1-year graft survival rates exceeding 
8%.1 However, in the long run, a considerable number of grafts are lost, mainly due 
to chronic rejection. Moreover, the continuous suppression of the immune system 
increases the risk for infections and malignancies. Therefore, the preferable approach 
to improve transplantation outcome is the induction of transplant tolerance: the 
acceptance of the graft in the absence of chronic immunosuppression.2 Tolerance 
induction is believed to involve, at least in part, a T-cell–mediated process of immune 
regulation.3 Indeed, animal studies have revealed that regulatory T (Treg) cells form 
an intricate part of the tolerance-maintaining network.4 Consequently, it is crucial 
that immunosuppressive drugs, administered to prevent acute graft rejection, do 
not interfere with the development of Treg cells. The ideal drug should not only 
inhibit effector T-cell function, but also enhance or facilitate Treg-cell function. 
FK778 is an immunosuppressive drug currently under development for use in organ 
transplantation. FK778 is a synthetic analog of the active metabolite of leflunomide, 
A77 1726. FK778 has a much shorter half-life than the parent drug, making it suitable 
for use in transplantation settings. These compounds belong to the malononitrilamides 
(MNAs), a family of low molecular-weight substances structurally different from other 
currently applied drugs.6 Their primary mode of action is the restriction of the de 
novo pyrimidine synthesis through the inhibition of dihydro-orotate dehydrogenase 
(DHODH), the rate- limiting enzyme in the de novo pyrimidine synthesis pathway.7-9 
Interestingly, several studies have shown that next to inhibition of pyrimidine synthesis, 
A77 1726 also interferes with the phosphorylation of several tyrosine kinases, proteins 
involved in initial T-cell activation.9-12 In vitro, A77 1726 blocked T-cell proliferation 
upon stimulation with anti-CD3 monoclonal antibody (mAb), anti-CD28 mAb and 
PMA, and interleukin-2 (IL-2).8 In addition, inhibition of both B-cell proliferation and 
production of immunoglobulin M (IgM) and IgG antibodies was observed.13 In animal 
models, A77 1726 alone or in combination with other immunosuppressive drugs was 
shown to prevent both acute and chronic graft rejections and reverse ongoing acute 
allograft rejection.14-18 Finally, recent studies showed that FK778 is a potent inhibitor 
of the replication of the cytomegalovirus (CMV), a virus responsible for considerable 
morbidity and mortality in immunocompromised patients.19 The first clinical data 
showed that FK778 is safe and well tolerated and reduced the incidence rate of acute 
rejection in human renal transplant recipients. The immunomodulatory effects of 
FK778 on human T cells have not been studied in detail before. In this study, we have 
investigated the tolerance-promoting potential of FK778 with an emphasis on CD4+ T 
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Figure 1. FK778 allows the activation but inhibits the proliferation of allogeneic stimulated 
PBMCs. (A) A primary MLC was performed with 105 responder PBMCs and 105 allogeneic stimulator cells. 
Increasing concentrations of FK778 were added at day 0. Proliferation was measured at day 6, by means of 
3H uptake, and percentage of inhibition of the primary MLC is depicted for increasing FK778 concentrations. 
Error bars represent SD counts. (B) The kinetics of proliferation during primary MLC (y-axis) was investigated 
during treatment with 0 μg/mL (I), 10 μg/mL (g), or 50 μg/mL FK778 (o). At the peak of proliferation (day 5), 
** p=0.002 for differences between untreated and FK778 treated cells. (C) Annexin-V expression was analyzed 
at day 6 of the primary MLC on CD3+CD4+ gated cells using flow cytometry. The number of annexin V+ cells 
is indicated in each plot. (D) At day 3, blast formation of untreated control cells (left panel), cells treated with 
50 μg/mL FK778 (middle panel), and naive responder PBMC (right panel) was analyzed on CD3+CD4+ cells 
using flow cytometry. The number of blasts is indicated in each plot. (E) Cell-surface marker expression at 
day 6 of the primary MLC (left column shows CD25; right column, HLA-DR) of untreated control cells (top 
row), FK778-treated cells (middle row), and unstimulated responder PBMCs (bottom row) was analyzed on 
CD3+CD4+ gated cells. Percentage of positive cells is depicted in each plot, and the mean fluorescent intensity 
(MFI) of CD25 expression in the positive fractions is given. One representative experiment of 8 is presented.
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cells, since these cells play a crucial role in the regulation of the immune response 
directed against the allograft. The results demonstrate that in vitro allogeneic priming 
of human CD4+CD2- T cells in the presence of FK778 leads to the induction of a 
regulatory CD4+CD2high T cell subset that is anergic and possesses suppressor activity.
Materials and methods
Cell isolation
Peripheral blood mononuclear cells (PBMCs) from healthy blood donors were 
isolated by density gradient centrifugation in LeucoSep tubes (Greiner Bio-One, 
Frickenhausen, Germany) using Lymphoprep (Nycomed Pharma AS, Oslo, Norway). 
Cells were stored in liquid nitrogen until further use. The CD4+CD2- cell fraction 
was isolated from PBMCs as described previously.20 In short, CD4+ T cells were isolated 
from PBMCs using a negative selection protocol in combination with magnetic beads. 
PBMCs (3x108) were incubated with mouse antihuman antibodies directed against 
CD14, CD16, CD6, CD19, CD8, and CD33 (BD Biosciences, Erembodegem, Belgium) 
for 4 minutes. Unbound antibodies were removed and cells were incubated with 
goat anti-mouse magnetic beads (Dynal, Oslo, Norway) for an additional 4 minutes. 
Bead-cell complexes were removed using a magnetic holder. The remaining CD4+ 
cells were incubated with CD2 micro beads (Miltenyi, Bergisch Gladbach, Germany) 
and CD2+ and CD2- subsets were separated using magneticactivated cell-sorting 
(MACS) columns (Miltenyi). To enhance purity, this latter step was repeated once. Cell 
purity was analyzed using flow cytometry (> 9%).
Culture conditions and immunosuppressive agents
All cultures were conducted in RPMI 1640 medium supplemented with 20 mM L-
glutamine, 20 mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin 
(Gibco, Carlsbad, CA), and 10% heat-inactivated human pooled serum (HPS). Cultures 
were incubated in a humidified incubator at 37°C with % CO2. FK778 (Astellas 
Pharma, Munich, Germany) was kindly provided for research purposes. Aliquots were 
prepared in DMSO at final concentrations of 100 mg/mL and stored at 4°C. The applied 
concentrations were selected on the basis of previously published values.8 FK06, 
rapamycin, and mycophenolic acid (MPA), the active metabolite of mycophenolate 
mofetil (MMF), were used at concentrations that showed optimal inhibition of 
the proliferation in the primary mixed lymphocyte culture (MLC). Uridine (40 μM; 
Amersham, Buckinghamshire, United Kingdom) was added to selected cultures to 
restore pyrimidine levels.
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Primary Mixed Lymphocyte Cultures (MLC)
Primary MLC were performed in 96-well round-bottom plates. Responder PBMCs (10) 
were stimulated with allogeneic human leukocyte antigen (HLA)–mismatched 30 
Gy γ-irradiated stimulator PBMCs (10) in 200 μL culture medium in the presence or 
absence of FK778. Proliferation was analyzed by 3H-thymidine incorporation using a 
gas scintillation counter (Matrix 96 Beta-counter; Canberra Packard, Meriden, CT). 
To this end, 0.037 MBq (1 μCi) 3H-thymidine (ICN Pharmaceuticals, Irvine, CA) was 
present during the last 8 hours of culture. The 3H-incorporation is expressed as mean 
± SD counts per  minutes of triplicate measurements.
Secondary MLC and suppression assay
Analysis of memory responses of allogeneic primed T cells was performed in a 
secondary MLC. After stimulation of responder cells (10) with HLA-mismatched 30 
Gy γ-irradiated stimulator cells (10) in the presence or absence of FK778 for 7 days, the 
cells were harvested, washed 3 times, and allowed to recuperate for 2 to 3 days. The 
viable cells were recovered by density gradient centrifugation (Lymphoprep; Nycomed 
Pharma, Oslo, Norway) and 2x104 cells were rechallenged with 10 γ-irradiated 
stimulator cells in 96-well round-bottom plates (Greiner Bio-One, Frickenhausen, 
Germany) in triplicate. Proliferation during the secondary MLC was measured by 
3H-thymidine uptake. The suppressive capacity of FK778-treated cells was analyzed 
in a co-culture assay. After T-cell priming, the recovered T cells were added at 
different ratios to a newly set-up primary MLC (consisting of original responder and 
stimulator cells). Proliferation was measured by 3H thymidine uptake at day 6, and 
suppressor activity was calculated as the percentage inhibition of the proliferation 
of the newly set-up primary MLC. Cell-cell contact dependency of suppressive activity 
was studied in transwell experiments using 24-well plates (Greiner, Frickenhausen, 
Germany). Responder PBMCs (1x106) and 1x106 stimulator cells were cultured in 
the lower compartment of the well. Titrated numbers of FK778-treated cells were 
cultured in the presence of 1x106 stimulator cells in the transwell insert (Greiner Bio-
One, Frickenhausen, Germany). At day 6, the proliferative response of the responder 
PBMCs in the lower compartment was analyzed.
Flow cytometric analysis
The phenotype of the cells was analyzed by 4-color flow cytometry. The cells were 
washed with phosphate-buffered saline–bovine serum albumin (PBS-BSA; 0.2%) and 
labeled with fluorochrome-conjugated mAbs. Samples were incubated in the dark for 
20 minutes, washed twice, and analyzed. Antibodies used were CD3-FITC, CD27-FITC, 
and CD4RA-PE (Dako, Glostrup, Denmark); CD4-ECD and CD8-ECD (Beckman Coulter, 
Miami, FL); CD4RO-ECD, CD62L-ECD, CD4-PC, CD8-PC, and CD2-PC (Immunotech, 
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Marseille, France); CD3/HLA-DR–FITC/PE (BD Biosciences, NY), and glucocorticoid-
induced tumor necrosis factor receptor (GITR)–PE (R&D Systems, Minneapolis, MN). 
For intracellular staining, cells were fixed and permeabilized (Fix and Perm; Caltag 
Laboratories, Vienna, Austria) according to the manufacturer’s procedure. Cells 
were stained with anti–cytotoxic T lymphocyte–associated antigen-4 (CTLA-4)–PE 
(BD Biosciences, Erembodegen, Belgium), anti–human FoxP3-FITC, or anti–mouse 
FoxP3-PE (both from eBioscience, San Diego, CA), all according to the manufacturer’s 
instructions. FITC-conjugated annexin V (Bender Medsystems, Vienna, Austria) was 
used according to the manufacturer’s instructions. Appropriate isotype control mAbs 
were used for marker settings. The cytokine-producing potential of viable recovered T 
cells activated in the presence or absence of FK778 was examined using intracellular 
cytokine staining. T cells (106) were stimulated with 12. ng/mL PMA and 00 ng/mL 
ionomycin for  hours. During the last 4 hours of stimulation, brefeldin A ( ng/mL) 
was present. The cells were washed and surface stained with mAb directed against 
CD3 and CD8. After washing, the cells were fixed and permeabilized (Fix and Perm) 
and stained with mAb directed against interferon-γ (IFN-γ), tumor necrosis factor-α 
(TNF-α), IL-2, IL-10, and IL-4 (BD Biosciences). All samples were measured on a Coulter 
Epics XL flow cytometer (Beckman Coulter, Erembodegen, Belgium) and analyzed 
using Coulter Epics Expo 32 software. Appropriate isotype control mAbs were used 
for marker settings.
CFSE-based cell division analysis
Cell division was studied by labeling T cells with CFSE (Molecular Probes, Eugene, 
OR). Human T cells were labeled with 1 to 2 μM CFSE, aliquoted in CFSE buffer (PBS 
containing 0.02% HPS), for 10 minutes at room temperature. After washing twice 
with CFSE buffer, the samples were analyzed using a Coulter Epics XL flow cytometer 
at indicated time points during cultures.
ELISA
IFN-γ production during co-culture assays was measured by enzyme-linked 
immunosorbent assay (ELISA; CLB, Amsterdam, The Netherlands). Supernatants were 
collected at stored at -80°C until further use. IFN- γ ELISA was used according to the 
manufacturer’s instructions.
Western blot analysis
CD4+CD2- T cells were stimulated with αCD3/αCD28 mAb–coated beads in the 
presence or absence of FK778. At the indicated time points, p27kip1 expression 
was analyzed by Western blot analysis using the DCS-72.F6 mAb against p27kip1 
(Biosource, Camarillo, CA).
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Fluorescent bead–based multiplex assay for the detection of protein phosphorylation
After flow cytometric cell sorting based on CD2 expression, the cells were rested 
for 2 to 3 days and subsequently reactivated using antibodies directed against CD3 
and CD28 for 1 hour, after which the cells were lysed in lysis buffer (PBS, 1% Igepal 
CA-630, 0.% sodium deoxycholate, 0.1% SDS, 1 mM EDTA [chemicals from Sigma-
Aldrich, St Louis, MO], and 2% protease inhibitor cocktail [BD Biosciences]). Total 
protein concentration was determined using a micro BCA protein assay according 
to the manufacturer’s instructions (Pierce, Hercules, IL). The phosphorylation of 
selected signal transduction proteins was analyzed using a bead-based multiplex 
assay according to the manufacturer’s instructions (Bio-Rad, Hercules, CA). Samples 
were analyzed using a Luminex-100 analyzer (Luminex, Austin, TX) with Bioplex 
Manager Software 3.0 (Bio-Rad). Proteins were discriminated based on the fluorescent 
label of the bead and the PE levels were corrected for background levels of negative 
control lysates.
Statistical analysis
The proliferative capacity of T cells was determined by means of 3H-thymidine uptake 
and expressed as mean ± SD counts per  minutes. The results were compared using 
an unpaired student t test. P values < 0.0 were considered statistically significant.
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Figure 2. FK778 inhibits the cytokine-producing potential of allogeneic stimulated CD4+ T cells. 
PBMCs were stimulated with allogeneic stimulator cells for 7 days in the presence or absence of FK778. After 
the 2- to 3-day rest period, the cytokine-producing potential was investigated by intracellular cytokine staining 
using flow cytometry. Analysis was performed on gated CD3+CD8- cells. The fluorescence intensity of the par-
ticular cytokine staining (x-axis) is plotted against the forward scatter of the cells (y-axis). The percentage of 
cytokine-positive cells is presented in each plot. One representative experiment of 3 is presented.
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Results
FK778 inhibits T-cell proliferation, but allows initial activation
To establish the immunosuppressive effects of FK778 on human T cells in vitro, we 
assessed the inhibitory potential of FK778 on T cell proliferation in MLCs. Freshly 
isolated PBMCs were activated with γ-irradiated HLA-mismatched stimulator PBMCs 
in the presence or absence of FK778. The addition of FK778 resulted in a dose-
dependent inhibition of T-cell proliferation in this alloantigen-driven system, with 
a 0% inhibitory concentration (IC0) of 20 μg/mL (Figure 1A). Toxicity of FK778, 
as was determined by cell viability using trypan blue exclusion, was observed at 
concentrations of 10 μg/mL and higher (data not shown). Based on these observations, 
a low and a high dose of 10 μg/mL and 0 μg/mL, respectively, were selected for 
further investigation. These doses showed inhibition of T cell proliferation of, 
on average, 2% and 90%, respectively (Figure 1A). The time-response kinetics of 
the primary MLC were not affected by FK778 treatment (Figure 1B). To investigate 
whether the observed inhibition was the result of reduction of the alloreactive T-
cell pool through the promotion of apoptosis, annexin V expression was followed 
during primary activation from days 2 to 6. There were no differences in the number 
of annexin V–positive cells between FK778-treated and -untreated cells at any of the 
time points of measurement, indicating that FK778 did not promote deletion of 
the effector pool by promotion of apoptosis (Figure 1C, day 6). Since CD4+ T cells 
are considered crucial regulators, we focused on the effects of FK778 on this cell 
population for the remainder of this study. First, the phenotypic changes following 
allogeneic stimulation of CD4+ T cells were assessed using flow cytometry. Untreated 
control CD4+ T cells typically became blastoid after 3 days of stimulation and showed 
an increased expression of activation markers such as CD2 and HLA-DR. Also, upon 
allogeneic stimulation in the presence of FK778, blast formation occurred (Figure 1D). 
However, on day 6, the number of cells expressing CD2 and HLA-DR expression was 
clearly lower (Figure 1E). Strikingly, the CD4+ T cells that did acquire CD2 showed 
a relatively high expression of the CD2 molecule compared with untreated control 
cells (Figure 1E).
FK778 affects the potential of alloreactive CD4+ T cells to produce effector cytokines
A typical result of allogeneic stimulation is the generation of cytokine-producing 
effector CD4+ T cells. We examined by intracellular cytokine staining whether 
treatment with FK778 influenced the production of the effector cytokines IL-2, IL-
4, IL-10, IFN-γ, and TNF-α. Whereas untreated alloantigen-primed control CD4+ T 
cells showed production of all cytokines, treatment with 0 μg/mL FK778 resulted 
in a substantial reduction in the number of CD4+ T cells producing the cytokines 
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Figure 3. FK778 induces T-cell anergy and suppressive capacity after allogeneic stimulation. 
PBMCs were stimulated with allogeneic stimulator cells for 7 days. Cells were harvested and rested for 2 to 3 
days. Viable cells were recovered by density gradient centrifugation. (A) Proliferation of recovered cells treated 
with 0 μg/mL (I), 10 μg/mL (∆), or 50 μg/mL (o) FK778 during primary allogeneic stimulation was investigated 
in a secondary MLC (in the absence of FK778). During the secondary MLC, the recovered cells (2x104) were 
restimulated with allogeneic stimulator cells (105) alone (left panel) or in the presence of 12.5 U/mL IL-2 (right 
panel); p<0.05 for differences between untreated and FK778 (50 μg/mL)–treated cells. (B) The proliferative 
capacity of PBMCs primed in the presence of FK506 (left panel), rapamycin (middle panel), or MPA (right pa-
nel) was analyzed in a secondary MLC, as described in panel A, in the absence of the respective drugs. (C) The 
suppressive potential of FK778-treated cells was investigated in a co-culture suppression assay. Proliferation of 
naive PBMCs (5x104) stimulated with allogeneic stimulator cells (5x104) was studied in the absence or presence 
of increasing numbers of untreated (I) or FK778 (50 μg/mL)–treated (o) cells (*p<0.05; ** p<0,01 for differen-
ces between untreated and FK778-treated cells. One representative experiment of 4 is presented. (D) PBMCs 
were stimulated with αCD3/αCD28 mAb–coated beads instead of allogeneic stimulator cells in the presence 
or absence of FK778. The proliferation of the recovered cells (2x104), untreated (I) or treated with 50 μg/mL 
FK778 (o) during the primary MLC, was examined during the secondary culture. At the peak of proliferation, 
*p<0.01 for differences between untreated and FK778-treated cells. One representative experiment of 3 is 
presented. Error bars represent SD counts.
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measured, except for IL-10 (Figure 2). The low number of IL-10–producing CD4+ T cells 
in the untreated control condition was slightly increased after treatment with 0 μg/
mL FK778 (Figure 2). Treatment with low-dose FK778 (10 μg/mL) had little inhibitory 
effect on the number of cytokine-producing CD4+ T cells (data not shown).
FK778 induces anergic T cells with suppressive capacity
Besides the induction of cytokine-producing effector T cells, allogeneic activation 
typically leads to the induction of allospecific memory T cells capable of rapid 
proliferation upon rechallenge with the alloantigen. The effect of FK778 treatment 
on the induction of functional memory T cells was investigated in a restimulation 
assay. After primary stimulation of PBMCs in the presence of FK778, the recovered 
cells were restimulated with alloantigen in the absence of the drug. Antigen-
specific restimulation was characterized by a fast proliferative response, reaching a 
maximum at day 3 (Figure 3A). However, cells that were primed in the presence of 
FK778 showed a significantly reduced proliferative capacity during the secondary 
MLC. This hyporesponsive state could be reversed by the addition of exogenous IL-
2, which is a hallmark of T-cell anergy (Figure 3A). In contrast, we examined the 
possibility of other immunosuppressive drugs to induce T-cell anergy. PBMCs were 
primed in the presence of FK06, rapamycin, or MPA, the active metabolite of MMF, 
and restimulated with alloantigen in the absence of the drug. As illustrated in Figure 
3B, none of the drugs were capable of inducing anergic T cells. Since T cell anergy is 
closely related to a regulatory phenotype,21 the question arose whether the anergic 
T cells induced upon FK778 treatment possessed regulatory capacity. This issue was 
addressed by performing co-culture experiments. Addition of the FK778-treated 
cells at different ratios to a newly set-up primary MLC revealed a dose-dependent 
suppression, with 0% inhibition at responder-suppressor ratios of 4:1 (Figure 3C). 
Thus, FK778 treatment during primary activation of PBMCs induced anergic CD4+ 
T cells that exerted suppressor activity in vitro. To analyze whether FK778 exerted 
its effect directly on T cells or rather worked indirectly through the modification of 
antigen-presenting cells, we also stimulated PBMCs with αCD3/αCD28 mAb–coated 
beads in the presence of FK778. Restimulation assays showed that also in this system, 
FK778 treatment led to the induction of T cell anergy (Figure 3D). This indicates that 
the induction of regulatory function is a direct effect of FK778 on T cells.
FK778 treatment results in the de novo induction of regulatory function in CD4+CD25- T cells, 
independent of CD4+CD25+ regulatory T cells
The previous results were observed after stimulation of whole PBMCs, comprising 
both CD4+CD2- alloreactive T cells and naturally occurring CD4+CD2+ regulatory 
T cells. In such conditions, there can be at least 2 possible explanations for the 
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Figure 4. FK778 treatment results in the induction of regulatory function in CD4+CD25- T cells 
independent of CD4+CD25+ regulatory T cells. (A) CD25+ cells were depleted from total CD4+ T cells 
(top panel) using magnetic cell isolation; the protocol included 2 passages.  Typically, the resultant CD25- popu-
lation (bottom panel) was more than 99% pure. (B) CD4+CD25- T cells (5x104) were stimulated with allogeneic 
stimulator cells (5x104) in the presence or absence of 50 μg/mL FK778 for 7 days. Viable cells were recovered 
by density gradient centrifugation. Proliferation of recovered T cells after treatment with 0 μg/mL (♦), 10 μg/mL 
(∆), or 50 μg/mL (o) FK778 during the primary MLC, was examined in a secondary MLC in the absence (left 
panel) or presence (right panel) of 12.5 U/mL IL-2. (C) The suppressive capacity was investigated in a co-culture 
assay. At day 6, proliferation (y-axis) of allogeneic stimulated naive CD4+CD25- responder T cells (5x104) was 
studied in the absence or presence of increasing numbers of untreated (I) or FK778 (50 μg/mL)–treated (o) 
cells. One representative experiment of 5 is presented. (D) The inhibitory effect on proliferation by the FK778-
treated cells was confirmed by CFSE labeling (x-axis) of the responder cells. The percentage of divided cells was 
assessed at day 6 of co-culture assays and is depicted in each plot. One of 2 independent experiments is shown. 
(E) The potential of FK778-treated cells to inhibit the production of the effector cytokine IFN-γ, produced 
by responder cells, was analyzed in supernatants of co-culture assays by ELISA. At day 5, the concentration of 
IFN-γ (y-axis) is shown at increasing numbers of untreated (I) or FK778-treated (o) cells. (F) Cell-cell contact 
dependency of the FK778-treated cells to mediate suppression was analyzed in transwell co-culture assays. The 
FK778-treated cells were added either directly to the responder cells in the lower compartment (o) or, to dis-
rupt cell-cell contact, to the upper transwell chamber (I). 3H incorporation (y-axis) was measured at day 6. (G) 
The suppressive capacity of αCD3/αCD28–stimulated CD4+CD25- T cells that were primed in the presence 
(o) or absence (I) of FK778. One representative experiment of 3 is shown. *p<0.05; **p<0.01 for differences 
between untreated and FK778-treated cells. In panels B, C, E, and G, error bars represent SD counts.
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suppressive effect observed. First, FK778 treatment may have led simply to a reduction 
in the effector T-cell pool, changing the effector T cell (T effector)/regulatory T (Treg)–
cell ratio and thereby facilitating the activity of the latter. Second, FK778 may have 
induced regulatory function within the CD4+CD2- T-cell fraction. To examine this in 
more detail, CD4+CD2- T cells were isolated (>99% pure; Figure 4A) and primed in the 
presence of FK778. Similar to the results obtained with the whole PBMC pool, purified 
CD4+CD2- T cells that had been allogeneically primed in the presence of FK778 
appeared anergic upon restimulation (Figure 4B). Moreover, co-culture suppression 
assays indicated that these cells also harbored suppressive capacity (Figure 4C). These 
results were confirmed by CFSE labeling of the responder cells in co-culture assays. 
Cell division analysis of the responder cells at day 6 showed that the addition of FK778-
treated cells indeed inhibited their proliferation, in contrast to addition of untreated 
control cells (Figure 4D). Next to their effect on proliferation, FK778-treated cells 
also inhibited the production of IFN-γ by the responder cells (Figure 4E). To analyze 
whether the suppression mediated by the FK778-treated cells was cell-cell contact 
dependent, transwell experiments were performed. The FK778-treated cells were 
capable of suppressing the proliferation of responder cells when added directly to the 
same well, but lost their suppressive capacity when cell-cell contact was disrupted 
(Figure 4F). Taken together, these data indicate that the induction of regulatory 
activity by FK778 occurs within the CD4+CD2- T-cell population, independent of the 
presence of naturally occurring CD4+CD2+ Treg cells. The FK778-induced Treg cells 
were capable of suppressing both the proliferation and cytokine production of naive 
responder cells in a cell-cell contact–dependent manner. To confirm that the effects 
of FK778 on CD4+CD2- T cells were a direct effect of FK778 on the CD4+CD2- T cells, 
as observed with whole PBMCs, we stimulated CD4+CD2- T cells with αCD3/αCD28 
mAb–coated beads instead of stimulator cells. Figure 4G shows that, as seen after 
allogeneic stimulation, treatment with FK778 during primary activation resulted in 
the induction of regulatory activity within the CD4+CD2- T-cell subset.
After FK778 treatment, the regulatory capacity is contained within the CD25highCD27-CD62L-
CD45RO+ T-cell subset that expresses FoxP3, CTLA-4, and GITR
Detailed flow cytometric analysis revealed that after priming of purified CD4+CD2- T 
cells with allogeneic stimulator cells in the presence of FK778, 3 distinct populations 
could be distinguished based on the level of CD2 expression, namely a CD2neg, a 
CD2intermediate, and a CD2high subset (Figure A). We subsequently separated the 3 
subsets found in the FK778-treated population using flow cytometric cell sorting, and 
analyzed their functional capacity. During restimulation in the absence of FK778, 
the CD2neg population did not respond to the cognate alloantigen, not even after 
addition of IL-2, implying that this population mainly comprised ignorant CD4+ T 
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cells without specificity for the particular alloantigen (Figure B). The CD2intermediate 
population proliferated in a similar way as that of the untreated primed control cells. 
Importantly, only the CD2high cells were anergic (Figure B). Accordingly, of the 3 
subsets, only the CD2high T cells revealed dose-dependent suppression in a co-culture 
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Figure 5. Regulatory capacity is contained within the CD25highCD27-CD62L-CD45RO+ T-cell sub-
set that expresses FoxP3, CTLA-4, and GITR. (A) CD4+CD25- T cells were stimulated with allogeneic 
stimulator cells. CD25 expression was analyzed in the CD4+ T-cell fraction of FK778-treated cells (top plot) 
and untreated control cells (bottom plot). (B) The subsets formed upon FK778 treatment, separated using flow 
cytometric cell sorting, and were restimulated (2x104) with allogeneic stimulator cells (5x104). Proliferation 
during the secondary culture, in the absence of FK778, was examined in the absence (left panel) or presence 
(right panel) of 12.5 U/mL IL-2. At the peak of proliferation, p=0.002 for differences between untreated and 
FK778-treated CD25high cells. (C) The suppressive capacity of the sorted subsets, after stimulation in the 
presence (top graph) or absence (bottom graph) of FK778, was investigated in a co-culture assay. At day 6, 
proliferation of naive CD4+CD25- responder T cells (5x104) stimulated with allogeneic stimulator cells (5*104) 
was studied in the absence or presence of increasing numbers of the CD25neg-, CD25intermediate, or CD25high cells 
(*p<0.05; **p<0.01 for differences between untreated and FK778-treated cells). (D) Flow cytometric FoxP3 
analysis (x-axis) plotted against CD4 expression (y-axis) of the sorted CD25high and CD25intermediate subsets 
from the FK778-treated (left panels) and the untreated control groups (right panels). (E) Flow cytometry was 
performed directly after cell sorting of the CD4+CD25high T cells at day 6. One representative experiment of 2 
is presented. For panels B and C, error bars represent SD counts.
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suppression assay (Figure C). Functional analysis of the untreated control subsets 
showed that none of these cell populations contained regulatory activity (Figure 
C). Analysis of FoxP3 expression of the FK778-treated cells showed that 70% of the 
CD2high and 44% of the CD2intermediate cells expressed FoxP3. Using the same marker 
setting for the untreated control cells, FoxP3 expression was observed in 30% of the 
CD2high and 12% of the CD2intermediate cells (Figure D). Importantly, the FK778-treated 
CD2high cells showed a relatively high expression of FoxP3 compared with the other 
subsets (mean fluorescence intensity [MFI], 89 vs 2; Figure D). Since the relatively 
high proportion of CD2+FoxP3+ cells after FK778 treatment could have reflected 
an enrichment of these cells due to a decrease in the number of effector cells, we 
also determined the absolute cell numbers of CD2+FoxP3+ cells. While CD2+FoxP3+ 
cells were not present at the start of culture, the absolute number of these cells at 
the end of the primary culture was about 2-fold higher condition (data not shown). 
This indicates de novo generation of FK778-induced Treg cells rather than a mere 
enrichment of existing cells. Further phenotypic characterization of the regulatory 
CD2high subset directly after cell sorting showed that these cells expressed CD4RO, 
but not CD27 and CD62L, indicating an effector memory phenotype. CTLA-4 and 
GITR, not expressed by the initial CD4+CD2- T-cell population, were now expressed 
by 98% and 90% of the CD2highCD27-CD62L-CD4RO+ T cells, respectively (Figure E). 
After a 3-day rest period, the high expression of CD2 and GITR was sustained on the 
CD2high subset but not on untreated control cells (data not shown). In conclusion, 
allogeneic stimulation in the presence of FK778 in vitro resulted in the de novo 
generation of an anergic regulatory CD2highCD27-CD62L-CD4RO+ population that 
expresses FoxP3, CTLA-4, and GITR.
The induction of regulatory T cells by FK778 is critically dependent on inhibition of pyrimidine 
synthesis and characterized by delayed p27kip1 degradation and enhanced STAT3 
phosphorylation
FK778’s primary mechanism of action is the restriction of pyrimidine synthesis, but 
interactions with tyrosine kinase signaling have also been observed. To investigate 
whether the induction of regulatory activity by FK778 is dependent on inhibition of 
pyrimidine synthesis, we restored the pyrimidine pool during primary cultures in 
the presence of FK778 by addition of exogenous uridine. The proliferative capacity 
of CD4+CD2- T cells primed in the presence of FK778 was indeed restored by the 
addition of uridine (data not shown). Furthermore, restimulation assays showed 
that the CD4+CD2- T cells primed in the presence of both FK778 and uridine were 
not anergic (Figure 6A), and these cells did not show any regulatory activity (Figure 
6B). T-cell anergy has been characterized by impaired degradation of the cyclin-
dependent kinase inhibitor p27kip1.22;23 To determine whether FK778 treatment 
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resulted in impaired p27kip1 degradation, we analyzed p27kip1 expression in 
cell lysates of CD4+CD2- T cells stimulated with αCD3/αCD28–coated beads using 
Western blot analysis. We found that p27kip1 is rapidly degraded in T cells after 2 
hours following T-cell receptor (TCR) stimulation. However, in the presence of FK778, 
p27kip1 degradation was delayed and p27kip1 was detectable up to 24 hours after 
the start of the culture (Figure 6C). To examine whether the induction of Treg cells 
by FK778 was associated with changes in signal transduction pathways important 
for T-cell activation, we examined a number of these pathways using a bead-based 
multiplex assay. Comparison of the CD2intermediate and the CD2high cell populations 
of both the untreated control and the FK778-treated condition showed that IB, p70, 
and STAT3 were actively phosphorylated in all cell populations at the time point 
of measurement. Interestingly, STAT3 phosphorylation was enhanced in the FK778-
induced CD2high subset compared with that in the FK778-induced CD2intermediate 
subset and CD2intermediate and CD2high cell populations in the control condition 
(Figure 6D).
Discussion
In this study, we have investigated the potential of the new immunosuppressive drug 
FK778, a synthetic analog of leflunomide, to promote immune tolerance toward allo-
antigens. We focused on the effects of FK778 on CD4+ T cells given the fact that these 
cells play an established role in allograft rejection as well as in immune regulation. 
Interestingly, we found that FK778 treatment of human CD4+CD2- T cells during 
in vitro stimulation induces an anergic and regulatory CD4+CD2high T-cell subset, 
independent of the presence of naturally occurring regulatory T cells. To our 
understanding, this is the first explicit demonstration of induction of regulatory 
activity in CD4+CD2- T cells by an immunosuppressive drug. 
FK778 induced T cells with regulatory activity in the absence of naturally occurring 
CD4+CD2+ regulatory T cells. Immunosuppressive drugs that are currently used to 
prevent graft rejection largely act by reducing the size of the effector T-cell pool, 
mainly through the inhibition of T-cell proliferation and cytokine production. 
Although some of these drugs, such as rapamycin, have been shown to allow the 
induction of T-cell anergy,24 these findings were not observed in our system and more 
likely reflected an enrichment of the pre-existing CD4+CD2+ Treg-cell pool rather 
than de novo induction of regulatory activity in CD4+CD2- T cells.2-27 Apparently, 
for the induction of regulatory capacity, FK778 does not need the additional help of 
CD4+CD2+ regulatory cells; rather, it appears to directly program the CD4+CD2- cell 
toward a regulatory phenotype. IB, p70, and STAT3 are examples of phosphoproteins 
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important in T-cell activation signaling pathways. In the suppressive CD2high cells, 
these proteins were found to be actively phosphorylated, supporting the notion that 
FK778 treatment does not cause a signaling “defect,” but indeed directs the cell 
toward a different phenotype. The relatively high degree of STAT3 phosphorylation 
is in line with recent data indicating that increased levels of STAT3 protein are a 
feature of allo-tolerant cells,28 and that signaling via the immunosuppressive cytokine 
IL-10 requires STAT3 activation.29;30 The phenotype of the Treg cells induced by FK778 
was further characterized by the presence of CD4RO and lack of CD27 and CD62L 
expression. This fits an effector-memory phenotype, making these cells suitable to 
act at a site of inflammation.31 Notably, the cells showed high expression of CD2, 
together with CTLA-4, GITR, and FoxP3, all markers that have been associated with 
regulatory activity of T cells.32-34 However, none of these markers have been shown to 
be uniquely expressed on Treg cells and also up-regulated on activated T cells.34-36 
Through which mechanism does FK778 induce this regulatory capacity? FK778’s 
primary mode of action is the inhibition of de novo pyrimidine synthesis leading 
to a cell-cycle arrest in the late G1 phase.37 Previous data have suggested that 
progression through the cell cycle is crucial for T-cell anergy avoidance.38 We observed 
that restoration of the pyrimidine pool by the addition of uridine prevented the 
induction of regulatory activity within CD4+CD2- T cells, indicating that pyrimidine 
restriction is an indispensable requirement for the development of regulatory 
activity. Furthermore, treatment with FK778 resulted in delayed degradation of the 
cyclin-dependent kinase inhibitor p27kip1, which has been associated with impaired 
transition from G1 to S phases in the cell cycle and the induction of T-cell anergy.22;23 
However, it appears that cell-cycle arrest alone does not suffice for the induction 
of T-cell anergy. When CD4+ T cells were treated in vitro with the purine inhibitor 
MMF, also arresting T cells at the G1 phase, we did not observe the induction of T-cell 
anergy. In concordance, Munitic et al 39 showed that murine T cells arrested in the 
G1 phase following short-term stimulation did not become anergic, but appeared to 
remain in a state of readiness for prolonged periods of time and showed memory-like 
secondary responses. These data indicate that additional signals are essential for T-
cell anergy induction.24 
FK778 has several additional effects, in addition to inhibition of pyrimidine synthesis, 
that might play a role in the induction of T-cell anergy. First of all, following T-cell 
activation, the purine nucleotide pool is expanded 2-fold, while the pyrimidine 
pool is expanded up to 8-fold. This disproportional expansion is explained by the 
extra demand for pyrimidines used for massive cell membrane expansion.40 In 
addition, pyrimidine restriction was shown to indirectly inhibit the activation of 
ATP-dependent enzymes, essential for full T-cell activation.7 Consequently, FK778 
inhibition through restriction of pyrimidines might inhibit signals that are crucial 
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for full T-cell activation and anergy avoidance. Secondly, the FK778 analog A77 1726 
was shown to inhibit the phosphorylation of several tyrosine kinases, including 
p6lck.9-13 A defect in the phosphorylation of the tyrosine kinase p6lck results in 
suboptimal TCR triggering, which in turn may lead to the induction of T-cell anergy.41 
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Figure 6. The induction of regulatory activity by FK778 is critically dependent on inhibition of 
pyrimidine synthesis, and CD4+CD25- T cells treated with FK778 show impaired p27kip1 degra-
dation and enhanced STAT3 phosphorylation. (A) Exogenous uridine was added to primary cultures to 
restore the pyrimidine pool in the presence of FK778. At day 7, the cells were harvested and subsequently res-
timulated in a secondary MLC in the absence of FK778 and uridine. The restimulation pattern of CD4+CD25- T 
cells primed in the presence (o) or absence (I) of FK778 alone (left panel) or in combination with exoge-
nous uridine (right panel). One representative experiment of 2 is presented. (B) The suppressive capacity 
of CD4+CD25- T cells primed in the presence of FK778 alone (o) or combined FK778 and uridine (I) was 
analyzed in co-culture suppression assays. 3H incorporation was measured at day 6. (C) p27kip1 degradation in 
FK778-treated CD4+CD25- T cells. Western blot analysis of p27kip1 expression in CD4+CD25- T cells stimu-
lated with αCD3/αCD28–coated beads in the presence or absence of 50 μg/mL FK778. One representative 
experiment of 2 is presented. (D) Phosphorylation of STAT3 was analyzed in cell lysates using a bead-based 
multiplex assay. The level of fluorescence, as marker for phosphorylation, is shown for the CD25intermediate and 
the CD25high cell populations of the untreated control (left panel) and the FK778-treated setting (right panel). 
One representative experiment of 2 is presented. *p<0.05; **p<0.01 for differences between untreated and 
FK778-treated cells. In panels A and B, error bars represent SD counts.
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We have investigated the phosphorylation of p6lck during allogeneic stimulation in 
the presence of FK778 using Western blot analysis but found similar phosphorylation 
compared with untreated controls (data not shown). Finally, Zeyda et al 42;43 showed 
that FK778 can inhibit both the formation of the immunologic synapse and nuclear 
factor kappa -B (NFκB) activation in human dendritic cells (DCs), suggesting an effect 
of FK778 on APC function. Inhibition of NFκB activation during DC maturation 
freezes the DCs in an immature state, and T-cell activation with immature DCs 
can lead to the formation of anergic CD4+ T cells with regulatory capacity.44 In our 
system, regulatory activity could also be induced during αCD3/αCD28 stimulation, 
indicating that FK778 acts, at least for the effects observed in this study, directly on 
the CD4+CD2- T cells. Taken together, the induction of regulatory activity by FK778 
probably involves several mechanisms, including blockade of cell-cycle progression. 
We cannot exclude that FK778 may facilitate the development of pre-existing CD2- 
regulatory cells that were previously described to reside within the total CD4+CD2- 
T cell pool. Upon TCR triggering, these cells were shown to up-regulate CD2 and 
FoxP3.36;4;46 These cells might be in a “ready” state and would only require TCR 
triggering for full development. Since this in itself is not affected by FK778, these 
cells would emerge as CD2+ regulatory cells upon stimulation. However, if this 
were true we would also expect to see a similar population emerging in the control 
setting; this was not the case. 
In conclusion, this study provides the first evidence that in vitro treatment of human 
CD4+CD2- T cells with FK778 results in the induction of a CD4+CD2high subset with 
regulatory capacity. In clinical transplantation, these cells, formed in the presence 
of FK778, might be able to regulate anti-donor responses, thereby facilitating the 
induction of transplantation tolerance.
Acknowledgments
The authors thank Esther Fasse for excellent technical assistance. RobWoestenenk 
is thanked for flow cytometric cell sorting. FK778 was kindly provided by Astellas 
Pharma BV for research purposes.
140
Chapter7
References
1.  Vincenti F. A decade of progress in kidney transplantation. Transplantation 2004;77:S2-
S61.
2.  Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nature Reviews 
Immunology 2003;3:199-210.
3.  Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in 
transplantation tolerance. Nature Reviews Immunology 2003;3:147-18.
4.  Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoim-
mune disease. Int.Rev.Immunol. 200;24:211-226.
.  Vanrenterghem Y, van Hooff JP, Klinger M et al. The effects of FK778 in combination with 
tacrolimus and steroids: A phase II Multicenter study in renal transplant patients. Trans-
plantation 2004;78:9-14.
6.  Fitzsimmons WE, First MR. FK778, a synthetic malononitrilamide. Yonsei Med.J. 
2004;4:1132-113.
7.  Ruckemann K, Fairbanks LD, Carrey EA et al. Leflunomide inhibits pyrimidine de Novo 
synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J.Biol.Chem. 
1998;273:21682-21691.
8.  Chong ASF, Rezai K, Gebel HM et al. Effects of leflunomide and other immunosuppressive 
agents on T cell proliferation in vitro. Transplantation 1996;61:140-14.
9.  Elder RT, Xu XL, Williams JW et al. The immunosuppressive metabolite of leflunomide, 
A77 1726, affects murine T cells through two biochemical mechanisms. J.Immunol. 
1997;19:22-27.
10.  Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the Epidermal 
Growth-Factor Receptor Tyrosine Kinase-Activity by Leflunomide. FEBS Lett. 1993;334:161-
164.
11.  Xu XL, Williams JW, Bremer EG, Finnegan A, Chong ASF. Inhibition of Protein-Tyrosine 
Phosphorylation in T-Cells by A Novel Immunosuppressive Agent, Leflunomide. J.Biol.
Chem. 199;270:12398-12403.
12.  Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks 
TNF-dependent nuclear factor-kappa B activation and gene expression. J.Immunol. 
1999;162:209-2102.
13.  Siemasko K, Chong ASF, Jack HM et al. Inhibition of JAK3 and STAT6 tyrosine phosphory-
lation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. 
J.Immunol. 1998;160:181-188.
14.  Yamamoto S, Okuda T, Yamasaki K et al. FK778 and FK06 combination therapy to con-
trol acute rejection after rat liver allotransplantation. Transplantation 2004;78:1618-162.
1.  Deuse T, Schrepfer S, Koch-Nolte F et al. FK778 directly prevents and suppresses allospe-
cific cellular immuno response after rat cardiac transplantation - In vivo and in vitro 
studies. American Journal of Transplantation 2004;4:196-197.
16.  Bilolo KK, Ouyang J, Wang X et al. Synergistic effects of malononitrilamides (FK778, 
FK779) with tacrolimus (FK06) in prevention of acute heart and kidney allograft 
rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 
2003;7:1881-1887.
17.  Pan F, Ebbs A, Wynn C et al. FK778, a powerful new immunosuppressant, effectively 
reduces functional and histologic changes of chronic rejection in rat renal allografts. 
141
FK778inducesregulatoryactivityinCD4+CD25-Tcells
Transplantation 2003;7:1110-1114.
18.  Qi SJ, Zhu SY, Xu DS et al. Significant prolongation of renal allograft survival by delayed 
combination therapy of FK778 with tacrolimus in nonhuman primates. Transplantation 
2003;7:1124-1128.
19.  Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES. Inhibition of human cytome-
galovirus signaling and replication by the immunosuppressant FK778. Antiviral Res. 
200;6:1-12.
20.  Koenen HJPM, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive 
alloantigen-specific human regulatory T cells. J.Immunol. 200;174:773-783.
21.  Jonuleit H, Schmitt E, Stassen M et al. Identification and functional characterization of 
human CD4(+)CD2(+) T cells with regulatory properties isolated from peripheral blood. 
J.Exp.Med. 2001;193:128-1294.
22.  Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Helper T 
cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J.Mol.Med. 
2001;78:673-683.
23.  Jackson SK, DeLoose A, Gilbert KM. Induction of anergy in Th1 cells associated with 
increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. J.Immunol. 
2001;166:92-98.
24.  Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamy-
cin induces T cell clonal anergy even in the presence of costimulation. J.Immunol. 
1999;162:277-2784.
2.  Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands 
CD4(+)CD2(+)FoxP3(+) regulatory T cells. Blood 200;10:4743-4748.
26.  Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD2(+) immune regulatory cells are required 
for induction of tolerance to alloantigen via costimulatory blockade. J.Exp.Med. 
2001;193:1311-1317.
27.  Coenen JJ, Koenen HJ, Rijssen EV, Hilbrands LB, Joosten I. Rapamycin, and not Cyclospo-
rin A, preserves the highly suppressive CD27+ subset of human CD4+CD2+ regulatory T 
cells. Blood 200
28.  Metcalfe SM, Watson TJ, Shurey S, Adams E, Green CJ. Leukemia inhibitory factor is lin-
ked to regulatory transplantation tolerance. Transplantation 200;79:726-730.
29.  Murray PJ. The primary mechanism of the IL-10-regulated anti inflammatory response is 
to selectively inhibit transcription. Proc.Natl.Acad.Sci.U.S.A. 200;102:8686-8691.
30.  Anderson PO, Sundstedt A, Yazici Z et al. IL-2 overcomes the unresponsiveness but fails 
to reverse the regulatory function of antigen-induced T regulatory cells. J.Immunol. 
200;174:310-319.
31.  Hamann D, Baars P, Rep MHG et al. Phenotypic and functional separation of memory and 
effector human CD8(+) T cells. J.Exp.Med. 1997;186:1407-1418.
32.  Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcrip-
tion factor Foxp3. Science 2003;299:107-1061.
33.  Muriglan SJ, Ramirez-Montagut T, Alpdogan O et al. GITR activation induces an opposite 
effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J.Exp.Med. 
2004;200:149-17.
34.  Janeway CA, Bottomly K. Signals and Signs for Lymphocyte-Responses. Cell 1994;76:27-
28.
3.  Morgan ME, van Bilsen JHM, Bakker AM et al. Expression of FOXP3 mRNA is not confined 
142
Chapter7
to CD4(+)CD2(+) T regulatory cells in humans. Hum.Immunol. 200;66:13-20.
36.  Walker MR, Kasprowicz DJ, Gersuk VH et al. Induction of FoxP3 and acquisition of T regu-
latory activity by stimulated human CD4+. J Clin.Invest 2003;112:1437-1443.
37.  Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid 
arthritis. Ann.Rheum.Dis. 2000;9:841-849.
38.  Schwartz RH. T cell anergy. Annu.Rev.Immunol. 2003;21:30-334.
39.  Munitic I, Ryan PE, Ashwell JD. T cells in G(1) provide a memory-like response to secon-
dary stimulation. J.Immunol. 200;174:4010-4018.
40.  Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of Ribonucleotide 
Availability to Proliferating T-Lymphocytes from Healthy Humans - Disproportionate 
Expansion of Pyrimidine Pools and Contrasting Effects of De-Novo Synthesis Inhibitors. 
J.Biol.Chem. 199;270:29682-29689.
41.  Thomas S, Kumar R, Preda-Pais A, Casares S, Brumeanu TD. A model for antigen-specific 
T-cell anergy: Displacement of CD4-p6(lck) signalosome from the lipid rafts by a soluble, 
dimeric peptide-MHC class II chimera. J.Immunol. 2003;170:981-992.
42.  Zeyda M, Stuhlmeier KM, Kirsch B et al. The malononitrilamide FK778 inhibits activation 
of NF-kappa B in human dendritic cells. Transplant.Proc. 200;37:1968-1969.
43.  Zeyda M, Geyeregger R, Poglitsch M et al. The novel immunosuppressant FK778 inhibits 
formation of the immunologic synapse. Transplant.Proc. 200;37:1970-1971.
44.  Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, 
nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with 
allogeneic immature human dendritic cells. J.Exp.Med. 2000;192:1213-1222.
4.  Sakaguchi S. Naturally arising Foxp3-expressing CD2(+) CD4(+) regulatory T cells in im-
munological tolerance to self and non-self. Nature Immunology 200;6:34-32.
46.  Stephens LA, Mason D. CD2 is a marker for CD4(+) thymocytes that prevent autoimmu-
ne diabetes in rats, but peripheral T cells with this function are found in both CD2(+) 
and CD2(-) subpopulations. J.Immunol. 2000;16:310-3110.
Chapter 8
Restriction of pyrimidine synthesis in alloreactive CD8+ T 
cells interferes with clonal expansion and differentiation into 
effector CD8+ T cells
Ellen Kreijveld, Hans JPM Koenen, Esther Fasse, Emine Bolat, 
Luuk B Hilbrands, Irma Joosten
Binnen de perken zijn de mogelijkheden even onbeperkt als 
daarbuiten.
 
- Jules Deelder (1994-present), Dutch writer and poet -
143
TheeffectofFK778onalloreactiveCD8+Tcells
Chapter 8
Restriction of pyrimidine synthesis in alloreactive CD8+ T 
cells interferes with clonal expansion and differentiation into 
effector CD8+ T cells
Ellen Kreijveld, Hans JPM Koenen, Esther Fasse, Emine Bolat, 
Luuk B Hilbrands, Irma Joosten
Binnen de perken zijn de mogelijkheden even onbeperkt als 
daarbuiten.
 
- Jules Deelder (1994-present), Dutch writer and poet -
144
Chapter8
Abstract
The immunosuppressive drug FK778 interferes with de novo pyrimidine 
synthesis. Previously, we have reported that FK778 induced regulatory capacity 
in allogeneic stimulated CD4+CD2- T cells. In this study, we have investigated the 
immunosuppressive effects of FK778 on alloreactive CD8+ T cells. 
Using an in vitro human allogeneic stimulation model, we observed that FK778 
allowed initial activation of alloreactive CD8+ T cells, but strongly inhibited the 
proliferative capacity. Allogeneic stimulation in the presence of FK778 resulted 
in a reduced potential of recovered CD8+ T cells to produce IFN-γ, but not TNF-α, 
which could be explained by a smaller fraction of cells that underwent cell division. 
Likewise, inhibition of the cell cycle progression by FK778 reduced the number of 
cells expressing FasL or Granzyme B, as well as the number of cytotoxic alloreactive 
CD8+ T cells. However, FK778 was unable to affect the granzyme B expression and 
cytotoxic potential of alloreactive CD8+ T cells primed in the absence of FK778. 
Allogeneic stimulation of CD8+ T cells during exposure to FK778 did not result in T 
cell anergy or regulatory capacity.    
In conclusion, FK778 inhibits the proliferation and related acquirement of effector 
function of alloreactive CD8+ T cells, but does not affect the established effector 
function of CD8+ T cells. In addition, FK778 does not induce anergy or regulatory 
capacity in alloreactive CD8+ T cells.
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Introduction
Following solid organ transplantation, alloreactive CD8+ T cells become activated 
by cross-reaction with polymorphic HLA class I molecules presented by passenger 
leucocytes or by the presentation of donor-derived peptides in the context of self HLA 
class I molecules. In response to allo-antigen, CD8+ T cells undergo clonal expansion 
and acquire effector function and, together with CD4+ effector T cells, can mount a 
vigorous immune response against the allograft.1
Naive CD8+ T cells require, in addition to recognition of HLA-peptide complexes and 
costimulatory molecules CD80 and CD86, a third signal for efficient programming of 
T cell survival, differentiation, and memory development.2 This third signal can be 
delivered by IL-12 or type I interferons (IFN) 3;4 and in its absence CD8+ T cells are able 
to undergo a number of cell divisions but fail to acquire effector function. Combined 
stimulation however efficiently triggers naive CD8+ T cell activation, leading to the 
clonal expansion of antigen-specific CD8+ T cells and differentiation into cytotoxic 
T lymphocytes (CTL). Cytotoxic killing of target cells is mediated by the secretion 
of effector molecules, including perforin, granzymes and Fas ligand (FasL), which 
requires direct cell-to-cell contact between the CTL and the target cell.6
In transplantation, allospecific CTL play a major role in the process of acute rejection 
and can mediate graft injury ultimately leading to graft loss.1 The administration 
of immunosuppressive drugs is used to prevent allograft rejection mainly through 
inhibition of the activation and proliferation of alloreactive T cells.7 Calcineurin 
inhibitors (CNI), the cornerstone of most immunosuppressive regimens inactivate 
the phosphatase calcineurin and prevent subsequent IL-2 transcription.7 Rapamycin 
blocks the mammalian target of rapamycin (mTOR) thereby preventing cell cycle 
progression.8 The malonitrilamide FK778, a synthetic analogue of A77 1726, the active 
metabolite of leflunomide, is an inhibitor of de novo pyrimidine nucleotide synthesis.9-
11 It thereby acts at a similar phase of T cell activation as the immunosuppressive 
drugs azathioprine and mycophenolate mofetil (MMF), that target the de novo 
purine synthesis.12 While resting T cells can use the salvage pathway for nucleotide 
expansion, activated T cells depend on the de novo pathway to fulfill the rapid need 
for nucleotide expansion.13 
We have previously reported that FK778 possesses immunoregulatory capacity with 
respect to CD4+ T cells. FK778 not only inhibited the proliferation of CD4+ T cells upon 
allogeneic stimulation, but also induced regulatory capacity within the CD4+CD2- T 
cell subset.14 In this study, we have investigated the immunosuppressive effects of 
FK778 on alloreactive CD8+ T cells, and observed that pyrimidine restriction inhibited 
the generation but not the effector function of alloreactive CD8+ T cells.  
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Material & Methods
Cell isolation
Peripheral Blood Mononuclear Cells (PBMC) from healthy blood donors were isolated 
by density gradient centrifugation using Lymphoprep (Nycomed Pharma AS, Oslo, 
Norway). CD8+ T cells were isolated using MACS CD8 microbeads (Miltenyi GmbH, 
Bergisch Gladbach, Germany) according to the manufacturer’s procedures.  Cell 
purity was analyzed using flow cytometry and typically exceeded 9%. 
Culture conditions 
All cultures were conducted in RPMI 1640 medium supplemented with 20 mM L-
glutamine, 20 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin 
(Gibco), and 10% heat-inactivated human pooled serum (HPS). Cultures were 
incubated in a humidified incubator at 37°C with % CO2. FK778 (Astellas Pharma 
GmbH, Munich, Germany) was kindly provided for research purposes. Aliquots were 
prepared in DMSO at final concentrations of 100 mg/ml and stored at 4ºC. The applied 
concentrations were selected on the basis of previously published data.14  
Primary Mixed Lymphocyte Cultures 
Primary Mixed Lymphocyte Cultures (MLC) were performed in 96-wells round 
bottom plates (Greiner Bio-One, Frickenhausen, Germany). Responder PBMC (1x10) 
or purified CD8+ T cells (x104) were stimulated with allogeneic HLA mismatched 30 
Gy γ-irradiated stimulators PBMC (1x10) in 200 μl culture medium in the presence or 
absence of 0 μg/ml FK778. Proliferation was analyzed by 3H-thymidine incorporation 
using a Gas Scintillation Counter (Canberra Packard, Matrix 96 Beta-counter, Meriden, 
U.S.A.). To this end, 1 µCi 3H-thymidine (ICN Pharmaceuticals, Irvine, CA, USA) was 
present during the last 8 hours of culture. The 3H-incorporation is expressed as mean 
± SD counts per  minutes of triplicate measurements.
Secondary MLC 
Analysis of secondary proliferative responses of allogeneic primed T cells was 
performed in a secondary MLC. After stimulation of responder cells (10) with HLA 
mismatched 30 Gy γ-irradiated stimulator cells (10) in the presence or absence of FK778 
for 7 days, the cells were harvested, washed three times and allowed to recuperate 
for 2 to 3 days. The viable cells were recovered by density gradient centrifugation 
(Lymphoprep, Oslo, Norway) and 2x104 cells were rechallenged with 10 γ-irradiated 
stimulator cells in 96-wells round bottom plates in triplicates. Proliferation during 
the secondary MLC was measured by 3H-thymidine uptake.
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51Chromium (51Cr) release assay
The cytolytic potential of CD8+ T cells was analyzed in a standard 1Cr release assay. 
PBMC or purified CD8+ T cells were primed with allogeneic stimulator cells for 7 days 
in the presence or absence of 0 μg/ml FK778. PHA blasts from the original allogeneic 
stimulator PBMC were labeled with 1Cr and used as targets at several effector: 
target ratios in a -hour 1Cr release assay. Supernatants were harvested and 1Cr 
was detected in a γ-counter (Wallac 1470 γ-counter, Turku, Finland). The percentage 
specific lysis was calculated as follows: percentage specific lysis = ((experimental 
release – spontaneous release)/(maximum release – spontaneous release)) * 100%. 
Flowcytometry
The phenotype of the T cells was analyzed by four-color flow cytometry. Briefly, the 
cells were washed with PBS-BSA (0.2%) and labeled with fluorochrome-conjugated 
monoclonal antibodies (mAb). Samples were incubated in the dark for 20 minutes, 
washed twice and analyzed. The following antibodies were used: CD3-FITC, CD2-
PE, (Dako, Glostrup, Denmark), CD4-ECD, CD8-ECD (Beckman Coulter Corporation, 
Miami, FI, USA), CD4-PC, CD8-PC, CD2-PC (Immunotech, Marseille, France), HLA-
DR-FITC, FasL-Biotin, CD69-PC (BD Biosciences, NY, USA). 
For intracellular staining, cells were fixed and permeabilized (eBioscience, San 
Diego, USA) according to the manufacturer’s procedure. Cells were stained with 
anti-Granzyme B-PE (Immuno Tools GmbH, Friesoythe, Germany). FITC-conjugated 
annexin-V (Bender Medsystems, Vienna, Austria) was used according to the 
manufacturer’s instructions to detect early apoptosis. 
The cytokine producing potential of viable recovered CD8+ T cells (Lymphoprep, 
Oslo, Norway) activated in the presence or absence of FK778 was examined using 
intracellular cytokine staining. One million T cells were stimulated with 12. ng/ml 
PMA and 00 ng/ml ionomycin for  hours. During the last 4 hours of stimulation, 
brefeldin A ( ng/ml) was present. The cells were washed and stained with mAb 
directed against CD3 and CD8 on the cell surface. Subsequently, the cells were fixed 
and permeabilized (eBioscience, San Diego, USA) and stained with mAb directed 
against IFN-γ and TNF-α (FITC-labeled, from BD-Biosciences, NY, USA).  
All samples were measured on a Coulter Epics XL flowcytometer (Beckman Coulter, 
Fullerton, CA) and analyzed using Coulter Epics Expo 32 software. Appropriate 
isotype control mAbs were used for marker settings.
CFSE based cell division analysis
Cell division was studied by CFSE dilution patterns. PBMC or purified CD8+ T cells 
were labeled with 1-2 μM CFSE (Molecular Probe, Eugene, OR, USA), aliquoted in CFSE 
buffer (PBS containing 0.02% HPS) for 10 minutes at RT in the dark. The reaction was 
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stopped by the addition of equal volumes of HPS. Subsequently, cells were washed 
twice with CFSE labeling buffer and resuspended in 10% culture medium. Cells were 
analyzed using flowcytometry.
Statistical analysis
The proliferative capacity of T cells was determined by means of 3H-Thymidine uptake 
and expressed as mean ± SD counts per  minutes. The results of different conditions 
were compared using an unpaired student t-test. P-values ≤ 0.0 were considered 
statistically significant.
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Figure 1. FK778 inhibits the activation and proliferation of alloreactive CD8+ T cells. (A) PBMC 
were stimulated with γ-irradiated HLA mismatched stimulator cells in the presence or absence of 50 μg/ml 
FK778. CD69 expression (x-axis) measured on day 3 of the primary MLC is plotted against the forward scatter 
of untreated control cells (left panel), FK778 treated cells (middle panel) and unstimulated CD3+CD8+ cells 
(right panel). The percentage of positive cells is indicated in each dot plot. (B) CD25 (upper row) and HLA-DR 
(lower row) expression (x-axis) against the forward scatter of gated CD3+CD8+ cells at day 6 of the primary 
MLC. Numbers indicate the percentage of positive cells. (C) CFSE labeled PBMC were stimulated with HLA 
mismatched stimulator cells in the presence or absence of 50 μg/ml FK778. Depicted is the CFSE dilution pat-
tern of gated CD3+CD8+CD56- cells at day 6 of the primary MLC, stimulated in the absence (left) or presence 
of FK778 (right). Numbers indicate the percentage of divided cells. Representative results of five independent 
experiments are shown. (D) Proliferation (y-axis, expressed as average 3H counts) of purified CD8+ T cells 
stimulated with HLA mismatched stimulator cells in the presence of 0 μg/ml (I), 25 μg/ml (g) or 50 μg/ml (o) 
FK778 supplemented with 10 U/ml IL-2. One out of 3 independent experiments is shown. 
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Results
FK778 inhibits the activation and clonal expansion of alloreactive CD8+ T cells
We have previously reported that FK778 has potent effects on the activation and 
proliferation of alloreactive CD4+ T cells.14 To address the inhibitory potential of 
FK778 on CD8+ T cells, we stimulated PBMC in vitro with γ-irradiated stimulator PBMC 
from HLA-mismatched donors in the absence or presence of FK778. Dose-dependent 
inhibition was observed with optimal inhibition at 0 μg/ml (data not shown). T cell 
activation was followed during the primary MLC by measuring the expression of 
the activation markers CD69, HLA class II, and CD2. Irrespective of the presence 
or absence of FK778, the proportion of CD8+ T cells that expressed CD69 at day 3 
of the primary MLC was comparable between the untreated and the FK778 treated 
PBMC fractions (Figure 1A), suggesting that FK778 does not interfere with early T cell 
signaling events. However, by day 6, the percentage of CD8+ T cells that expressed the 
activation markers CD2 and HLA-DR was strongly inhibited by FK778 (Figure 1B). 
The effect of FK778 on the clonal expansion of alloreactive CD8+ T cell was examined 
by CFSE dilution. CFSE labeled PBMC were stimulated with allogeneic stimulator 
cells in the presence or absence of FK778 and at day 6 of the primary MLC, the CFSE 
dilution pattern of CD3+CD8+ T cells was examined. The addition of 0 μg/ml FK778 
resulted in an inhibition of the proliferation of alloreactive CD8+ T cells of 7 ± 12 % 
(mean of  donors, Figure 1C). 
To exclude that the observed inhibitory potential of FK778 resulted from an indirect 
effect of FK778 on other cell types within the PBMC fraction, CD8+ T cells were 
purified and stimulated with allogeneic stimulator cells in the presence or absence 
of FK778. Exogenous IL-2 (10 U/ml) was added to the cultures to facilitate CD8+ T cell 
proliferation. Comparable to the results obtained with the total PBMC fraction, the 
addition of FK778 inhibited the proliferation of alloreactive CD8+ T cells in a dose-
dependent manner (Figure 1D).
FK778 does not induce apoptosis in alloreactive CD8+ T cells
Allogeneic stimulation in the presence of FK778 allowed the initial activation of 
alloreactive CD8+ T cells, but resulted in reduced numbers of activated alloreactive 
CD8+ T cells at day 6 of the primary MLC. This reduction might be completely 
attributable to restricted proliferation of activated cells by FK778 but might also, 
at least in part, be the result of other mechanisms such as increased apoptosis. 
Therefore, we analyzed annexin-V expression as a marker for apoptosis during the 
primary MLC. The number of annexin-V+ CD8+ T cells, measured at days 3, 4, , and 6 
of the primary MLC in the presence of FK778, was not different from that observed in 
cultures of CD8+ T cells stimulated in the absence of FK778. These data suggest that 
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FK778 does not induce nor inhibit the induction of apoptosis in alloreactive CD8+ T 
cells (Figure 2).
FK778 inhibits the number of IFN-γ producing, but not the number of TNF-α producing  CD8+ 
T cells
The production of cytokines, including IFN-γ and TNF-α, is a key feature of effector 
CD8+ T cells. Following primary allogeneic stimulation in the presence or absence 
of FK778, the potential of the recovered CD8+ T cell pool to produce IFN-γ and TNF-
α upon stimulation with PMA/ionomycin was investigated. A large proportion 
of the untreated control CD8+ T cells produced IFN-γ and TNF-α (Figure 3A). 
The presence of FK778 during allogeneic stimulation resulted in a significantly 
reduced percentage of IFN-γ producing CD8+ T cells (32 ± 1% versus 3 ± 27 %, 
p=0.012) but did not affect the number of TNF-α producing CD8+ T cells (Figure 
3A). This data suggests that IFN-γ production, but not TNF-α production, was 
correlated with the proliferative response of CD8+ T cells. Therefore, we analyzed 
the IFN-γ and TNF-α producing potential of divided and undivided CD8+ T cell 
fractions. To avoid any indirect effects of FK778 on stimulator cells and to obtain 
sufficient cells for analysis, we used polyclonal stimulation with αCD3/αCD28 
coated expander beads in combination with IL-2 for stimulation of purified CD8+ 
T cells and sorted the fractions of divided and undivided cells at four days after 
stimulation. As illustrated in Figure 3B, FK778 strongly reduced the size of the 
fraction of divided CD8+ T cells in this polyclonal stimulation setting (Figure 3B). 
Analysis of the two fractions separately, showed that the majority of divided cells 
produced IFN-γ, while in the fraction of undivided cells low numbers of IFN-γ 
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Figure 2. FK778 does not interfere with apoptosis. The number of annexin-V+ CD8+ cells was measured at days 
3, 4, 5 and 6 during allogeneic stimulation of PBMC. Results show annexin-V expression (x-axis) at day 6 for 
untreated control cells (left panel), FK778 treated cells (middle panel) and unstimulated control CD8+ T cells 
(right panel). Numbers represent percentages of positive cells. One out of 2 similar experiments is shown.
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producing cells were observed (Figure 3C). In this respect, no differences were 
observed between the untreated control and FK778 treated CD8+ T cells. These 
data support our hypothesis that the reduced number of IFN-γ producing cells 
after an MLC in the presence of FK778, was caused by a decrease in the proportion 
of divided alloreactive cells. In contrast, both the divided and the undivided cells 
produced TNF-α, suggesting that the induction of TNF-α production involves 
mechanisms that are independent of cell cycle progression (Figure 3D). 
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Figure 3. FK778 inhibits the number of IFN-γ, but not TNF-α producing CD8+ T cells. Following 
allogeneic stimulation during 7 days in the presence or absence of FK778, the cytokine producing potential 
of CD8+ T cells was investigated using a rechallenge with PMA and ionomycin in combination with brefeldin 
A. (A) Intracellular staining of IFN-γ and TNF-α in untreated control cells (upper panels) and FK778 treated 
CD3+CD8+ T cells (lower panels). One out of 4 experiments is shown. (B) Purified CFSE labeled CD8+ T cells 
were stimulated with αCD3/αCD28 expander beads in combination with 10 U/ml IL-2 in the presence of 
absence of 50 μg/ml FK778. At day 4, the cells were sorted on the basis of CFSE (x-axis) dilution in divided 
cells (left from black line) and undivided cells (right from black line). (C) Histograms show the IFN-γ (x-axis) 
producing potential of the divided (left) and undivided (right) cell fractions sorted from the untreated control 
cells (upper plots) and FK778 treated cells (lower plots). Numbers indicate the percentage of positive cells. (D) 
The TNF-α (x-axis) producing potential of the separate cell fractions. Numbers represent the percentage of 
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and day 6 (lower panels) after allogeneic stimulation in the absence (untreated control) or presence (50 μg/ml) 
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Taken together, these data show that FK778 affects the frequency of IFN-γ-, but 
not TNF-α-, producing CD8+ T cells, through inhibition of proliferation.  
The generation, but not the function of cytotoxic effector CD8+ T cells is inhibited by FK778
Cytotoxic effector functions can be exerted by the Fas-dependent pathway and by the 
release of granzyme B (GrB) and perforin from cytoplasmic granules. The effect of 
FK778 on the expression of granzyme B and FasL was evaluated during the primary 
MLC. Only a minority of freshly isolated CD8+ T cells contained granzyme B (Figure 
4A). During the primary MLC, the expression of granzyme B was upregulated and 
reached a maximum at day 6. The addition of FK778 inhibited this induction of GrB-
expressing CD8+ T cells by about 0% (Figure 4A). Similar observations were made 
regarding the induction of FasL expression on CD8+ T cells (Figure 4B). 
We next evaluated whether the decrease in the numbers of granzyme B and FasL 
expresssing responder cells was associated with a reduced acquirement of cytotoxic 
capacity of this cell population.  PBMC that were stimulated with allogeneic stimulator 
cells in the presence or absence of FK778 were harvested after 7 days and allowed to rest 
for 2-3 days. The recovered cells were co-cultured at increasing ratios with allogeneic 
and autologous 1Cr-labeled PHA blasts for 4 hours. Untreated control cells were able 
to lyse allogeneic, but not autologous target cells in a dose-dependent manner (Figure 
4C). As anticipated, allogeneic stimulation in the presence of FK778 resulted in reduced 
levels of antigen-specific lysis (Figure 4C), indicating that inhibition of proliferation 
by FK778 reduced the proportion of CTLs within the responder cell population.
To determine whether FK778 could also interfere with the function of established 
CTLs, we examined the potential of FK778 to inhibit granzyme B production and 
cytotoxicity by primed CD8+ T cells. After allogeneic stimulation in the absence of 
FK778 for 7 days, primed CD8+ T cells were restimulated with the original stimulator 
cells in a secondary MLC in the presence or absence of 0 μg/ml FK778. Granzyme B 
expression was measured at 4, 24, and 48 hours after secondary stimulation. During 
the secondary MLC, FK778 was unable to inhibit the granzyme B production of primed 
CD8+ T cells (Figure 4D). In agreement with these results, the presence of FK778 during 
the 4 hour 1Cr release assay did not affect the degree of allogeneic target cell lysis 
(Figure 4E). Together, these data demonstrate that FK778 lessens the generation of 
alloreactive cytotoxic CD8+ T cells, but not their function once they are formed.
FK778 does not induce regulatory activity in alloreactive CD8+ T cells, but reduces the 
generation  of memory CD8+ T cells 
Finally, we examined whether the FK778 was able to induce regulatory activity in 
alloreactive CD8+ T cells. We have previously reported that FK778 was able to induce 
T cell anergy within the CD4+CD2- T cell population 14 and wondered whether 
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FK778 could act in a comparable way on CD8+ T cells. Following allogeneic priming 
in the presence or absence of FK778, recovered CD8+ T cells were restimulated 
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Figure 5. FK778 does not induce CD8+ T cell anergy but rather inhibits the formation of  memory 
CD8+ T cells with proliferative capacity. (A) CD8+ T cells were stimulated with allogeneic stimulator cells 
in the presence of absence of FK778. At day 7, the cells were harvested and allowed to recuperate for 2-3 
days. Recovered CD8+ T cells were restimulated with the original stimulator cells in the absence of FK778. The 
proliferative response (y-axis) of CD8+ T cells primed in the absence (I) or presence (o) of FK778 is shown. 
(B) The restimulation pattern of CD8+ T cells in the presence of 10 U/ml exogenous IL-2. One out of 4 experi-
ments is shown. (C) Purified CFSE labeled CD8+ T cells were stimulated with αCD3/αCD28 expander beads 
in combination with 10 U/ml IL-2 in the presence of absence of 50 μg/ml FK778. At day 4, the cells were sorted 
on the basis of CFSE (x-axis) dilution in divided and undivided cell fractions. The proliferation of the separate 
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with the original stimulator cells in a secondary MLC in the absence of FK778 
and exogenous IL-2. As shown in Figure A, FK778 treated CD8+ T cells were 
hyporesponsive compared with the untreated control cells. However, the addition 
of exogenous IL-2 could not completely rescue the hyporesponsive state of the 
FK778 treated CD8+ T cells, but augmented the response of the untreated control 
cells as well as the FK778 treated cells. This observation suggests that FK778 did 
not induce CD8+ T cell anergy but rather reduced the number of CD8+ T cells able 
to proliferate upon restimulation with the alloantigen. To test this hypothesis, 
we separated the divided and undivided T cell fractions as described above 
(Figure 3B). The sorted fractions were restimulated with the original stimulator 
cells in the absence of FK778, and proliferation was monitored at days 2, 3, and 
4. As expected, the fraction of divided cells obtained from the untreated control 
and the FK778 treated condition respectively, showed comparable proliferation 
during restimulation, although the maximum proliferation of the FK778 treated 
cells lagged one day behind (Figure B). The CD8+ T cells that had not divided 
during the primary MLC, did neither respond during the secondary MLC. Taken 
together, these data indicate that FK778 does not induce T cell anergy within the 
CD8+ T cell pool, but reduced the number of memory CD8+ T cells that are able to 
proliferate upon restimulation.
In accordance with these findings, we were not able to demonstrate the 
acquirement of regulatory capacity in CD8+ T cells that were exposed to FK778 
during a primary MLC (data not shown).  
Discussion
In this study, we have investigated the immunosuppressive effects of FK778 on 
alloreactive CD8+ T cells in vitro and observed that restriction of pyrimidine synthesis 
by FK778 interfered with the generation of effector CD8+ T cells. Furthermore, we 
observed that FK778 was unable to inhibit the function of established CTLs. 
The extent of inhibition of the proliferation of alloreactive CD8+ T cells was comparable 
to the previously observed inhibition of CD4+ T cells, with optimal inhibition at a FK778 
concentration of 0 μg/ml.14 Cultures of purified CD8+ T cells were supplemented with 
exogenous IL-2 to compensate the lack of CD4+ T cell help. Despite the presence of 
IL-2, FK778 inhibited the proliferation of alloreactive CD8+ T cells. These observations 
were as expected, since nucleotide synthesis is a relatively late step in the process 
of cell cycle progression and does not depend on the presence of IL-2. Indeed, also 
mycophenolate mofetil (MMF), an inhibitor of the de novo purine synthesis, showed 
the ability to inhibit IL-2 driven T cell proliferation.1 Other immunosuppressive 
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drugs that are currently used to prevent allograft rejection, including CNI, interfere 
at earlier stages of T cell activation. The inhibition of calcineurin reduces the IL-2 
production of T cells, and addition of exogenous IL-2 is able to reverse the inhibitory 
potential of CNI on T cell proliferation.16 
FK778 showed differential effects on the production of IFN-γ and TNF-α by CD8+ T 
cells. Allogeneic stimulation in the presence of FK778 resulted in reduced numbers 
of IFN-γ- but not TNF-α-producing CD8+ T cells, suggesting that there is no uniform 
relationship between cell cycle progression and cytokine production. Indeed, it 
has been shown that in CD4+ T cells the DNA demethylation, required for the 
transcription of a number of effector cytokine genes, including IFN-γ, is controlled 
by the cell cycle.17;18 Our data suggest that comparable mechanisms are responsible 
for IFN-γ production by CD8+ T cells. In contrast, TNF-α production by CD8+ T cells has 
been observed as soon as 2 hours after TCR triggering and does not require cell cycle 
progression.19 
Next to the production of effector cytokines, CD8+ effector T cells can acquire 
cytotoxic function. It has been reported that granzyme B production is directly 
correlated with cytolytic function.20 FK778 reduced the frequency of cytotoxic 
effector CD8+ T cells during primary stimulation, which was reflected in reduced 
numbers of Granzyme B expressing CD8+ T cells as well as decreased levels of target 
cell lysis in functional assays. The mechanism by which inhibition of proliferation 
can abrogate the induction of cytotoxic function, is unclear but Meng et al. showed 
that the induction of cytotoxic granules, even by memory CD8+ T cells, required at 
least one cell division.20 Thus, FK778 inhibited the proliferation and subsequent 
acquisition of effector function of alloreactive CD8+ T cells. In accordance with our 
data, Quemeneur et al. (1) previously reported that, also in the murine setting, 
pyrimidine restriction interfered with the proliferation of antigen-specific CD8+ T 
cells and the subsequent generation of effector cells.
The number of reports on the effects of immunosuppressive drugs on CD8+ 
T cell function is limited. Jones et al.21 reported that the immunosuppressive 
drugs cyclosporine, tacrolimus and rapamycin all inhibited the proliferation and 
subsequent formation of effector memory CD8+ T cells, although calcineurin 
inhibitors, tacrolimus as well as cyclosporine, showed higher efficacy compared with 
rapamycin. Previous studies from our group showed that whereas single treatment 
of cyclosporine and rapamycin hardly affected CTL function, tacrolimus was quite 
effective in inhibiting the formation of CTL, with even higher efficacy in combination 
with rapamycin.22 We compared the efficacy of CTL inhibition by FK778 with that of 
tacrolimus and rapamycin. At the dose where all immunosuppressive drugs inhibited 
T cell proliferation by 90%, we observed that FK778 showed comparable efficacy of 
inhibition of CTL formation as tacrolimus (data not shown). 
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We have previously reported that allogeneic stimulation of CD4+CD2- T cells in 
the presence of FK778 induced an anergic T cell subset with regulatory activity.14 In 
clinical transplantation, allospecific suppressor T cells might favor the induction 
of transplantation tolerance. Although the mechanism by which FK778 induced 
regulatory activity in CD4+ cells is still unclear, we hypothesized that FK778 might 
be able to induce regulatory T cells within the CD8+ T cell pool as well. However, we 
did not observe the induction of regulatory activity in CD8+ T cells. Recently, Uss et 
al. observed that rapamycin enhanced the number of alloantigen-induced regulatory 
CD8+CD103+ T cells in vitro.23 In our system, we did not observe increased numbers of 
CD8+CD103+ T cells (data not shown). 
In conclusion, our data show that FK778 treatment during primary stimulation 
of CD8+ T cells inhibited the proliferation. Likely secondary to this inhibition of 
proliferation, the generation of IFN-γ producing CD8+ T cells, cytotoxic T cells, and 
memory T cells was reduced. Once CD8+ effector T cells are formed, their function 
is not inhibited by FK778. These data suggest that in the transplant setting, optimal 
efficacy of FK778 may be achieved if the drug is administered as early as allo-antigen 
presentation takes place, i.e. from the time of transplantation.  
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9.1 Introduction 
Kidney transplantation is the preferred treatment for patients with end-stage renal 
disease. Organ replacement from either a living or a deceased donor is preferred 
over dialysis treatment because transplantation provides a better quality of life 
and improved survival.1;2 The major limitation of successful transplantation is the 
risk of allograft rejection. The recipient’s immune system recognizes non-self HLA 
molecules expressed on the allograft and elicits an immune response against it. In 
the process of graft rejection, T cells play a central role.3 Upon activation, alloreactive 
CD4+ and CD8+ T cells undergo clonal expansion and acquire effector function. In 
addition, activated CD4+ T cells stimulate other immune compartments, including 
B cells, dendritic cells and macrophages which together results in a potent immune 
response against the transplanted organ, ultimately leading to graft rejection.
The use of immunosuppressive drugs markedly decreases the risk of graft rejection.4 
Most immunosuppressive drugs target the recipient’s T cells, either by preventing the 
activation or proliferation of T cells, or through inhibition of the cytokine producing 
potential of alloreactive T cells. Optimization of immunosuppressive regimens, 
including the use of combinations of immunosuppressive drugs to target multiple 
aspects of the immune response at the same time, has further improved the results 
and one-year graft survival rates are currently exceeding 90%. Unfortunately, the 
(continuous) administration of immunosuppressive drugs is accompanied by serious 
adverse events.4 Due to the antigen non-specific nature of the immunosuppressive 
drugs, patients are at increased risk of opportunistic infections and the development 
of malignancies. In addition, each immunosuppressive drug has its own array of 
side-effects. 
The adverse events of immunosuppressive drugs can contribute to long-term graft 
loss. Especially the continued use of calcineurin inhibitors (CNI) is associated with 
irreversible nephrotoxicity, which can ultimately lead to graft failure.6;7 Therefore, 
CNI withdrawal, once stable graft function is achieved, is an attractive strategy but is 
known to be associated with an increased risk of graft rejection. On the other hand, 
successful discontinuation of CNI generally results in improved renal function and 
blood pressure control, and long-term follow up of patients after CNI withdrawal 
showed a favorable clinical outcome.8-10 It is therefore highly desirable to be able to 
identify transplant recipients at risk of acute rejection following the discontinuation 
of CNI. In vitro monitoring tools, to follow the immune status of the transplant 
recipient could be helpful to reach this goal. 
Next to optimization of immunosuppressive regimens, there is a continuous search 
for new or improved immunosuppressive drugs, or new combinations of existing 
drugs. New immunosuppressive drugs should ideally target only the alloimmune 
response, leaving the immune system’s ability to respond to infections and cancer 
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development intact. Furthermore they should be devoid of negative side-effects as 
much as possible.
The ultimate goal in transplantation medicine remains the induction of 
transplantation tolerance, a state of donor-specific immune unresponsiveness in the 
absence of immunosuppression, while the immune responsiveness to non-transplant 
antigens is maintained.11 Today, it is well established that the immune system 
possesses intricate immunoregulatory systems, that involve at least mechanisms 
of clonal deletion, ignorance, induction of T cell anergy, and active regulation by 
suppressor cells.12 In clinical transplantation, anecdotal stories of tolerant transplant 
recipients have indicated that transplantation tolerance is achievable in selected 
cases.13 Importantly, in 199, Sakaguchi et al. showed that the subset of CD4+ T 
cells with the highest expression of CD2, the α-chain of the IL-2 receptor, contains 
suppressor activity and protects against the induction of autoimmunity.14 Since 
then, CD4+CD2high regulatory T cells (Treg) have received a lot of attention in the 
field of transplant immunology. Accumulating evidence now shows that Treg are 
able to control immune responses against allo-antigens as well, and facilitation of 
Treg may contribute to the induction of transplantation tolerance.11;1;16 Therefore, it 
is of utmost importance to determine the exact role of Treg in the immune response 
against the allograft and to ensure that the immunosuppressive drugs administered 
to prevent graft rejection do not interfere with, but rather promote Treg function.  
The main focus of the research described in this thesis is the identification of an 
immunological marker in peripheral blood to identify transplant recipients in whom 
immunosuppression can be safely reduced. In order to address the role of Treg in 
the protection against rejection following the reduction of immunosuppression, we 
aimed to study both the presence and the function of Treg in the blood of transplant 
recipients. Analysis of Treg function however, is hampered by the low concentration 
of Treg in the peripheral blood. To overcome this problem, we have developed an 
ex vivo expansion protocol that is described in chapter 2. Subsequently, the ex vivo 
Treg expansion protocol was applied in a case-control study of transplant recipients 
who underwent reduction of the level of immunosuppression following renal 
transplantation. The role of Treg in the protection against rejection is described in 
chapter 3, together with an analysis of the function and phenotype of CD4+ and CD8+ 
T cells. In addition, we evaluated in chapter 4 whether the distribution of NK cell 
subsets or NK cell alloreactivity based on KIR gene analysis was associated with the 
occurrence of acute rejection following the discontinuation of tacrolimus. The impact 
of circulating HLA antibodies in transplant patients in whom immunosuppression 
was reduced is addressed in chapter 5. 
164
Chapter9
In addition to the evaluation of immunological markers to predict acute rejection 
following the reduction of immunosuppression, we need to have a clear picture 
of the effects of immunosuppressive drugs on the immune system. Therefore, we 
investigated whether daclizumab, a humanized monoclonal antibody directed 
against CD2, interfered with the presence or function of Treg in transplant patients 
since this might hamper the development of transplantation tolerance (chapter 6). 
Furthermore, we have investigated the immunosuppressive potential of FK778, a new 
immunosuppressive drug under consideration for use in clinical transplantation. 
Interestingly, we observed that FK778 was able to induce regulatory activity within 
allogeneic stimulated CD4+CD2- T cells in the absence of the naturally occurring 
Treg. These findings are described in chapter 7, and in chapter 8 we describe FK778’s 
immunosuppressive effects on alloreactive CD8+ T cells.
In this chapter, our main findings are summarized and discussed in light of recent 
findings. Furthermore, we discuss the clinical implications of our findings and 
present recommendations for future research. 
9.2  Immunological monitoring to identify transplant recipients in whom immunosuppression 
can be safely reduced
In vitro monitoring tools to assess the immune status of the transplant recipient are 
of interest for several reasons. First, the availability of such tools would allow the 
development of individualized immunosuppressive regimens, thereby preventing 
under-immunosuppression in a subset of recipients with a higher risk of rejection, 
and simultaneously minimizing long-term drug toxicity in the majority of patients. 
Furthermore, monitoring assays may allow the detection of a rejection episode 
without the need of more invasive techniques like biopsies.
For the studies described in this thesis, we took advantage of the fact that in our 
renal transplant center an immunosuppressive treatment regimen was employed 
that included the withdrawal of a calcineurin inhibitor in immunological low-risk 
patients with stable graft function. The rationale for this treatment protocol was that 
despite an increased risk of acute rejection (about 2%, based on previous experience), 
long-term follow-up of patients after CNI withdrawal shows a favorable outcome with 
improved renal function and blood pressure 8-10. Patients were selected for reduction 
of their immunosuppression when they met the following inclusion criteria: at least 
for 4 months after transplantation, stable graft function, and at least 1 HLA-B and 
1 HLA-DR match between donor and recipient. Patients who received a kidney from 
a HLA-identical living donor, patients with two or more previously failed grafts, 
patients with PRA > 8%, non-Caucasian patients, and patients that had experienced 
a steroid-resistant acute rejection episode after their current transplantation were 
excluded. Standard triple-therapy immunosuppression consisted of tacrolimus 
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in combination with mycophenolate mofetil and prednisolone. The tapering 
schedule was as follows: at first instance, MMF was substituted for azathioprine, 
and prednisolone was supplemented if patients did not use steroids anymore. Two 
months later, the tacrolimus dose was gradually reduced to zero over a period of 
4 weeks. The resulting maintenance immunosuppressive therapy after conversion 
thus consisted of azathioprine and prednisolone.  A schematic overview of the 
minimization protocol is given in Figure 1.
To find a marker that would be informative for the occurrence of acute rejection after 
reduction of immunosuppression, we collected blood samples before transplantation 
(T0) and immediately before the withdrawal of tacrolimus (T1) (Figure 1). We analyzed 
a number of immunological parameters in these samples and compared the results 
between patients who experienced a rejection episode (cases) and transplant 
recipients in whom immunosuppression was successfully reduced (controls). Our 
main findings are summarized and discussed below.
9.2.1 (Effector) T cells
T cells are the central players in the process of allograft rejection.3 We evaluated a number 
of cell surface markers expressed on CD4+ and CD8+ T cells together with the proliferative 
capacity and the cytokine producing potential of T cells in blood samples taken before 
transplantation and before the start of tacrolimus dose reduction. As outlined above, we 
compared the results in patients with and without rejection after the discontinuation of 
tacrolimus.
The phenotypic analysis of CD4+ and CD8+ T cells, using flow cytometry, showed 
differential changes in the distribution of naive, effector and memory T cell subsets over 
time between rejectors and non-rejectors. Between the time of transplantation and the 
start of tacrolimus withdrawal, a relative increase in the percentage of naive T cells, with 
a reciprocal decrease in the percentage of effector T cells was observed in the peripheral 
blood of rejectors (chapter 3). In non-rejecting individuals, increases as well as decreases 
Transplantation:
tacrolimus
MMF
steroids
MMF Aza
(+ restart steroids)
T0 T1
100%o 50%
tacrolimus withdrawal
2 monthst 4 months
50%o 25%
2 wks 2 wks
25%o 0%
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in naive and effector T cell levels were observed. Although more pronounced in the CD4+ 
T cell compartment, this phenomenon was also observed in the CD8+ T cell compartment. 
Without the analysis of other immune compartments and graft tissue, it is difficult to 
interpret these intriguing findings. One explanation might be that recruitment of effector 
T cells to the allograft, resulting in a lower proportion in the peripheral blood, predisposes 
the patient for acute rejection after reduction of the level of immunosuppression. 
The precursor frequency of proliferating CD4+ and CD8+ alloreactive T cells was determined 
using a CFSE-based MLR method as described before.17;18 The advantage of this method 
is that with a minimal number of cells detailed information can be obtained on the 
number of dividing alloreactive T cells as well as the number of cell divisions each T cell 
has undertaken. In our study, we did not observe significant differences in the precursor 
frequency or the number of mitotic events of alloreactive CD4+ and CD8+ T cells between 
rejectors and non-rejectors (chapter 3). 
Finally, we determined the potential of CD4+ and CD8+ T cells to produce the effector 
cytokines IL-2 and IFN-γ after stimulation with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin. We did not observe significant differences between the number of IFN-γ or IL-2 
producing CD4+ and CD8+ T cells between rejectors and non-rejectors. 
9.2.2 Regulatory T cells
Treg have been described to play a role in the induction of transplantation tolerance. 
In our study, we observed a reduction in the proportion of Treg in the peripheral blood 
following transplantation, but this change did not differ between rejectors and non-
rejectors (chapter 3). However, immediately prior to the withdrawal of tacrolimus, the 
ratio between memory CD8+ T cells and Treg was significantly higher in rejectors than 
in non-rejectors (chapter 3). Furthermore, a CD4+ memory T cells: Treg ratio < 20 was 
only observed in patients in whom immunosuppression was safely reduced, and not in 
rejectors. Apparently, an enhanced memory T cell: Treg ratio did not result in rejection as 
long as sufficient immunosuppression was provided. Reduction of immunosuppression 
tipped the balance towards rejection in a number of these transplant recipients. Several 
reports have shown that Treg are indeed capable of inhibiting memory T cells.19-21 Our 
findings underscore the importance of a balance between effector/memory and regulatory 
mechanisms in the maintenance of immune homeostasis as has been demonstrated in 
several studies.22-24 
So far, to our knowledge, no data have been published on changes in the functional 
capacity of Treg after transplantation. Since studies in autoimmune disease have shown 
that the function rather than the size of the Treg pool was negatively affected during 
disease 2;26 we hypothesized that an enhancement of the anti-donor suppressive capacity 
of Treg may especially be present in patients who remained free of rejection after reduction 
of immunosuppression. Interestingly, we observed little variation in the suppressive 
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capacity of Treg before and after transplantation (chapter 3), indicating that in contrast 
to their relative number, the function of Treg tested ex vivo (using the expansion protocol 
as described in chapter 2), was not affected by treatment with immunosuppressive drugs 
or presence of the allograft.
Next to the naturally occurring Treg, a number of other cell subsets with regulatory 
activity have been reported, including CD8+CD28- T cells 27 and CD8+CD103+ T cells 28. We 
have analyzed whether the presence of these regulatory T cell subsets was associated 
with protection against rejection but found no association in our case-control study. 
Both Treg subsets were reported to arise in vitro after stimulation with allogeneic cells 
28;29, while in diseased animals, ex vivo isolated CD8+ T cells with the same phenotype 
appeared to have effector rather than regulatory function.30-33 Although these findings do 
not exclude that suppressor CD8+ T cells with the above mentioned phenotype can arise 
in vivo after transplantation, the data suggest that CD8+CD28- and CD8+CD103+ T cells are 
heterogeneous T cell populations which can not be used for immunological monitoring 
without further functional characterization. 
9.2.3 NK cells
Next to extensive analysis of CD4+ and CD8+ T cells, we evaluated whether several markers 
of NK cells in the peripheral blood were associated with the occurrence of acute rejection 
following the reduction of immunosuppression. With regard to the relative frequency of 
NK cell subsets, we found no difference between rejectors and non-rejectors (chapter 4). 
There are several ways in which NK cell alloreactivity could affect the outcome after 
transplantation. As postulated in the ‘missing self’ hypothesis, NK cell activation depends 
on the absence of an inhibitory signal delivered by self HLA class I molecules.34;3 In 
transplantation, the lacking expression of self HLA molecules on donor cells can mediate 
NK cell alloreactivity. On the other hand, NK cell alloreactivity may have some protective 
effect on graft rejection. Immediately after transplantation, donor-derived DC, present in 
the allograft, are responsible for the direct presentation of allo-antigens. Since dendritic 
cells abundantly express LFA-1, they should be susceptible to alloreactive NK cell killing.36 
The resulting depletion of donor-derived dendritic cells should disable the recipient to 
provoke potent alloimmune responses.37 We addressed the issue of NK cell alloreactivity 
by analyzing the killer-cell immunoglobulin receptors (KIR) genes and their ligands in 
recipients and their donors. Again, we found no association with the occurrence of acute 
rejection upon reduction of immunosuppression (chapter 4). It cannot be excluded that 
T cell reactivation as a result of tapering of immunosuppression may have masked the 
putative impact of NK cell alloreactivity in our setting. Therefore, the implications of 
NK cell alloreactivity, if any, on the outcome of solid organ transplantation remain to be 
further elucidated.
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9.2.4 HLA antibodies
The presence of HLA antibodies in transplant recipients has been demonstrated to have 
negative implications on graft outcome.38 We have analyzed whether the presence of 
HLA antibodies before and after transplantation could predict the occurrence of acute 
rejection following tapering of immunosuppression. In addition, we investigated the 
presence of HLA antibodies after tapering of immunosuppression and the association 
with the subsequent clinical course. Our data showed that the presence of HLA antibodies 
before transplantation or before the reduction of immunosuppression was not associated 
with acute rejection following the subsequent reduction of immunosuppression. 
Interestingly, the presence of donor-specific HLA class I IgG antibodies did not preclude 
successful reduction of immunosuppression. Furthermore, the number of recipients 
in whom donor-specific HLA antibodies arose after reduction of immunosuppression 
was low. Finally, two-year follow up of transplant recipients carrying donor-specific HLA 
antibodies showed that graft function was comparable to that in patients without HLA 
antibodies.
9.2.5 Limitations of the study
In search for an immunological marker that would help to predict the occurrence of 
acute rejection, we studied the involvement of T cells, NK cells, and HLA antibodies. The 
design of our study and the interpretation of the data have some limitations. 
To monitor immunological processes in our transplant recipients, we used lymphocytes 
isolated from peripheral blood. It remains a matter of debate whether the peripheral 
blood mirrors the immunological processes that occur in the allograft. Orosz et al. 
attempted to answer this question in a mouse model in which polyurethane sponges with 
allogeneic splenocytes were used as transplants.39 The number of donor specific cytotoxic 
T cells recovered from these allografts represented about 0.2% of the cells in these grafts, 
which is similar to the frequencies found in limiting dilution assays on peripheral blood 
from completely mismatched human samples.40 These data suggest that the analysis of 
peripheral blood lymphocytes may reflect to some extent intragraft processes. In our 
study, we observed that most of the analyzed markers were similar between transplant 
recipients and healthy individuals, suggesting that the impact of transplantation and 
immunosuppressive drug administration on peripheral blood lymphocytes is limited. 
However, we observed some clear differences between rejectors and non-rejectors, 
indicating that the peripheral blood can be a suitable compartment for non-invasive 
immunological monitoring (chapter 3).   
In our phenotypic analysis, we have focused on NK cell and T cell subsets expressed as 
percentages of the total lymphocyte pool rather than as absolute cell numbers (chapter 
3 and 4). It can be expected that in immunocompromised patients, lymphocyte subset 
distribution is affected as a result of immunosuppressive drug administration. Changes in 
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absolute, rather than relative, cell numbers have previously been associated with clinical 
outcome.41;42 Therefore it is possible that significant differences in absolute cell numbers 
between rejectors and non-rejectors remained undetected in our study.
We assessed the precursor frequency of proliferating alloreactive T cells with a CFSE-
MLR based method and found that this method was not informative for the prediction 
of rejection following the reduction of immunosuppression (chapter 3). In contrast, a 
previous study showed that a low frequency of precursors of cytotoxic T lymphocytes 
(CTLp) was a distinctive marker of renal transplant patients in whom immunosuppression 
could be safely reduced.43 A possible explanation for this discrepancy would be a weak 
correlation between the precursor frequencies of proliferating and cytotoxic T cells. We 
chose the CFSE-MLR based method to determine the precursor frequency of proliferating 
T cells because it is a fast and easy-to-perform method that requires minimal numbers of 
cells, while CTLp analysis is time-consuming and requires large amounts of cells. Since the 
observation that low CTLp frequencies can predict the absence of rejection has not been 
confirmed in subsequent studies, it remains unclear whether CTLp analysis would have 
provided more information than the measurement of proliferative precursor frequency 
in our study. 
The evaluation of the number of cytokine producing potential of CD4+ and CD8+ T cells 
following stimulation with PMA and ionomycin was not informative for the prediction 
of rejection in our study (chapter 3). Others have determined the number of cytokine 
producing T cells after stimulation with donor antigens in Elispot assays. These studies 
showed that low numbers of donor-specific IFN-γ producing T cells were associated with 
stable long-term renal function.44;4 Donor-specific assessment of the number of cytokine 
producing T cells may have been more informative in our study.
Our findings are based on a relatively small sample size and have not (yet) been validated in 
a second cohort of transplant recipients. Therefore, the clinical usefulness of our findings 
has not been firmly established. Nevertheless, our findings have markedly improved our 
insight on the applicability of a number of immunological markers in the peripheral 
blood of transplant recipients to predict the occurrence of acute rejection following 
the reduction of immunosuppression. It is now critically important to optimize and 
validate these findings in order to develop a reliable in vitro monitoring tool to identify 
immunological low-risk transplant patients.  
9.2.6 Clinical implications and future immunological monitoring
The results of our immunological monitoring study showed that the reduction of 
immunosuppression was successful in transplant patients with 1) a low ratio of 
memory T: Treg cells immediately prior to the start of immunosuppression reduction, 
or 2) a decrease in the percentage of naive T cells before start of tacrolimus reduction 
compared to pre-transplant values. The presence of one or both of these two markers 
170
Chapter9
could identify 16 of the 21 non-rejectors (76%), while both markers were absent in all 
rejecting patients. Before these markers can be used to select renal transplant patients for 
reduction of the level of immunosuppression, their predictive value should be validated 
in another cohort of patients. In our study, the ratio between memory T cells and Treg 
appeared to be informative. However, the memory T cell pool is a heterogeneous T cell 
population composed of T cell subsets with various effector functions.46 More detailed 
identification of the memory T cell subset that is particularly responsible for allograft 
destruction may allow the calculation of a ratio with even more clinical relevance. A 
better characterization of memory T cell subsets with alloreactive effector function may 
include the measurement of the expression of chemokine receptors 47 or CD127 48. Ideally, 
the analyses should be combined with measurement of CTLp frequencies, as performed 
by the group of Weimar et al., to validate the efficacy of both methods. 
Although the immunological monitoring of peripheral blood lymphocytes revealed 
significant differences between rejectors and non-rejectors, it remains unclear to what 
extent monitoring of peripheral blood lymphocytes mimics the immune response that 
takes place within the allograft. Therefore, assessment of peripheral blood samples 
should be compared with analysis of graft-infiltrating lymphocytes to determine their 
value. However, in clinical practice, it is not attractive to perform graft biopsies, given 
the risk of unforeseen adverse events. A promising alternative to obtain information on 
intragraft processes is the analysis of mRNA or proteins in urine.49
Almost certainly, no single monitoring assay will provide all the answers. Combining 
the results of several assays should allow the definition of a fingerprint of the immune 
response at any given time in a given individual. Blood monitoring assays may include 
analysis of memory T: Treg ratios, changes in the distribution of T cell subsets, absolute 
numbers of cell subsets, CTLp frequencies, the presence of HLA antibodies, and donor-
specific cytokine production using Elispot assays. 
9.3  Immunosuppressive drugs in kidney transplantation
Today, a wide variety of immunosuppressive drugs exist, each targeting the activation or 
proliferation of T cells in a different manner. Although the use of newer immunosuppressive 
drugs has markedly increased one-year graft survival rates, long-term survival rates have 
hardly changed over the past decades. Together with the frequent occurrence of non-
immunological adverse events associated with immunosuppressive drug administration, 
this underscores the need for optimization of long-term outcome. The recognition that 
Treg form an intrinsic part of the alloimmune response has encouraged the exploitation 
of this regulatory network to induce tolerance towards donor antigens. Therefore, it 
is of utmost importance that the immunosuppressive drugs do not interfere with the 
activation or induction of allospecific Treg. In this section, I will discuss our findings in 
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light of recent publications and discuss the possibilities of future immunosuppressive 
regimens. 
9.3.1  Effects of immunosuppressive drugs on the naturally occurring Treg population
CD4+CD2+ Treg have been implicated in the development of transplantation 
tolerance.11;1;16 To fully exploit the capacity of Treg to promote transplantation tolerance, 
immunosuppressive drug should not interfere with Treg function. Hallmarks of Treg 
include constitutive expression of CD2, the α-chain of the IL-2 receptor, and of the 
forkhead transcription factor FoxP3. It has been shown that both these markers are of 
critical importance in the development, homeostasis, or function of Treg.0-3 In this 
section, the differential effect of several immunosuppressive drugs will be discussed.
Daclizumab is a humanized monoclonal antibody directed against CD2. It targets 
activated alloreactive T cells that express CD2, but it is imaginable that this drug also 
affects the CD2 expressing Treg. In chapter 6, we analyzed the impact of daclizumab 
therapy on the size and function of the Treg pool in transplant recipients. Used as 
induction therapy, daclizumab efficiently blocks CD2 expression during the first 7-11 
weeks after transplantation. After clearance of the antibody, we observed that a Treg pool, 
normal in size and function, was present in transplant recipients (chapter 6). However, 
data during blockade (from one patient) suggested that Treg were depleted from the 
circulation. This observation is in agreement with recent findings that IL-2 delivers an 
indispensable signal for the homeostasis of Treg in the periphery.0;1 Blockade of the IL-2 
receptor, e.g. by daclizumab, will deprive Treg of essential IL-2 signaling resulting in cell 
death. Basiliximab, a chimeric antibody against CD2, is expected to have comparable 
effects, although data are lacking. 
The indispensable role for IL-2 in the homeostasis of Treg has also questioned the 
effects of CNI on Treg. CNI block the transcription of the IL-2 gene through inhibition of 
calcineurin.4 This suggests that CNI, by preventing IL-2 production by alloreactive CD4+ 
T cells, can indirectly interfere with Treg homeostasis. We observed reduced Treg levels 
in transplant recipients at six months after transplantation (during CNI treatment) as 
compared with pretransplant levels (chapter 3). Furthermore, our group has shown that 
treatment of mice with cyclosporine results in a reduction of Treg levels in all immune 
compartments.4 Also in the clinical setting CNI administration has been associated with 
a reduction in Treg levels.;6 These data indicate that CNI can have detrimental effects 
on the size of the Treg pool. Next to an indirect effect by decreasing IL-2 concentrations, 
CNI might also have a direct effect on Treg. Recent data show that the formation of a 
FoxP3:NFAT complex is essential for Treg to mediate suppressor function.2 Inhibition of 
calcineurin activity prevents the translocation of NFAT and might this way hamper Treg 
function. We have evaluated the function of Treg of transplant recipients isolated before 
transplantation and six months after transplantation (during CNI treatment) but did not 
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observe significant alterations in the suppressive potential of Treg (chapter 3).
Rapamycin inhibits T cell proliferation by blocking the mammalian target of rapamycin 
(mTOR), thereby preventing progression of the cell cycle.4 Murine data have shown that in 
comparison with CNI, rapamycin preserves and can even expand the Treg population.4;7 
In addition, treatment with rapamycin, in contrast to cyclosporine, selectively preserves 
the highly suppressive CD27+  subset of Treg.19;8 These data indicate that rapamycin has 
beneficial effects on the Treg population.
9.3.2 Modulation of the alloreactive T cell population 
While each family of immunosuppressive drugs targets the alloimmune response in a 
specific manner, the net result is reduction of the alloreactive T cell pool. FK778 is a new 
immunosuppressive drug that is under consideration for use in kidney transplantation. 
We have investigated the immunosuppressive effects of FK778 on CD4+ T cells (chapter 
7) and CD8+ T cells (chapter 8). Our main finding was that FK778, next to efficient 
reduction of the alloreactive T cell pool, could induce regulatory activity in CD4+CD2- T 
cells (chapter 7). To our understanding, this was the first demonstration of induction of 
regulatory activity by an immunosuppressive drug. In agreement with our findings, it 
was recently reported that leflunomide, a drug with a similar mode of action as FK778, 
induced regulatory T cells in a murine model of contact allergen sensitivity.9 However, 
in this murine model, regulatory activity was contained in both CD4+ and CD8+ T cells, 
while we did not observe the induction of regulatory activity in the alloreactive CD8+ T 
cell pool (chapter 8).  
Understanding the mechanism of Treg induction by FK778 might provide useful insights 
for the future design of immunosuppressive regimens. FK778’s primary mechanism of 
action is the inhibition of dihydro-orotate dehydrogenase (DHODH), the enzyme essential 
for the de novo synthesis of pyrimidines.60 Subsequent inhibition of cell cycle progression 
efficiently prevents the clonal expansion of alloreactive T cells. The action of FK778 takes 
place in one of the last phases of T cell activation. It has been proposed that late phase 
inhibition of T cell activation results in the accumulation of so-called anergy factors, 
which renders the T cell unresponsive upon re-encounter with the antigen.61 This would 
suggest that other anti-proliferative agents, such as azathioprine and mycophenolate 
mofetil (MMF), should also have Treg inducing capacities, similar to FK778. However, so 
far no reports have been published on T cell anergy induction by these agents. Next to 
pyrimidine synthesis, restriction of tyrosine kinase activity, including inhibition of p6 
phosphorylation, has been suggested to be a mechanism of action of FK778.62 Although 
we could not observe inhibitory effects of FK778 on the phosphorylation of p6 (chapter 
7), it has been shown that interference with p6 mediated signals can result in T cell 
anergy.63 Evidence is now accumulating that several states of T cell anergy exist with 
varying underlying molecular mechanisms.64 Elucidation of the molecular pathways 
173
Summaryanddiscussion
responsible for T cell anergy induction might provide clues to decipher the mechanism 
of Treg induction by FK778.  
The observation that allogeneic stimulation of CD4+CD2- T cells in the presence of FK778 
resulted in the induction of CD4+CD2highFoxP3+ regulatory T cell subset, shows that reactive 
T cells can convert into regulatory T cells (chapter 7). The formation of a comparable 
Treg subset has also been shown by others after allogeneic stimulation of T cells.6 The 
responsible mechanism appeared to involve TGF-β and B7 costimulation.66-68 Interestingly, 
the TGF-β studies showed that the presence of IL-2 was required for TGF-β expression and 
subsequent Treg induction. This suggests that IL-2 signaling, which is allowed by FK778 
but is inhibited by immunosuppressive drugs such as CNI and rapamycin, might deliver 
an indispensable signal for conversion of CD4+CD2- T cells into Treg. 
The induction of a Treg subset appeared to be a direct effect of FK778 on CD4+CD2- T cells 
since we also observed Treg induction in αCD3/αCD28 stimulated cultures. On the other 
hand, Zeyda et al. found that FK778 prevents DC maturation 69. Since stimulation of CD4+ 
T cells with immature DC results in the induction of T cell anergy, FK778 can in this way 
have indirect effects of T cells as well. Taken together, there are multiple pathways along 
which FK778 may induce T cell anergy. 
9.3.3 Future immunosuppressive regimens
The thoughts on future immunological regimens presented here are based on 
immunological findings and focus on regimens that may facilitate the induction of 
transplantation tolerance. It has been suggested that tolerance inducing protocols prevent 
the development of chronic rejection and are therefore expected to improve long-term graft 
survival.70 It should be noted however, that the ultimate choice of immunosuppression 
will always be dominated by clinical experience and will be influenced by efficacy, safety, 
and adverse events. 
Facilitation of the naturally occurring Treg population is believed to be of crucial 
importance for the induction of transplantation tolerance. Treg sparing regimens might 
include the use of rapamycin which was shown to preserve and even expand the Treg 
pool. Anti-proliferative agents, such as azathioprine, MMF, or FK778 might be added 
to this regimen, since these agents may allow critical tolerizing signals. Next to their 
positive effects on the Treg pool, both rapamycin and azathioprine have been proposed to 
promote apoptosis of alloreactive T cells.71;72 Efficient reduction of the effector pool, while 
maintaining Treg function, would tip the balance towards regulation and might favor the 
induction of transplantation tolerance.
Facilitation of Treg function can also be achieved by the infusion of large amounts of ex 
vivo expanded Treg at the time of transplantation. In case of kidney donation by a living 
donor, Treg can even be expanded with donor-specificity. The first promising results in an 
experimental model have recently been published 73 and results on the clinical potential 
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of Treg infusion are expected in the next few years. Along the same line, dendritic cell 
(DC) vaccination protocols are under investigation for clinical use. In tumor immunology, 
DC vaccination is used to invoke an anti-tumor response 74 and in transplantation the 
vaccination with immature or alternatively-activated DC, which induces T cell anergy 
rather than T cell activation, holds promise for the induction of transplantation tolerance 
7;76. However, it is of critical importance that the injected immature DC do not convert 
into immune competent DC and activate instead of inhibit the alloreactivity. 
The facilitation of Treg will promote the induction of peripheral tolerance. However, 
central tolerance mechanisms can also be exploited. During T cell development, T cells 
with high affinity for self-antigens expressed in the thymus are deleted. Experimental 
studies on intrathymic injection of donor antigens resulted in the deletion of alloreactive 
T cells in the periphery.77;78
9. 4  Optimization of kidney transplantation: towards transplantation tolerance.
Over the past years, the success rate of renal transplantation has markedly increased. 
With current one-year graft survival rates exceeding 90%, the focus has turned 
towards optimization of long-term graft survival rates and minimization of adverse 
events to further increase the quality of life of transplant patients. The major goal in 
transplantation immunology remains the induction of transplantation tolerance, donor-
specific unresponsiveness against the allograft while immune competence against other 
antigens is maintained. Much effort is being put in elucidating the immunological process 
of transplantation tolerance in rodents. However, translation of successful experimental 
protocols of tolerance induction from mice to man is hampered by the obvious disparities 
between humans, in which T cell memory plays an important role, and pathogen-free bred 
mice.79;80 However, the most crucial information on transplantation tolerance comes from 
the other end of the line. Immunological fingerprinting of tolerant human transplant 
recipients may provide the most interesting data. In this regard, interest is also focused on 
liver allografts, that exhibit a form of immune privilege since operational tolerance can 
be achieved more easily. Mechanisms involved in the development of tolerance towards 
a liver allograft are believed to include clonal deletion and active regulation by Treg.81 A 
recent report on liver transplant patients revealed that tolerant liver transplant recipients 
indeed carried increased levels of peripheral blood Treg compared to healthy individuals.82 
Data on tolerant renal transplant recipients are scarce. The data available so far suggest 
that the immunological compartments of tolerant renal transplant recipients resemble 
that of healthy individuals.83;84 Treg levels in tolerant renal transplant patients were 
comparable to levels observed in healthy individuals.84 Moreover, in part of the tolerant 
transplant patients the humoral response to influenza vaccination was similar to that in 
healthy individuals.83 Clinical characterization of ten tolerant renal transplant patients 
showed that the median age of the kidney donor was younger in tolerant patients than 
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in the general transplant population.8 In addition, immunosuppression reduction had 
taken place over a long period of time (4 years) and despite several blood transfusions, HLA 
antibody formation was rarely observed in tolerant transplant recipients. Interestingly, 
two tolerant patients did carry donor-specific HLA class II antibodies suggesting that the 
presence of HLA antibodies does not rule out a tolerant state. 
The observation that tolerant patients received a kidney from a younger donor suggests 
that graft quality may be one of the conditions favoring transplantation tolerance and 
underscores the need of ‘good quality’ donors. However, due to the enormous shortage of 
organ donors an increase in the proportion of extended criteria (or ‘marginal’) donors has 
been inevitable during recent years. Today, approximately 1100 patients are on the waiting 
list for a kidney transplantation in The Netherlands and every year 20% of the patients 
on the waiting list die while waiting for a kidney transplantation. One major advantage 
of kidney transplantation is the option of donation by a living donor. In fact, this type 
of renal transplantation is associated with superior results, since dialysis duration can 
be shortened and cold ischemia injury can be evaded, two factors which on their own 
have been negatively associated with transplant outcome.86;87 However, in some cases the 
identification of a suitable living donor is problematic due to immunological reasons 
such as ABO incompatibility or a positive cross-match between donor and recipient. The 
introduction of living donor-exchange programs and undirected donation has lowered 
these immunological hurdles to living donation. The introduction of a donation allowance 
for living donors may further increase the number of available donors. Nevertheless, a 
large part of transplant recipients still remain dependent on an organ from a deceased 
donor. In The Netherlands, a donor registry exists in which adults who are willing to 
donate their organs after death are registered. Facts show that only  of 12 million 
people are registered today of which 0% is willing to donate their organs. These figures 
indicate that 7 million people are left unregistered and their opinion on organ donation 
remains unknown. A retrospective analysis on the number of potential donors from IC-
units indicated that the number of potential organ donors was substantially higher than 
the number of actual donors, and that the difference was mainly caused by objection 
from family members.88 Redirection of the Dutch organ donation law from voluntary 
donation to voluntary non-donation, meaning that every adult allows organ donation 
unless indicated otherwise, can be expected to result in a considerable increase of the 
number of organ donors. Unfortunately, due to ethical and political reasons, this remains 
a matter of debate.
Taken together, the induction of transplantation tolerance will remain the major focus of 
research in the field of transplant immunology. Increasing the number of organ donors 
will facilitate the choice of a suitable donor and will increase the chance of successful 
induction of transplantation tolerance in the future. 
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Niertransplantatie is de beste behandelmethode voor patiënten met nierfalen. 
Transplantatie van een donornier, afkomstig van een levende of overleden 
donor, verhoogt de overlevingskans en verbetert de kwaliteit van leven voor 
nierpatiënten en heeft daarom de voorkeur boven dialyse. Een belangrijk probleem 
bij transplantatie is het optreden van een afstotingsreactie. Ons immuunsysteem, 
ontwikkeld om op efficiënte wijze lichaamsvreemde indringers, zoals virussen en 
bacteriën, op te sporen en te vernietigen, herkent het getransplanteerde orgaan ook 
als lichaamsvreemd en zal een immuunrespons tegen het orgaan in gang zetten. 
De T cellen, van het immuunsysteem, grofweg te verdelen in CD4+ en CD8+ T cellen 
spelen een centrale rol in het afstotingsproces. Activatie van CD4+ en CD8+ T cellen 
die specifiek het getransplanteerde orgaan herkennen, zogenaamde alloreactieve T 
cellen, leidt tot een snelle vermeerdering (proliferatie) van deze cellen, waarna ze 
hun effector functie verwerven. Voorbeelden van effector functie zijn het produceren 
van ontstekingseiwitten (cytokines) of cytotoxische activiteit, d.w.z. dat de T cellen in 
staat zijn andere cellen te vernietigen. Daarnaast zijn CD4+ T cellen in staat om andere 
delen van het immuunsysteem te activeren, zoals antistof producerende B cellen 
en macrofagen. Uiteindelijk leidt dit alles tezamen tot een sterke immuunrespons 
tegen de donornier wat kan resulteren in verlies van het orgaan.     
De introductie van immuunsuppressieve medicijnen heeft de kans op afstoting enorm 
verkleind. De meeste immuunsuppressieve medicijnen grijpen aan op de T cellen van de 
patiënt en voorkomen o.a. de activatie, proliferatie of het verkrijgen van effector functie 
van de alloreactieve CD4+ en CD8+ T cellen. Optimalisatie van immuunsuppressieve 
regimes, waaronder het gecombineerde gebruik van verschillende medicijnen 
tegelijkertijd, heeft ertoe geleid dat de 1-jaars overlevingskans van het transplantaat 
nu hoger is dan 90%. Helaas heeft het (langdurig) gebruik van immuunsuppressieve 
medicatie een aantal ernstige bijwerkingen. Omdat de medicijnen het gehele 
immuunsysteem onderdrukken hebben transplantatiepatiënten een verhoogde 
kans op infecties of het ontwikkelen van tumoren. Daarnaast heeft elk medicijn 
zijn eigen specifieke bijwerkingen. Calcineurineremmers (CNI), zoals cyclosporine 
en tacrolimus, zijn immuunsuppressieve medicijnen die goed in staat zijn om een 
afstotingsreactie te voorkomen, maar zij kunnen ook onomkeerbare nierschade 
veroorzaken. Paradoxaal genoeg kan het gebruik van immuunsuppressiva op 
de lange termijn daardoor bijdragen aan orgaanverlies. Daarom is geprobeerd 
om op gecontroleerde wijze de immuunsuppressie op een gegeven moment na 
transplantatie te verminderen maar dit bleek gepaard te gaan met een verhoogde 
kans op afstoting. Aan de andere kant heeft de afbouw van immuunsuppressie 
ook voordelen, want patiënten bij wie de immuunsuppressie zonder afstoting kon 
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worden afgebouwd lieten een verbeterde nierfunctie en verlaagde bloeddruk zien. 
Derhalve is het zeer gewenst om onderscheid te kunnen maken tussen patiënten met 
een verhoogd risico op afstoting na afbouw van immuunsuppressie en patiënten bij 
wie immuunsuppressie succesvol kan worden afgebouwd. 
Het ultieme doel in de transplantatie immunologie is de inductie van 
transplantatie tolerantie, de permanente acceptatie van het orgaan in afwezigheid 
van immuunsuppressie. De afgelopen jaren is duidelijk geworden dat het 
immuunsysteem over elegante mechanismen beschikt om tolerantie tegen 
lichaamseigen eiwitten te behouden. Onderdeel hiervan zijn de regulatoire T cellen; 
natuurlijk voorkomende suppressor cellen die in staat zijn de effector functie van 
andere cellen te onderdrukken. Uit recente studies blijkt dat regulatoire T cellen 
ook de immuunrespons tegen een getransplanteerd orgaan kunnen moduleren 
en mogelijk een cruciale rol spelen in het ontstaan van transplantatie tolerantie. 
Hierbij is het natuurlijk uitermate belangrijk dat de functie en de ontwikkeling van 
regulatoire T cellen niet gehinderd wordt door de immuunsuppressieve medicijnen 
die transplantatie patiënten gebruiken om afstoting te voorkomen.
Naast de optimalisatie van immuunsuppressieve regimes, wordt er continu gewerkt 
aan de ontwikkeling van nieuwe immuunsuppressieve medicijnen en methoden. 
Nieuwe medicijnen en methoden moeten bij voorkeur alleen de donorspecifieke 
immuunrespons remmen en het afweersysteem gericht tegen micro-organismen 
en tumoren intact laten. Daarnaast moeten ze minder bijwerkingen hebben dan 
de momenteel gebruikte medicijnen en de werking van regulatoire T cellen niet 
hinderen. Het optimale immuunsuppressieve medicijn zou de kans op afstoting 
wegnemen, de werking van de regulatoire T cellen intact laten, en leiden tot 
transplantatie tolerantie.
  
Het hoofddoel van het onderzoek beschreven in dit proefschrift is de identificatie 
van een immunologische marker die kan voorspellen bij welke patiënten er een 
verhoogd risico is op afstoting na afbouw van de immuunsuppressieve medicatie en 
bij welke patiënten de immuunsuppressiva veilig kunnen worden verminderd. Een 
belangrijk onderdeel hiervan is het bestuderen van de exacte rol van de regulatoire 
T cellen in de bescherming tegen afstoting. Uit studies in autoimmuunziekten is 
duidelijk geworden dat niet zozeer het aantal regulatoire T cellen maar juist hun 
functie aangetast was. Functionele analyse van de regulatoire T cellen wordt echter 
bemoeilijkt door het lage percentage van deze cellen in het bloed. Om dit probleem 
op te lossen hebben we een in vitro expansie protocol ontwikkeld waarmee we de 
regulatoire T cellen op het lab kunnen vermeerderen tot voldoende aantallen voor 
functionele analyse. Dit expansie protocol is beschreven in hoofdstuk 2. 
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Voor de identificatie van een marker met voorspellende waarde voor het optreden van 
afstoting hebben we gebruik gemaakt van een cohort niertransplantatiepatiënten 
bij wie de immuunsuppressie volgens een standaardprotocol na transplantatie werd 
verminderd. Als gevolg van dit afbouw regime kreeg een deel van de patiënten een 
afstotingsreactie, terwijl de therapie bij het merendeel van de patiënten succesvol 
kon worden gereduceerd. Gelukkig waren vrijwel alle afstotingsreacties goed te 
behandelen. Bij deze patiënten is bloed afgenomen voorafgaand aan de transplantatie, 
en voor en na de afbouw van de immuunsuppressie. De resultaten verkregen vóór 
de afbouw van immuunsuppressie, en dus voorafgaand aan het optreden van 
een afstotingsreactie, bij patiënten die een afstoting kregen na de afbouw van 
immuunsuppressie (rejectoren) werden vergeleken met de bevindingen in een 
geselecteerde groep transplantatiepatiënten die de afbouw succesvol doorstonden 
(non-rejectoren). 
Omdat de CD4+ en CD8+ T cellen een zeer belangrijke rol spelen bij de afstotingsreactie, 
hebben we uitgebreid gekeken naar een aantal T cel markers, waaronder de 
aanwezigheid van verschillende populaties T cellen, zoals naïeve, effector en memory 
(‘geheugen’) T cellen, en de capaciteit van CD4+ en CD8+ T cellen om te prolifereren 
en cytokines te produceren. Ook is de aanwezigheid en de functie van regulatoire 
T cellen met behulp van het eerder beschreven expansie protocol bestudeerd in 
rejectoren en non-rejectoren. De resultaten hiervan zijn beschreven in hoofdstuk 
3. Uit de analyses bleek dat rejectoren een verhoogde ratio tussen het percentage 
memory CD8+ T cellen en regulatoire T cellen (CD8+ TMEM: TREG) in het perifere bloed 
hadden voorafgaande aan de afbouw van immunosuppressie. Daarnaast bleek 
dat alle patiënten met een CD4+ TMEM: TREG ratio <20 geen afstotingsreactie kregen 
wanneer vervolgens de immunosuppressie werd gereduceerd. De hoge ratio bij 
rejectoren kan duiden op een verstoorde immunologische balans. Uit eerdere studies 
is duidelijk geworden dat er een balans bestaat tussen reactiviteit en regulatie en 
dat het omslaan van de balans in de richting van reactiviteit kan leiden tot ziekte. 
Een lage CD4+ TMEM: TREG ratio kan duiden op een staat van immunologische rust 
die beschermt tegen het ontstaan van een afstotingsreactie op het moment dat de 
immuunsuppressie wordt afgebouwd. De functionele capaciteit van regulatoire 
T cellen bleek na de transplantatie niet te veranderen. Daarnaast zagen we geen 
verschillen in de functie van regulatoire T cellen tussen rejectoren en non-rejectoren. 
Hieruit concludeerden we dat functionele analyse van Treg geen voorspellende 
waarde heeft voor het optreden van een afstotingsreactie. Vervolgens leverde ook de 
analyse van veranderingen in de tijd (tussen het moment van transplantatie en het 
tijdstip dat gestart werd met afbouw van immunosuppressie) verschillen op tussen 
rejectoren en non-rejectoren. Bij rejectoren zagen we in het bloed een toename van 
het percentage naïeve CD4+ T cellen en een afname van het percentage effector CD4+ 
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T cellen. Bij non-rejectoren zagen we een meer divers patroon met zowel stijgers als 
dalers. Deze resultaten kunnen mogelijk betekenen dat de effector CD4+ T cellen het 
bloed verlaten en naar het orgaan migreren als voorbode op de afstotingsreactie. 
Als onderdeel van de T cel analyses hebben we ook gekeken naar de capaciteit van 
CD4+ en CD8+ T cellen om te prolifereren en ontstekingseiwitten te produceren maar 
hierin vonden we geen verschillen tussen rejectoren en non-rejectoren. Uiteindelijk 
konden we met behulp van de T cel analyses op twee manieren de non-rejectoren 
onderscheiden van rejectoren. Zowel een CD4+ TMEM: TREG ratio <20 als een afname van 
het percentage naïeve CD4+ T cellen vonden we namelijk alleen bij non-rejectoren. 
Door deze markers te combineren  konden we 16 van de 21 non-rejectoren (76 %) 
identificeren. Voordat deze methode echter kan worden toegepast om prospectief 
transplantatie patiënten te identificeren die in aanmerking komen voor afbouw van 
immuunsuppressie moeten onze bevindingen gevalideerd worden in een tweede 
cohort transplantatie patiënten.
Naast de T cellen, kunnen ook ‘natural killer’ (NK) cellen geactiveerd worden als gevolg 
van een transplantatie. NK cellen zijn van nature cytotoxisch, d.w.z. dat ze in staat 
zijn om andere cellen te vernietigen. NK cellen hoeven niet geactiveerd te worden 
zoals T cellen, maar worden juist continu in bedwang gehouden door lichaamseigen 
receptoren. Op het moment dat deze lichaamseigen signalen ontbreken op de 
cellen van het donor-orgaan, kunnen de NK cellen hun effectorfunctie uitoefenen. 
In hoofdstuk 4 hebben we de rol van NK cellen onderzocht door de aanwezigheid 
van verschillende NK cel subpopulaties in het perifere bloed te bestuderen en 
door op basis van een genetische analyse te voorspellen of NK cel remming wel of 
niet plaats zou vinden. We vonden geen associatie tussen de geanalyseerde NK cel 
markers en het ontstaan van een afstotingsreactie als gevolg van de afbouw van 
immuunsuppressie. 
In hoofdstuk 5 hebben we bekeken of de aanwezigheid van HLA antistoffen 
(antistoffen gericht tegen HLA-eiwitten van de donor) een rol speelt bij het optreden 
van afstoting. Uit vele studies is gebleken dat de aanwezigheid van HLA antistoffen 
een negatieve invloed heeft op het beloop na transplantatie. Uit onze resultaten 
bleek dat de aanwezigheid van HLA antistoffen de kans op afstoting na afbouw 
van immuunsuppressie niet vergroot. Het feit dat een bij een aantal patiënten met 
HLA antistoffen de medicatie succesvol kon worden gereduceerd betekent dat de 
aanwezigheid van HLA antistoffen geen exclusiecriterium hoeft te zijn voor afbouw 
van immuunsuppressie. Slechts enkele patiënten ontwikkelden HLA antistoffen na 
de afbouw van immuunsuppressie. Bij alle patiënten met HLA antistoffen hebben we 
getest of deze antistoffen ook functioneel actief waren, hetgeen een indicatie is voor 
de schadelijkheid van de antistoffen. Functionele analyse van de HLA antistoffen liet 
zien dat de enige patiënt met HLA antistoffen en een afstotingsreactie, tevens de 
Chapter9
18
Nederlandsesamenvatting
enige patiënt was die cytotoxische HLA antistoffen bezat. Deze resultaten suggereren 
dat niet alleen de aanwezigheid maar ook de functie van HLA antistoffen een 
belangrijke indicatie kan geven voor het beloop na transplantatie.   
In hoofdstuk 6 werd onderzocht of het immuunsuppressieve medicijn daclizumab 
een negatieve werking heeft op de regulatoire T cel populatie in het perifere bloed 
van niertransplantatie patiënten. Daclizumab is een monoclonaal antilichaam 
gericht tegen CD2, de α-keten van de IL (interleukine)-2 receptor. De receptor voor 
IL-2 (een T cel stimulerend eiwit) bevindt zich op het oppervlak van geactiveerde 
effector T cellen, en door blokkade van de α-keten van deze receptor kan afstoting 
worden voorkomen. Daclizumab wordt meestal gebruikt als inductie therapie, 
d.w.z. dat het enkele malen wordt toegediend in de beginfase na transplantatie. Het 
blokkeert vervolgens gedurende 7-11 weken de IL-2 receptor. Aangezien regulatoire 
T cellen eveneens gekenmerkt worden door een hoge expressie van CD2 omdat zij 
afhankelijk zijn van IL-2 om te overleven, is het voorstelbaar dat blokkade van de 
IL-2 receptor door daclizumab schadelijke gevolgen kan hebben voor de regulatoire 
T cel populatie en de ontwikkeling van transplantatie tolerantie. Analyse van de 
regulatoire T cellen nadat daclizumab verdwenen was, liet zien dat daclizumab geen 
onomkeerbare schade had aangericht aan de grootte en de functie van de regulatoire 
T cel populatie. Bij één patiënt waren we in staat het effect van daclizumab tijdens 
behandeling te bestuderen en daarbij bleek dat het aantal regulatoire T cellen tijdens 
daclizumab behandeling drastisch verlaagd was. Hoewel daclizumab dus geen 
onomkeerbare schade toebrengt aan de grootte en de functie van de regulatoire T 
cel populatie, kan het mogelijk wel tijdelijk de regulatoire T cel populatie aantasten 
en de kans op tolerantie inductie in gevaar brengen.  
Tot slot hebben we de werking van het immuunsuppressieve medicijn FK778 
onderzocht. FK778 is een nieuw immuunsuppressief medicijn dat onderzocht is 
voor gebruik bij transplantatie. Wij vonden dat FK778 niet alleen in staat is om 
verschillende aspecten van het immuunsysteem te onderdrukken, zoals de meeste 
immuunsuppressieve medicijnen, maar dat FK778 ook regulatoire capaciteit 
kan induceren in alloreactieve CD4+ T cellen (hoofdstuk 7). Het middel bleek dus 
in staat om een deel van de ‘agressieve’ alloreactieve T cellen te converteren naar 
regulatoire T cellen. Dit betekent dat het in principe, met gebruik van de juiste 
immuunsuppressieve medicijnen, mogelijk is om de immuunrespons te sturen in de 
richting van transplantatie tolerantie. 
In hoofdstuk 8 is beschreven hoe FK778 de alloreactieve CD8+ T cel populatie kan 
onderdrukken. FK778 bleek niet in staat om regulatoire capaciteit te induceren in 
CD8+ T cellen, maar kon goed de proliferatie en het verwerven van effector functie 
van alloreactieve CD8+ T cellen onderdrukken. De functie van reeds gevormde CD8+ 
effector T cellen kon niet worden geremd door FK778. 
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In hoofdstuk 9 worden onze bevindingen samengevat en bediscussieerd vanuit een 
breder oogpunt. Onze bevindingen onderstrepen dat een correcte balans tussen 
reactiviteit en regulatie uitermate belangrijk is voor behoud van het getransplanteerde 
orgaan. Doorslag van de balans richting immuunreactiviteit verhoogt de kans op een 
afstotingsreactie terwijl  bevordering van immuunregulatie zal beschermen tegen 
afstoting. Ontwikkeling van medicijnen of methoden die de balans laten doorslaan 
in de richting van immuunregulatie zal bijdragen aan de inductie van langdurige 
transplantatie tolerantie en het succes van transplantatie verder verhogen.   
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